Treatment of facial muscular dyskinesia

By injecting modified BoNT/A on multiple facial sites, the existing problems of short-term efficacy and serious side effects in the treatment of blepharospasm and mitosm spasm are solved, achieving a longer-lasting and safer treatment effect, reducing injection frequency and side effects risk.

CN119095868APending Publication Date: 2024-12-06IPSEN BIOPHARM LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380036925.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-29
Filing Date
2023-03-23
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing treatments for blepharospasm and mitospasm have problems with short-term efficacy, severe side effects and high injection frequency, making it difficult to provide a lasting and safe treatment plan.

Method used

Using modified Botox neurotoxin A (BoNT/A), by intramuscular injection at multiple facial sites, including BoNT/A light chain and BoNT/B receptor binding domain, extends the time of action and improves safety, allowing Use higher doses to improve therapeutic effect.

Benefits of technology

Achieve longer-lasting therapeutic effects, reduce the frequency of injections, provide a wider range of treatment options, reduce the risk of under-administration and over-administration, and improve the quality of life of patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005105231240001061
    Figure BDA0005105231240001061
  • Figure BDA0005105231240001071
    Figure BDA0005105231240001071
  • Figure BDA0005105231240001221
    Figure BDA0005105231240001221
Patent Text Reader

Abstract

The present invention relates to a modified botulinum neurotoxin A (BoNT / A) for use in the treatment of facial muscular dystonia, including blepharospasm and lateral spasm, where the modified BoNT / A has a unit dose of at least 240 pg of the modified BoNT / A, where the modified BoNT / A is administered to affected muscles in a subject by intramuscular injection, wherein the total dose of the modified BoNT / A administered during treatment is greater than 24,000 pg and up to 82, 500 pg (e.g. Up to 75,000 pg), and wherein the modified BoNT / A comprises a BoNT / A light chain and translocation domain (HN) and a BoNT / B receptor binding domain (HC domain).
Need to check novelty before this filing date? Find Prior Art

Description

Field of the Invention

[0001] The present invention relates to the treatment of disorders affecting the eyelid muscles of an individual. Background Art

[0002] Disorders affecting the eyelid muscles can have a negative impact on the patient's life. Among these disorders, blepharospasm and facial spasms (e.g., hemifacial spasm) are particularly unpleasant.

[0003] The main feature of blepharospasm is the abnormal contraction of the orbicularis oculi muscle. More specifically, blepharospasm can manifest as uncontrollable excessive blinking and spasms of one or both eyes, further characterized by uncontrollable eyelid closure that lasts longer than the typical blink reflex. Blepharospasm symptoms may recur and can last for hours or days at a time, and in some cases, symptoms (e.g., twitching) may be chronic and persistent, causing lifelong challenges to individuals with the condition. Other symptoms may include twitching that may radiate to the nose, face, and neck, dry eyes, and sensitivity to sunlight and bright light.

[0004] The cause of blepharospasm is unknown. It has been suggested that certain medications (e.g., medications for Parkinson's disease, estrogen replacement therapy, or acute benzodiazepine withdrawal) may induce blepharospasm. Blepharospasm may also be associated with brain disorders (e.g., including neurodegenerative disorders, malfunction of the basal ganglia, and multiple sclerosis), brain injury, or head injury (e.g., concussion).

[0005] Hemifacial spasm is a movement disorder characterized by involuntary tonic-clonic contractions of the facial muscles on one side of the face. Although bilateral cases sometimes occur, this is extremely rare. The muscles affected are those innervated by the facial nerve (cranial nerve VII). The initial symptoms of this disorder are usually localized to the orbicularis oculi muscle and can spread to include other muscles of facial expression. There are two forms of hemifacial spasm (HFS): typical HFS and atypical HFS. In the typical form, the twitch / spasm usually starts in the lower eyelid in the orbicularis oculi muscle. Over time, it spreads to the entire eyelid and then to the orbicularis oris muscle around the lip and the buccinator muscle in the cheekbone area. In atypical HFS, the twitch / spasm usually starts in the orbicularis oris muscle around the lip and the buccinator muscle in the lower cheekbone area and then develops over time to the orbicularis oculi muscle in the eyelid. The most common form is the typical form, and the atypical form is only seen in about 2-3% of patients with hemifacial spasm.

[0006] Medical treatments for disorders affecting individual eyelid muscles have proven to be often unpredictable and of short-lived effectiveness. Anticholinergics, sedatives, and botulinum neurotoxins (e.g. or ) are the most commonly used treatment options. However, these treatment options are not optimal and are associated with serious side effects, including toxicity and unwanted paralysis of facial muscles. In some cases, invasive surgery may be considered for patients who do not respond well to medications or botulinum toxin injections. Therefore, new and effective therapies for the treatment of blepharospasm are constantly being tested or sought.

[0007] In more detail, botulinum neurotoxin A (BoNT / A) selectively inhibits the release of acetylcholine from presynaptic nerve endings and, therefore, blocks cholinergic transmission at the neuromuscular junction, thereby inducing muscle contraction and a decrease in muscle tone, resulting in relaxation of the injected muscle. However, the duration of action of currently available BoNT / A products is approximately 12 to 14 weeks, i.e., when new nerve endings sprout, allowing nerve function to return to normal and the original symptoms to reappear. Therefore, in order to maintain the effect, injections need to be repeated regularly. Therefore, given the potential chronicity of the condition and the long-term nature of the required treatment, the frequency of BoNT / A injections is an important consideration in the treatment of disorders affecting the eyelid muscles of an individual, such as blepharospasm and / or hemifacial spasm. In practice, this affects direct and indirect medical costs for patients and caregivers, the logistics of injections within the hospital / clinic, and, most importantly, the quality of life of the patient.

[0008] Approved for the treatment of blepharospasm and hemifacial spasm, the maximum total dose per treatment period is 120 units per eye. Clinicians should administer The dose is capped at 120 units per eye per treatment period (i.e., 240 units when treating both eyes). Clinicians are forced to make difficult choices during the treatment of their patients. In other words, in conventional treatment regimens, clinicians must balance the relatively low total amount of BoNT / A that can be administered (necessary due to the high toxicity of BoNT / A) with the effective amount in multiple different muscles and / or their sites. As a result, some muscles may be neglected, while other muscles receive suboptimal amounts of BoNT / A, resulting in suboptimal treatment effects.

[0009] Furthermore, conventional treatment regimens for these disorders are complex and result in under-dosing by clinicians in an effort to avoid toxicity to patients. Therefore, there is a need for a convenient, safe, and effective single-dose unit and corresponding guidance on the number of units that can be applied to the eyelid muscles during treatment (e.g., including the number of injection sites per muscle) without causing patient toxicity.

[0010] In summary, there is a need for an improved therapeutic approach to treat disorders affecting individual eyelid muscles (e.g., blepharospasm and / or hemifacial spasm) that would allow a personalized, patient-centered approach to tailor treatment to the targeted clinical pattern, allow different combinations of injections of muscles and / or their sites depending on the distribution, extent, and severity of the disorder, while avoiding toxicity and providing longer-lasting treatment (thereby reducing the frequency of administration).

[0011] The present invention overcomes one or more of the above-identified problems. Summary of the invention

[0012] The inventors have surprisingly discovered that modified BoNT / As are particularly useful in treating disorders affecting eyelid muscles in an individual, such as blepharospasm and / or hemifacial spasm. The modified BoNT / A may include a BoNT / A light chain and a translocation domain and a BoNT / B receptor binding domain (H C domain), which results in increased retention of the modified BoNT / A at the administration site (reduced diffusion away from the administration site) and / or increased duration of action (e.g., 6-9 months).

[0013] Advantageously, when compared to unmodified BoNT / A (e.g. ) compared to the modified BoNT / A. This improved safety profile can be represented by the high safety ratio of the modified BoNT / A described herein.

[0014] Based on the preclinical data herein, it has been shown that a higher total amount of modified BoNT / A can be administered to an individual while achieving comparable efficacy to unmodified BoNT / A (e.g., ). Thus, in the treatment of disorders affecting individual eyelid muscles (e.g., blepharospasm and / or hemifacial spasm), more modified BoNT / A can be injected and / or more muscles and / or sites thereof can be injected before a maximum total dose is reached. This is an important and advantageous discovery and provides improved treatment for such disorders while providing clinicians with a wider range of treatment options. When compared to treatment with unmodified BoNT / A (e.g., ) treatment, the treatment may be improved because it provides a more durable treatment (thereby reducing the frequency of administration) and / or can be customized to an individual and / or improves the quality of life of an individual. Thus, the treatment of the present invention is improved over conventional treatment regimens.

[0015] In addition, the present invention provides a convenient, safe and effective single unit dose and a total (maximum) dose that can be safely administered in a single treatment. The present invention also provides corresponding guidance on the number of times (e.g., including the number of each intramuscular injection site) that the unit dose can be applied to the muscle without producing patient toxicity. Therefore, treating disorders affecting individual eyelid muscles (e.g., blepharospasm and / or hemifacial spasm) according to the present invention is much simpler for clinicians and helps avoid insufficient and / or excessive administration. In addition, compared with conventional treatments, the treatment methods of the present invention are more suitable for the needs of patients, so patients are more satisfied. DETAILED DESCRIPTION

[0016] Broad aspects of the invention provide:

[0017] - A modified botulinum neurotoxin A (BoNT / A) for use in a method of treating blepharospasm in a subject, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of the subject;

[0018] - A method of treating blepharospasm in a subject, wherein the method comprises administering a modified BoNT / A by intramuscular injection at multiple sites on the face of the subject;

[0019] - Use of a modified botulinum neurotoxin A (BoNT / A) in the preparation of a medicament for treating blepharospasm in an individual, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of the individual;

[0020] wherein the modified BoNT / A is administered in a unit dose comprising at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A,

[0021] wherein the total dose administered during the treatment period is greater than 24,000 pg and up to 82,500 pg (e.g., up to 75,000 pg) of the modified BoNT / A, and

[0022] wherein the modified BoNT / A comprises a botulinum neurotoxin A (BoNT / A) light chain and a translocation domain (H N ) and the BoNT / B receptor binding domain (H C domain).

[0023] Other broad aspects of the invention provide:

[0024] - A modified botulinum neurotoxin A (BoNT / A) for use in a method of treating classic hemifacial spasm, wherein the modified BoNT / A is administered to a subject via multiple sites on the face of the subject.

[0025] Administered by intramuscular injection;

[0026] - A method of treating classic hemifacial spasm, the method comprising administering a modified BoNT / A by intramuscular injection at multiple sites on the face of an individual;

[0027] - Use of a modified botulinum neurotoxin A (BoNT / A) for the preparation of a medicament for treating classic hemifacial spasm, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of a subject;

[0028] wherein the modified BoNT / A is administered in a unit dose comprising at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A,

[0029] wherein the total dose administered during the treatment period is greater than 24,000 pg and up to 82,500 pg (e.g., up to 75,000 pg) of the modified BoNT / A, and

[0030] wherein the modified BoNT / A comprises a botulinum neurotoxin A (BoNT / A) light chain and a translocation domain (H N ) and the BoNT / B receptor binding domain (H C domain).

[0031] Other broad aspects of the invention provide:

[0032] - A modified botulinum neurotoxin A (BoNT / A) for use in a method of treating atypical hemifacial spasm, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of a subject;

[0033] - A method of treating atypical hemifacial spasm, the method comprising administering a modified BoNT / A by intramuscular injection at multiple sites on the face of an individual;

[0034] - Use of a modified botulinum neurotoxin A (BoNT / A) for the preparation of a medicament for treating atypical hemifacial spasm, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of an individual;

[0035] wherein the modified BoNT / A is administered in a unit dose comprising at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A,

[0036] wherein the total dose administered during the treatment period is greater than 24,000 pg and up to 82,500 pg (e.g., up to 75,000 pg) of the modified BoNT / A, and

[0037] wherein the modified BoNT / A comprises a botulinum neurotoxin A (BoNT / A) light chain and a translocation domain (H N ) and the BoNT / B receptor binding domain (H C domain).

[0038] In one aspect, provided is a modified botulinum neurotoxin A (BoNT / A) for use in a method of treating blepharospasm in an individual, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of the individual, the method comprising:

[0039] a) administering a unit dose of a modified BoNT / A at each of up to six different injection sites proximate to the superior orbicularis oculi muscle of a first eye of the individual, wherein the up to six different injection sites are selected from:

[0040] i) the medial superior orbicularis oculi muscle (eg, in the preseptal portion or orbital portion of the medial superior orbicularis oculi muscle, preferably the preseptal portion);

[0041] ii) superior orbital orbicularis oculi;

[0042] iii) the lateral superior orbicularis oculi muscle (eg, in the preseptal portion or the orbital portion of the lateral superior orbicularis oculi muscle, preferably the preseptal portion);

[0043] iv) lateral orbital orbicularis oculi;

[0044] v) medial superior tarsal preorbital orbicularis oculi muscle; and

[0045] vi) Lateral superior tarsal preorbital orbicularis oculi muscle; and / or

[0046] b) administering a unit dose of the modified BoNT / A at up to two different injection sites proximate to the inferior orbicularis oculi muscle of a first eye of the individual, each injection site, wherein the up to two different injection sites are selected from:

[0047] i) the medial inferior orbicularis oculi muscle (eg, in the preseptal portion or orbital portion of the medial inferior orbicularis oculi muscle, preferably the preseptal portion); and

[0048] ii) the lateral inferior orbicularis oculi muscle (eg, in the preseptal portion or orbital portion of the lateral inferior orbicularis oculi muscle, preferably the preseptal portion); and / or

[0049] c) administering a unit dose of the modified BoNT / A at up to two different injection sites selected from:

[0050] i) two different injection sites on the corrugator supercilii muscle near the subject's first eye; and

[0051] ii) a site on the procerus muscle near the subject's first eye;

[0052] wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A, wherein the total dose administered during the treatment period is greater than 24,000 pg and up to 82,500 pg (e.g., up to 75,000 pg) of the modified BoNT / A, and wherein the modified BoNT / A comprises a BoNT / A light chain and a translocation domain (H N ) and the BoNT / B receptor binding domain (H C domain).

[0053] In one aspect, a method of treating blepharospasm in an individual is provided, the method comprising administering a modified botulinum neurotoxin A (BoNT / A) by intramuscular injection at multiple sites on the face of the individual, the method comprising:

[0054] a) administering a unit dose of a modified BoNT / A at each of up to six different injection sites proximate to the superior orbicularis oculi muscle of a first eye of the individual, wherein the up to six different injection sites are selected from:

[0055] i) the medial superior orbicularis oculi muscle (eg, in the preseptal portion or orbital portion of the medial superior orbicularis oculi muscle, preferably the preseptal portion);

[0056] ii) superior orbital orbicularis oculi;

[0057] iii) the lateral superior orbicularis oculi muscle (eg, in the preseptal portion or the orbital portion of the lateral superior orbicularis oculi muscle, preferably the preseptal portion);

[0058] iv) lateral orbital orbicularis oculi;

[0059] v) medial superior tarsal preorbital orbicularis oculi muscle; and

[0060] vi) Lateral superior tarsal preorbital orbicularis oculi muscle; and / or

[0061] b) administering a unit dose of the modified BoNT / A at up to two different injection sites proximate to the inferior orbicularis oculi muscle of a first eye of the individual, each injection site, wherein the up to two different injection sites are selected from:

[0062] i) the medial inferior orbicularis oculi muscle (eg, in the preseptal portion or orbital portion of the medial inferior orbicularis oculi muscle, preferably the preseptal portion); and

[0063] ii) the lateral inferior orbicularis oculi muscle (eg, in the preseptal portion or orbital portion of the lateral inferior orbicularis oculi muscle, preferably the preseptal portion); and / or

[0064] c) administering a unit dose of the modified BoNT / A at up to two different injection sites selected from:

[0065] i) two different injection sites on the corrugator supercilii muscle near the subject's first eye; and

[0066] ii) a site on the procerus muscle near the subject's first eye;

[0067] wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A, wherein the total dose administered during the treatment period is greater than 24,000 pg and up to 82,500 pg (e.g., up to 75,000 pg) of the modified BoNT / A, and wherein the modified BoNT / A comprises a BoNT / A light chain and a translocation domain (H N ) and the BoNT / B receptor binding domain (H C domain).

[0068] In one aspect, there is provided a use of a modified botulinum neurotoxin A (BoNT / A) in the preparation of a medicament for treating classic hemifacial spasm, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of an individual, the treatment comprising:

[0069] (a) administering a unit dose of a modified BoNT / A at each of up to six different injection sites proximate to the superior orbicularis oculi muscle of a first eye of the individual, wherein the up to six different injection sites are selected from:

[0070] (i) the medial superior orbicularis oculi muscle (e.g., at the preseptal portion or the orbital portion of the medial superior orbicularis oculi muscle, preferably the preseptal portion);

[0071] (ii) supraorbital orbicularis oculi;

[0072] (iii) the lateral superior orbicularis oculi muscle (e.g., the preseptal portion or the orbital portion of the lateral superior orbicularis oculi muscle, preferably the preseptal portion);

[0073] (iv) lateral orbital orbicularis oculi;

[0074] (v) medial superior tarsal preorbital orbicularis oculi muscle; and

[0075] (vi) lateral superior tarsal preorbital orbicularis oculi muscle; and / or

[0076] (b) administering a unit dose of a modified BoNT / A at each of up to two different injection sites proximate to the inferior orbicularis oculi muscle of a first eye of the individual, wherein the up to two different injection sites are selected from:

[0077] (i) the medial inferior orbicularis oculi muscle (e.g., in the preseptal portion or orbital portion of the medial inferior orbicularis oculi muscle, preferably the preseptal portion); and

[0078] (ii) the lateral inferior orbicularis oculi muscle (e.g., in the preseptal portion or orbital portion of the lateral inferior orbicularis oculi muscle, preferably the preseptal portion); and / or

[0079] (c) administering a unit dose of a modified BoNT / A at up to two different injection sites selected from:

[0080] (i) two different injection sites on the corrugator supercilii muscle proximal to the subject's first eye; and

[0081] (ii) a site on the procerus muscle near the subject's first eye;

[0082] wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A, wherein the total dose administered during the treatment period is greater than 24,000 pg and up to 82,500 pg (e.g., up to 75,000 pg) of the modified BoNT / A, and wherein the modified BoNT / A comprises a BoNT / A light chain and a translocation domain (H N ) and the BoNT / B receptor binding domain (H C domain).

[0083] In the present disclosure, the injection site "outer orbital orbicularis oculimuscle" is referred to in the context of the injection site of the "superior orbicularis oculimuscle" because, for example, the site "outer orbital orbicularis oculimuscle" is closer to the upper eyelid than the lower eyelid. That is, in any aspect of the embodiments described herein (whether for treating blepharospasm, typical hemifacial spasm, or atypical hemifacial spasm), the following terms as referenced in (1) may be used synonymously with the following terms as referenced in (2): (1) "administering a unit dose of a modified BoNT / A at up to six different injection sites proximal to the orbicularis oculi muscle of a first eye (and / or a second eye) of an individual, each injection site being selected from:

[0084] (iii) the medial superior orbicularis oculi muscle (eg, at the preseptal portion or the orbital portion of the medial superior orbicularis oculi muscle, preferably the preseptal portion);

[0085] (iv) superior orbital orbicularis oculi muscle;

[0086] (v) the lateral superior orbicularis oculi muscle (e.g., in the preseptal portion or orbital portion of the lateral superior orbicularis oculi muscle, preferably the preseptal portion);

[0087] (vi) lateral orbital orbicularis oculi muscle;

[0088] (vii) medial superior tarsal preorbital orbicularis oculi muscle; and

[0089] (viii) Lateral superior tarsal preorbital orbicularis oculi muscle”;

[0090] (2) "administering a unit dose of a modified BoNT / A at up to six different injection sites proximal to the superior orbicularis oculi muscle and / or the lateral orbital orbicularis oculi muscle of a first eye (and / or a second eye) of the individual, each injection site being selected from:

[0091] (i) the medial superior orbicularis oculi muscle (e.g., at the preseptal portion or the orbital portion of the medial superior orbicularis oculi muscle, preferably the preseptal portion);

[0092] (ii) supraorbital orbicularis oculi;

[0093] (iii) the lateral superior orbicularis oculi muscle (e.g., the preseptal portion or the orbital portion of the lateral superior orbicularis oculi muscle, preferably the preseptal portion);

[0094] (iv) lateral orbital orbicularis oculi;

[0095] (v) medial superior tarsal preorbital orbicularis oculi muscle; and

[0096] (vi) Lateral superior tarsal preorbital orbicularis oculi muscle”.

[0097] The modified BoNT / A may preferably be administered by intramuscular injection at at least six different sites on the face of an individual. In other words, the modified BoNT / A may preferably be administered by intramuscular injection to at least six different sites on the face of an individual. In yet other words, the number of different injection sites at which a unit dose is administered may preferably be at least six.

[0098] The injection protocol of the present invention allows the clinician to adjust the injection location according to the muscle engagement pattern of the participant's blepharospasm, thereby determining the injection location. At the same time, the risk of ptosis can also be reduced.

[0099] If the pretarsal muscles of the upper eyelid are affected, preferably up to two injections may be made in the pretarsal portion of the orbicularis oculi muscle of the upper eyelid. This approach preferably avoids the upper eyelid furrow, thus reducing the likelihood of developing ptosis. If the corrugator / procerus muscles are affected, preferably up to two injections may be made between the eyebrows on each side.

[0100] A method of treating blepharospasm may also include:

[0101] (a) administering a unit dose of a modified BoNT / A at each of up to six different injection sites proximate to the superior orbicularis oculi muscle of a second eye of the individual, wherein the up to six different injection sites are selected from:

[0102] (i) the medial superior orbicularis oculi muscle (e.g., in the preseptal portion or orbital portion of the medial superior orbicularis oculi muscle, preferably the preseptal portion);

[0103] (ii) supraorbital orbicularis oculi;

[0104] (iii) the lateral superior orbicularis oculi muscle (e.g., the preseptal portion or the orbital portion of the lateral superior orbicularis oculi muscle, preferably the preseptal portion);

[0105] (iv) lateral orbital orbicularis oculi;

[0106] (v) medial superior tarsal preorbital orbicularis oculi muscle; and

[0107] (vi) lateral superior tarsal preorbital orbicularis oculi muscle; and / or

[0108] (b) administering a unit dose of a modified BoNT / A at each of up to two different injection sites proximate to the inferior orbicularis oculi muscle of a second eye of the individual, wherein the up to two different injection sites are selected from:

[0109] (i) the medial inferior orbicularis oculi muscle (e.g., in the preseptal portion or orbital portion of the medial inferior orbicularis oculi muscle, preferably the preseptal portion); and

[0110] (ii) lateral inferior orbicularis oculi muscle; and / or

[0111] (c) administering a unit dose of a modified BoNT / A at up to two different injection sites selected from:

[0112] (i) two different injection sites on the corrugator supercilii muscle near the subject's second eye; and

[0113] (ii) a site on the procerus muscle near the subject's second eye;

[0114] The modified BoNT / A may preferably be administered by intramuscular injection at at least six different sites on the face of an individual. In other words, the modified BoNT / A may preferably be administered by intramuscular injection to at least six different sites on the face of an individual. In yet other words, the number of different injection sites at which a unit dose is administered may preferably be at least six.

[0115] A method for treating blepharospasm may preferably include:

[0116] (a) administering a unit dose of a modified BoNT / A to the lateral superior orbicularis oculi muscle proximal to a first eye of an individual (e.g., in the preseptal or orbital portion of the muscle, preferably the lateral superior preseptal orbicularis oculi muscle);

[0117] (b) administering a unit dose of a modified BoNT / A to the medial superior orbicularis oculi muscle proximal to a first eye of the individual (e.g., in the preseptal or orbital portion of the muscle, preferably the medial superior preseptal orbicularis oculi muscle); and

[0118] (c) administering a unit dose of the modified BoNT / A to the lateral inferior orbicularis oculi muscle proximal to the first eye of the individual (e.g., in the preseptal portion or the orbital portion of the muscle, preferably the lateral inferior orbicularis oculi muscle); in other words, the method of treating blepharospasm may preferably comprise administering a unit dose of the modified BoNT / A to each of the following sites:

[0119] (a) the lateral superior orbicularis oculi muscle proximal to the individual's first eye (e.g., in the preseptal or orbital portion of the muscle, preferably the lateral superior preseptal orbicularis oculi muscle);

[0120] (b) the medial superior orbicularis oculi muscle proximal to the individual's first eye (e.g., in the preseptal or orbital portion of the muscle, preferably the medial superior preseptal orbicularis oculi muscle); and

[0121] (c) the lateral inferior orbicularis oculi muscle proximal to the individual's first eye (e.g., in the preseptal or orbital portion of the muscle, preferably the lateral inferior orbicularis oculi muscle);

[0122] In one aspect, provided is a modified botulinum neurotoxin A (BoNT / A) for use in a method of treating blepharospasm in an individual, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of the individual, the method comprising:

[0123] a) administering a unit dose of a modified BoNT / A to the lateral superior orbicularis oculi muscle (preferably the lateral superior preseptal orbicularis oculi muscle) proximal to a first eye of the individual;

[0124] b) administering a unit dose of the modified BoNT / A to the medial superior orbicularis oculi muscle (preferably the medial superior preseptal orbicularis oculi muscle) proximal to a first eye of the individual; and

[0125] c) administering a unit dose of the modified BoNT / A to the lateral inferior orbicularis oculi muscle (preferably the lateral inferior preseptal orbicularis oculi muscle) proximal to the first eye of the individual;

[0126] wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A,

[0127] wherein the total dose administered during the treatment period is greater than 24,000 pg (e.g., preferably greater than 24,100 pg; more preferably greater than 35,000 pg) and at most 82,500 pg (e.g., at most 75,000 pg) of the modified BoNT / A, and

[0128] wherein the modified BoNT / A comprises a BoNT / A light chain and a translocation domain (H N ) and the BoNT / B receptor binding domain (H C domain).

[0129] In a related aspect, the present invention provides a modified botulinum neurotoxin A (BoNT / A) for use in a method of treating blepharospasm in an individual for a duration of treatment that is longer than the duration of treatment with an unmodified BoNT / A (e.g., SEQ ID NO: 2 [e.g., a di-chain form of SEQ ID NO: 2]), wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of the individual, the method comprising: a) administering a unit dose of the modified BoNT / A to a lateral superior orbicularis oculi muscle (preferably a lateral superior preseptal orbicularis oculi muscle) proximal to a first eye of the individual;

[0130] b) administering a unit dose of the modified BoNT / A to the medial superior orbicularis oculi muscle (preferably the medial superior preseptal orbicularis oculi muscle) proximal to a first eye of the individual; and

[0131] c) administering a unit dose of the modified BoNT / A to the lateral inferior orbicularis oculi muscle (preferably the lateral inferior preseptal orbicularis oculi muscle) proximal to the first eye of the individual;

[0132] wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A,

[0133] wherein the total dose administered during the treatment period is greater than 24,000 pg (e.g., preferably greater than 24,100 pg; more preferably greater than 35,000 pg) and at most 82,500 pg (e.g., at most 75,000 pg) of the modified BoNT / A, and

[0134] wherein the modified BoNT / A comprises a BoNT / A light chain and a translocation domain (H N ) and the BoNT / B receptor binding domain (H C domain).

[0135] In a related aspect, the present invention provides a method of treating blepharospasm in an individual, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of the individual, the method comprising:

[0136] a) administering a unit dose of a modified BoNT / A to the lateral superior orbicularis oculi muscle (preferably the lateral superior preseptal orbicularis oculi muscle) proximal to a first eye of the individual;

[0137] b) administering a unit dose of the modified BoNT / A to the medial superior orbicularis oculi muscle (preferably the medial superior preseptal orbicularis oculi muscle) proximal to a first eye of the individual; and

[0138] c) administering a unit dose of the modified BoNT / A to the lateral inferior orbicularis oculi muscle (preferably the lateral inferior preseptal orbicularis oculi muscle) proximal to the first eye of the individual,

[0139] wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A,

[0140] wherein the total dose administered during the treatment period is greater than 24,000 pg (e.g., preferably greater than 24,100 pg; more preferably greater than 35,000 pg) and at most 82,500 pg (e.g., at most 75,000 pg) of the modified BoNT / A, and

[0141] The modified BoNT / A comprises a BoNT / A light chain and a translocation domain (HN) and a BoNT / B receptor binding domain (HC domain).

[0142] In a related aspect, the invention provides a method of treating blepharospasm in an individual for a duration of treatment greater than the duration of treatment with an unmodified BoNT / A (e.g., SEQ ID NO: 2 [e.g., a di-chain form of SEQ ID NO: 2]), wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of the individual, the method comprising:

[0143] a) administering a unit dose of a modified BoNT / A to the lateral superior orbicularis oculi muscle (preferably the lateral superior preseptal orbicularis oculi muscle) proximal to a first eye of the individual;

[0144] b) administering a unit dose of the modified BoNT / A to the medial superior orbicularis oculi muscle (preferably the medial superior preseptal orbicularis oculi muscle) proximal to a first eye of the individual; and

[0145] c) administering a unit dose of the modified BoNT / A to the lateral inferior orbicularis oculi muscle (preferably the lateral inferior preseptal orbicularis oculi muscle) proximal to the first eye of the individual;

[0146] wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A,

[0147] wherein the total dose administered during the treatment period is greater than 24,000 pg (e.g., preferably greater than 24,100 pg; more preferably greater than 35,000 pg) and at most 82,500 pg (e.g., at most 75,000 pg) of the modified BoNT / A, and

[0148] The modified BoNT / A comprises a BoNT / A light chain and a translocation domain (HN) and a BoNT / B receptor binding domain (HC domain).

[0149] In one aspect, the present invention provides a use of a modified botulinum neurotoxin A (BoNT / A) in the preparation of a medicament for treating blepharospasm in an individual, comprising:

[0150] a) administering a unit dose of a modified BoNT / A to the lateral superior orbicularis oculi muscle (preferably the lateral superior preseptal orbicularis oculi muscle) proximal to a first eye of the individual;

[0151] b) administering a unit dose of the modified BoNT / A to the medial superior orbicularis oculi muscle (preferably the medial superior preseptal orbicularis oculi muscle) proximal to a first eye of the individual; and

[0152] c) administering a unit dose of the modified BoNT / A to the lateral inferior orbicularis oculi muscle (preferably the lateral inferior preseptal orbicularis oculi muscle) proximal to the first eye of the individual;

[0153] wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A,

[0154] wherein the total dose administered during the treatment period is greater than 24,000 pg (e.g., preferably greater than 24,100 pg; more preferably greater than 35,000 pg) and at most 82,500 pg (e.g., at most 75,000 pg) of the modified BoNT / A, and

[0155] The modified BoNT / A comprises a BoNT / A light chain and a translocation domain (HN) and a BoNT / B receptor binding domain (HC domain).

[0156] In one aspect, the present invention provides a use of a modified botulinum neurotoxin A (BoNT / A) in the preparation of a medicament for treating blepharospasm in an individual for a treatment duration longer than that of an unmodified BoNT / A (e.g., SEQ ID NO: 2 [e.g., a di-chain form of SEQ ID NO: 2]), comprising: a) administering a unit dose of the modified BoNT / A to a lateral superior orbicularis oculi muscle (preferably a lateral superior preseptal orbicularis oculi muscle) proximal to a first eye of the individual;

[0157] b) administering a unit dose of the modified BoNT / A to the medial superior orbicularis oculi muscle (preferably the medial superior preseptal orbicularis oculi muscle) proximal to a first eye of the individual; and

[0158] c) administering a unit dose of the modified BoNT / A to the lateral inferior orbicularis oculi muscle (preferably the lateral inferior preseptal orbicularis oculi muscle) proximal to the first eye of the individual;

[0159] wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A,

[0160] wherein the total dose administered during the treatment period is greater than 24,000 pg (e.g., preferably greater than 24,100 pg; more preferably greater than 35,000 pg) and at most 82,500 pg (e.g., at most 75,000 pg) of the modified BoNT / A, and

[0161] The modified BoNT / A comprises a BoNT / A light chain and a translocation domain (HN) and a BoNT / B receptor binding domain (HC domain).

[0162] In one aspect, a modified botulinum neurotoxin A (BoNT / A) is provided for use in a method of treating classic hemifacial spasm, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of an individual, the method comprising:

[0163] (a) administering a unit dose of a modified BoNT / A at each of up to six different injection sites proximate to the superior orbicularis oculi muscle of a first eye of the individual, wherein the up to six different injection sites are selected from:

[0164] (i) the medial superior orbicularis oculi muscle (e.g., in the preseptal or orbital portion of the muscle, preferably the preseptal portion);

[0165] (ii) supraorbital orbicularis oculi;

[0166] (iii) the lateral superior orbicularis oculi muscle (e.g., in the preseptal or orbital portion of the muscle, preferably the preseptal portion);

[0167] (iv) lateral orbital orbicularis oculi;

[0168] (v) medial superior tarsal preorbital orbicularis oculi muscle; and

[0169] (vi) lateral superior tarsal preorbital orbicularis oculi muscle; and / or

[0170] (b) administering a unit dose of a modified BoNT / A at each of up to two different injection sites proximate to the inferior orbicularis oculi muscle of a first eye of the individual, wherein the up to two different injection sites are selected from:

[0171] (i) the medial inferior orbicularis oculi muscle (e.g., in the preseptal or orbital portion of the muscle, preferably the preseptal portion); and

[0172] (ii) the lateral inferior orbicularis oculi muscle (e.g., in the preseptal or orbital portion of the muscle, preferably the preseptal portion); and / or

[0173] (c) administering a unit dose of a modified BoNT / A at up to two different injection sites selected from:

[0174] (i) two different injection sites on the corrugator supercilii muscle proximal to the subject's first eye; and

[0175] (ii) a site on the procerus muscle near the subject's first eye; and / or

[0176] (d) administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by said hemifacial spasm according to the following dosing regimen:

[0177] (i) applying one unit dose to the superior orbicularis oris muscle;

[0178] (ii) administering one unit dose to the inferior orbicularis oris muscle;

[0179] (iii) administering a unit dose to the zygomaticus major muscle;

[0180] (iv) administering a unit dose to the zygomaticus minor muscle;

[0181] (v) administering up to five unit doses (preferably one unit dose) to the frontalis muscle;

[0182] (vi) administering a unit dose to the mentalis muscle;

[0183] (vii) administering a unit dose to the platysma muscle;

[0184] (viii) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle;

[0185] (ix) administering a unit dose to the buccinator muscle;

[0186] (x) administering up to two unit doses (preferably one unit dose) to the masseter muscle;

[0187] (xi) administering a unit dose to the procerus muscle;

[0188] (xii) administering a unit dose to the nasal muscle; and / or

[0189] (xiii) administering one unit dose to the levator palpebrae superioris muscle;

[0190] wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A, wherein the total dose administered during the treatment period is greater than 24,000 pg and up to 82,500 pg (e.g., up to 75,000 pg) of the modified BoNT / A, and wherein the modified BoNT / A comprises a botulinum neurotoxin A (BoNT / A) light chain and a translocation domain (H N ) and the BoNT / B receptor binding domain (H C domain).

[0191] In one aspect, a method of treating classic hemifacial spasm is provided, the method comprising administering a modified BoNT / A by intramuscular injection at multiple sites on the face of an individual, the method comprising:

[0192] (a) administering a unit dose of a modified BoNT / A at each of up to six different injection sites proximate to the superior orbicularis oculi muscle of a first eye of the individual, wherein the up to six different injection sites are selected from:

[0193] (i) the medial superior orbicularis oculi muscle (e.g., in the preseptal or orbital portion of the muscle, preferably the preseptal portion);

[0194] (ii) supraorbital orbicularis oculi;

[0195] (iii) the lateral superior orbicularis oculi muscle (e.g., in the preseptal or orbital portion of the muscle, preferably the preseptal portion);

[0196] (iv) lateral orbital orbicularis oculi;

[0197] (v) medial superior tarsal preorbital orbicularis oculi muscle; and

[0198] (vi) lateral superior tarsal preorbital orbicularis oculi muscle; and / or

[0199] (b) administering a unit dose of a modified BoNT / A at each of up to two different injection sites proximate to the inferior orbicularis oculi muscle of a first eye of the individual, wherein the up to two different injection sites are selected from:

[0200] (i) the medial inferior orbicularis oculi muscle (e.g., in the preseptal or orbital portion of the muscle, preferably the preseptal portion); and

[0201] (ii) the lateral inferior orbicularis oculi muscle (e.g., in the preseptal or orbital portion of the muscle, preferably the preseptal portion); and / or

[0202] (c) administering a unit dose of a modified BoNT / A at up to two different injection sites selected from:

[0203] (i) two different injection sites on the corrugator supercilii muscle proximal to the subject's first eye; and

[0204] (ii) a site on the procerus muscle near the subject's first eye; and / or

[0205] (d) administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by said hemifacial spasm according to the following dosing regimen:

[0206] (i) administering one unit dose to the superior orbicularis oris muscle;

[0207] (ii) administering one unit dose to the inferior orbicularis oris muscle;

[0208] (iii) administering a unit dose to the zygomaticus major muscle;

[0209] (iv) administering a unit dose to the zygomaticus minor muscle;

[0210] (v) administering up to five unit doses (preferably one unit dose) to the frontalis muscle;

[0211] (vi) administering a unit dose to the mentalis muscle;

[0212] (vii) administering a unit dose to the platysma muscle;

[0213] (viii) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle;

[0214] (ix) administering a unit dose to the buccinator muscle;

[0215] (x) administering up to two unit doses (preferably one unit dose) to the masseter muscle;

[0216] (xi) administering a unit dose to the procerus muscle;

[0217] (xii) administering a unit dose to the nasal muscle; and / or

[0218] (xiii) administering one unit dose to the levator palpebrae superioris muscle;

[0219] wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A, wherein the total dose administered during the treatment period is greater than 24,000 pg and up to 82,500 pg (e.g., up to 75,000 pg) of the modified BoNT / A, and wherein the modified BoNT / A comprises a botulinum neurotoxin A (BoNT / A) light chain and a translocation domain (H N ) and the BoNT / B receptor binding domain (H C domain).

[0220] In one aspect, there is provided a use of a modified botulinum neurotoxin A (BoNT / A) in the preparation of a medicament for treating classic hemifacial spasm, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of an individual, the treatment comprising:

[0221] (a) administering a unit dose of a modified BoNT / A at each of up to six different injection sites proximate to the superior orbicularis oculi muscle of a first eye of the individual, wherein the up to six different injection sites are selected from:

[0222] (i) the medial superior orbicularis oculi muscle (e.g., in the preseptal or orbital portion of the muscle, preferably the preseptal portion);

[0223] (ii) supraorbital orbicularis oculi;

[0224] (iii) the lateral superior orbicularis oculi muscle (e.g., in the preseptal or orbital portion of the muscle, preferably the preseptal portion);

[0225] (iv) lateral orbital orbicularis oculi;

[0226] (v) medial superior tarsal preorbital orbicularis oculi muscle; and

[0227] (vi) lateral superior tarsal preorbital orbicularis oculi muscle; and / or

[0228] (b) administering a unit dose of a modified BoNT / A at each of up to two different injection sites proximate to the inferior orbicularis oculi muscle of a first eye of the individual, wherein the up to two different injection sites are selected from:

[0229] (i) the medial inferior orbicularis oculi muscle (e.g., in the preseptal or orbital portion of the muscle, preferably the preseptal portion); and

[0230] (ii) the lateral inferior orbicularis oculi muscle (e.g., in the preseptal or orbital portion of the muscle, preferably the preseptal portion); and / or

[0231] (c) administering a unit dose of a modified BoNT / A at up to two different injection sites selected from:

[0232] (i) two different injection sites on the corrugator supercilii muscle proximal to the subject's first eye; and

[0233] (ii) an injection site on the procerus muscle proximal to the subject's first eye; and / or

[0234] (d) administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by said hemifacial spasm according to the following dosing regimen:

[0235] (i) administering one unit dose to the superior orbicularis oris muscle;

[0236] (ii) administering one unit dose to the inferior orbicularis oris muscle;

[0237] (iii) administering a unit dose to the zygomaticus major muscle;

[0238] (iv) administering a unit dose to the zygomaticus minor muscle;

[0239] (v) administering up to five unit doses (preferably one unit dose) to the frontalis muscle;

[0240] (vi) administering a unit dose to the mentalis muscle;

[0241] (vii) administering a unit dose to the platysma muscle;

[0242] (viii) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle;

[0243] (ix) administering a unit dose to the buccinator muscle;

[0244] (x) administering up to two unit doses (preferably one unit dose) to the masseter muscle;

[0245] (xi) administering a unit dose to the procerus muscle;

[0246] (xii) administering a unit dose to the nasal muscle; and / or

[0247] (xiii) administering one unit dose to the levator palpebrae superioris muscle;

[0248] wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A, wherein the total dose administered during the treatment period is greater than 24,000 pg and up to 82,500 pg (e.g., up to 75,000 pg) of the modified BoNT / A, and wherein the modified BoNT / A comprises a botulinum neurotoxin A (BoNT / A) light chain and a translocation domain (H N ) and the BoNT / B receptor binding domain (H C domain).

[0249] The modified BoNT / A may preferably be administered by intramuscular injection at at least six different sites on the face of an individual. In other words, the modified BoNT / A may preferably be administered by intramuscular injection to at least six different sites on the face of an individual. In yet other words, the number of different injection sites at which a unit dose is administered may preferably be at least six.

[0250] Treatment of typical hemifacial spasm may preferably include:

[0251] (a) administering a unit dose of a modified BoNT / A to the lateral superior orbicularis oculi muscle proximal to a first eye of an individual (e.g., in the preseptal or orbital portion of the muscle, preferably the lateral superior preseptal orbicularis oculi muscle);

[0252] (b) administering a unit dose of a modified BoNT / A to the medial superior orbicularis oculi muscle proximal to a first eye of the individual (e.g., in the preseptal or orbital portion of the muscle, preferably the medial superior preseptal orbicularis oculi muscle); and

[0253] (c) administering a unit dose of a modified BoNT / A to the lateral inferior orbicularis oculi muscle proximal to a first eye of the individual (e.g., in the preseptal or orbital portion of the muscle, preferably the lateral inferior orbicularis oculi muscle);

[0254] In other words, the method of treating classic hemifacial spasm may preferably include administering a unit dose of the modified BoNT / A to each of the following sites:

[0255] (a) the lateral superior orbicularis oculi muscle proximal to the individual's first eye (e.g., in the preseptal or orbital portion of the muscle, preferably the lateral superior preseptal orbicularis oculi muscle);

[0256] (b) the medial superior orbicularis oculi muscle proximal to the individual's first eye (e.g., in the preseptal or orbital portion of the muscle, preferably the medial superior preseptal orbicularis oculi muscle); and

[0257] (c) the lateral inferior orbicularis oculi muscle proximal to the individual's first eye (e.g., in the preseptal or orbital portion of the muscle, preferably the lateral inferior orbicularis oculi muscle);

[0258] In another aspect, provided is a modified botulinum neurotoxin A (BoNT / A) for use in a method of treating classic hemifacial spasm, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of an individual, the method comprising:

[0259] a) administering a unit dose of a modified BoNT / A to the lateral superior orbicularis oculi muscle (preferably the lateral superior preseptal orbicularis oculi muscle) proximal to the eye affected by hemifacial spasm;

[0260] b) administering a unit dose of the modified BoNT / A to the medial superior orbicularis oculi muscle (preferably the medial superior preseptal orbicularis oculi muscle) proximal to the eye affected by hemifacial spasm;

[0261] c) administering a unit dose of the modified BoNT / A to the lateral inferior orbicularis oculi muscle (preferably the lateral inferior preseptal orbicularis oculi muscle) proximal to the eye affected by hemifacial spasm; and

[0262] d) administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by said hemifacial spasm according to the following dosing regimen:

[0263] (i) administering one unit dose to the superior orbicularis oris muscle;

[0264] (ii) administering one unit dose to the inferior orbicularis oris muscle;

[0265] (iii) administering a unit dose to the zygomaticus major muscle;

[0266] (iv) administering a unit dose to the zygomaticus minor muscle;

[0267] (v) administering up to five unit doses (preferably one unit dose) to the frontalis muscle;

[0268] (vi) administering a unit dose to the mentalis muscle;

[0269] (vii) administering a unit dose to the platysma muscle;

[0270] (viii) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle;

[0271] (ix) administering a unit dose to the buccinator muscle;

[0272] (x) administering up to two unit doses (preferably one unit dose) to the masseter muscle;

[0273] (xi) administering a unit dose to the procerus muscle;

[0274] (xii) administering a unit dose to the nasal muscle; and / or

[0275] (xiii) administering one unit dose to the levator palpebrae superioris muscle;

[0276] wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A,

[0277] wherein the total dose administered during the treatment period is greater than 24,000 pg (e.g., preferably greater than 24,100 pg; more preferably greater than 35,000 pg) and at most 82,500 pg (e.g., at most 75,000 pg) of the modified BoNT / A, and

[0278] The modified BoNT / A comprises a BoNT / A light chain and a translocation domain (HN) and a BoNT / B receptor binding domain (HC domain).

[0279] In a related aspect, the present invention provides a modified botulinum neurotoxin A (BoNT / A) for use in a method of treating classic hemifacial spasm in an individual for a duration of treatment greater than the duration of treatment with an unmodified BoNT / A (e.g., SEQ ID NO: 2 [e.g., a di-chain form of SEQ ID NO: 2]), wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of the individual, the method comprising:

[0280] a) administering a unit dose of a modified BoNT / A to the lateral superior orbicularis oculi muscle (preferably the lateral superior preseptal orbicularis oculi muscle) proximal to the eye affected by hemifacial spasm;

[0281] b) administering a unit dose of the modified BoNT / A to the medial superior orbicularis oculi muscle (preferably the medial superior preseptal orbicularis oculi muscle) proximal to the eye affected by hemifacial spasm;

[0282] c) administering a unit dose of the modified BoNT / A to the lateral inferior orbicularis oculi muscle proximal to the eye affected by hemifacial spasm; and

[0283] d) administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by said hemifacial spasm (preferably the lateral inferior orbital septal preorbicularis oculi muscle) according to the following dosing regimen:

[0284] (i) administering one unit dose to the superior orbicularis oris muscle;

[0285] (ii) administering one unit dose to the inferior orbicularis oris muscle;

[0286] (iii) administering a unit dose to the zygomaticus major muscle;

[0287] (iv) administering a unit dose to the zygomaticus minor muscle;

[0288] (v) administering up to five unit doses (preferably one unit dose) to the frontalis muscle;

[0289] (vi) administering a unit dose to the mentalis muscle;

[0290] (vii) administering a unit dose to the platysma muscle;

[0291] (viii) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle;

[0292] (ix) administering a unit dose to the buccinator muscle;

[0293] (x) administering up to two unit doses (preferably one unit dose) to the masseter muscle;

[0294] (xi) administering a unit dose to the procerus muscle;

[0295] (xii) administering a unit dose to the nasal muscle; and / or

[0296] (xiii) administering one unit dose to the levator palpebrae superioris muscle;

[0297] wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A,

[0298] wherein the total dose administered during the treatment period is greater than 24,000 pg (e.g., preferably greater than 24,100 pg; more preferably greater than 35,000 pg) and at most 82,500 pg (e.g., at most 75,000 pg) of the modified BoNT / A, and

[0299] The modified BoNT / A comprises a BoNT / A light chain and a translocation domain (HN) and a BoNT / B receptor binding domain (HC domain).

[0300] In a related aspect, the present invention provides a method of treating classic hemifacial spasm in an individual, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of the individual, the method comprising:

[0301] a) administering a unit dose of a modified BoNT / A to the lateral superior orbicularis oculi muscle (preferably the lateral superior preseptal orbicularis oculi muscle) proximal to the eye affected by hemifacial spasm;

[0302] b) administering a unit dose of the modified BoNT / A to the medial superior orbicularis oculi muscle (preferably the medial superior preseptal orbicularis oculi muscle) proximal to the eye affected by hemifacial spasm;

[0303] c) administering a unit dose of the modified BoNT / A to the lateral inferior orbicularis oculi muscle (preferably the lateral inferior preseptal orbicularis oculi muscle) proximal to the eye affected by hemifacial spasm; and

[0304] d) administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by said hemifacial spasm according to the following dosing regimen:

[0305] (i) administering one unit dose to the superior orbicularis oris muscle;

[0306] (ii) administering one unit dose to the inferior orbicularis oris muscle;

[0307] (iii) administering a unit dose to the zygomaticus major muscle;

[0308] (iv) administering a unit dose to the zygomaticus minor muscle;

[0309] (v) administering up to five unit doses (preferably one unit dose) to the frontalis muscle;

[0310] (vi) administering a unit dose to the mentalis muscle;

[0311] (vii) administering a unit dose to the platysma muscle;

[0312] (viii) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle;

[0313] (ix) administering a unit dose to the buccinator muscle;

[0314] (x) administering up to two unit doses (preferably one unit dose) to the masseter muscle;

[0315] (xi) administering a unit dose to the procerus muscle;

[0316] (xii) administering a unit dose to the nasal muscle; and / or

[0317] (xiii) administering one unit dose to the levator palpebrae superioris muscle;

[0318] wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A,

[0319] wherein the total dose administered during the treatment period is greater than 24,000 pg (e.g., preferably greater than 24,100 pg; more preferably greater than 35,000 pg) and at most 82,500 pg (e.g., at most 75,000 pg) of the modified BoNT / A, and

[0320] The modified BoNT / A comprises a BoNT / A light chain and a translocation domain (HN) and a BoNT / B receptor binding domain (HC domain).

[0321] In a related aspect, the present invention provides a method of treating classic hemifacial spasm in an individual for a duration of treatment that is longer than the duration of treatment with an unmodified BoNT / A (e.g., SEQ ID NO: 2 [e.g., a di-chain form of SEQ ID NO: 2]), wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of the individual, the method comprising:

[0322] a) administering a unit dose of a modified BoNT / A to the lateral superior orbicularis oculi muscle (preferably the lateral superior preseptal orbicularis oculi muscle) proximal to the eye affected by hemifacial spasm;

[0323] b) administering a unit dose of the modified BoNT / A to the medial superior orbicularis oculi muscle (preferably the medial superior preseptal orbicularis oculi muscle) proximal to the eye affected by hemifacial spasm;

[0324] c) administering a unit dose of the modified BoNT / A to the lateral inferior orbicularis oculi muscle (preferably the lateral inferior preseptal orbicularis oculi muscle) proximal to the eye affected by hemifacial spasm; and

[0325] d) administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by said hemifacial spasm according to the following dosing regimen:

[0326] (i) administering one unit dose to the superior orbicularis oris muscle;

[0327] (ii) administering one unit dose to the inferior orbicularis oris muscle;

[0328] (iii) administering a unit dose to the zygomaticus major muscle;

[0329] (iv) administering a unit dose to the zygomaticus minor muscle;

[0330] (v) administering up to five unit doses (preferably one unit dose) to the frontalis muscle;

[0331] (vi) administering a unit dose to the mentalis muscle;

[0332] (vii) administering a unit dose to the platysma muscle;

[0333] (viii) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle;

[0334] (ix) administering a unit dose to the buccinator muscle;

[0335] (x) administering up to two unit doses (preferably one unit dose) to the masseter muscle;

[0336] (xi) administering a unit dose to the procerus muscle;

[0337] (xii) administering a unit dose to the nasal muscle; and / or

[0338] (xiii) administering one unit dose to the levator palpebrae superioris muscle;

[0339] wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A,

[0340] wherein the total dose administered during the treatment period is greater than 24,000 pg (e.g., preferably greater than 24,100 pg; more preferably greater than 35,000 pg) and at most 82,500 pg (e.g., at most 75,000 pg) of the modified BoNT / A, and

[0341] The modified BoNT / A comprises a BoNT / A light chain and a translocation domain (HN) and a BoNT / B receptor binding domain (HC domain).

[0342] In one aspect, the present invention provides a use of a modified botulinum neurotoxin A (BoNT / A) in the preparation of a medicament for treating classic hemifacial spasm in an individual, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of the individual, comprising:

[0343] a) administering a unit dose of a modified BoNT / A to the lateral superior orbicularis oculi muscle (preferably the lateral superior preseptal orbicularis oculi muscle) proximal to the eye affected by hemifacial spasm;

[0344] b) administering a unit dose of the modified BoNT / A to the medial superior orbicularis oculi muscle (preferably the medial superior preseptal orbicularis oculi muscle) proximal to the eye affected by hemifacial spasm;

[0345] c) administering a unit dose of the modified BoNT / A to the lateral inferior orbicularis oculi muscle (preferably the lateral inferior preseptal orbicularis oculi muscle) proximal to the eye affected by hemifacial spasm; and

[0346] d) administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by said hemifacial spasm according to the following dosing regimen:

[0347] (i) administering one unit dose to the superior orbicularis oris muscle;

[0348] (ii) administering one unit dose to the inferior orbicularis oris muscle;

[0349] (iii) administering a unit dose to the zygomaticus major muscle;

[0350] (iv) administering a unit dose to the zygomaticus minor muscle;

[0351] (v) administering up to five unit doses (preferably one unit dose) to the frontalis muscle;

[0352] (vi) administering a unit dose to the mentalis muscle;

[0353] (vii) administering a unit dose to the platysma muscle;

[0354] (viii) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle;

[0355] (ix) administering a unit dose to the buccinator muscle;

[0356] (x) administering up to two unit doses (preferably one unit dose) to the masseter muscle;

[0357] (xi) administering a unit dose to the procerus muscle;

[0358] (xii) administering a unit dose to the nasal muscle; and / or

[0359] (xiii) administering one unit dose to the levator palpebrae superioris muscle;

[0360] wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A,

[0361] wherein the total dose administered during the treatment period is greater than 24,000 pg (e.g., preferably greater than 24,100 pg; more preferably greater than 35,000 pg) and at most 82,500 pg (e.g., at most 75,000 pg) of the modified BoNT / A, and

[0362] The modified BoNT / A comprises a BoNT / A light chain and a translocation domain (HN) and a BoNT / B receptor binding domain (HC domain).

[0363] In one aspect, the present invention provides a use of a modified botulinum neurotoxin A (BoNT / A) for the preparation of a medicament for treating classic hemifacial spasm in an individual for a longer duration of treatment than the duration of treatment with an unmodified BoNT / A (e.g., SEQ ID NO: 2 [e.g., a di-chain form of SEQ ID NO: 2]), wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of the individual, comprising:

[0364] a) administering a unit dose of a modified BoNT / A to the lateral superior orbicularis oculi muscle (preferably the lateral superior preseptal orbicularis oculi muscle) proximal to the eye affected by hemifacial spasm;

[0365] b) administering a unit dose of the modified BoNT / A to the medial superior orbicularis oculi muscle (preferably the medial superior preseptal orbicularis oculi muscle) proximal to the eye affected by hemifacial spasm;

[0366] c) administering a unit dose of the modified BoNT / A to the lateral inferior orbicularis oculi muscle (preferably the lateral inferior preseptal orbicularis oculi muscle) proximal to the eye affected by hemifacial spasm; and

[0367] d) administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by said hemifacial spasm according to the following dosing regimen:

[0368] (i) administering one unit dose to the superior orbicularis oris muscle;

[0369] (ii) administering one unit dose to the inferior orbicularis oris muscle;

[0370] (iii) administering a unit dose to the zygomaticus major muscle;

[0371] (iv) administering a unit dose to the zygomaticus minor muscle;

[0372] (v) administering up to five unit doses (preferably one unit dose) to the frontalis muscle;

[0373] (vi) administering a unit dose to the mentalis muscle;

[0374] (vii) administering a unit dose to the platysma muscle;

[0375] (viii) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle;

[0376] (ix) administering a unit dose to the buccinator muscle;

[0377] (x) administering up to two unit doses (preferably one unit dose) to the masseter muscle;

[0378] (xi) administering a unit dose to the procerus muscle;

[0379] (xii) administering a unit dose to the nasal muscle; and / or

[0380] (xiii) administering one unit dose to the levator palpebrae superioris muscle;

[0381] wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A,

[0382] wherein the total dose administered during the treatment period is greater than 24,000 pg (e.g., preferably greater than 24,100 pg; more preferably greater than 35,000 pg) and at most 82,500 pg (e.g., at most 75,000 pg) of the modified BoNT / A, and

[0383] The modified BoNT / A comprises a BoNT / A light chain and a translocation domain (HN) and a BoNT / B receptor binding domain (HC domain).

[0384] In one aspect, a modified botulinum neurotoxin A (BoNT / A) is provided for use in treating atypical hemifacial spasm, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of an individual, the method comprising:

[0385] a) administering a unit dose of a modified BoNT / A to the orbicularis oris muscle affected by hemifacial spasm (e.g., administering one unit dose of the modified BoNT / A to the upper orbicularis oris muscle and / or administering one unit dose to the lower orbicularis oris muscle affected by hemifacial spasm; preferably administering one unit dose of the modified BoNT / A to the upper orbicularis oris muscle and one unit dose to the lower orbicularis oris muscle affected by said hemifacial spasm); and

[0386] b) optionally, administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by said hemifacial spasm according to the following dosing regimen:

[0387] (i) administering a unit dose to the zygomaticus major muscle;

[0388] (ii) administering a unit dose to the zygomaticus minor muscle;

[0389] (iii) administering up to five unit doses (preferably one unit dose) to the frontalis muscle;

[0390] (iv) administering a unit dose to the mentalis muscle;

[0391] (v) administering a unit dose to the platysma muscle;

[0392] (vi) administering a unit dose to the buccinator muscle;

[0393] (vii) administering up to two unit doses (preferably one unit dose) to the masseter muscle;

[0394] (viii) administering a unit dose to the nasal muscle;

[0395] (ix) administering a unit dose to the levator palpebrae superioris muscle; and / or

[0396] c) optionally, administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by said hemifacial spasm according to the following dosing regimen:

[0397] The unit dose is injected at each of up to six different injection sites in the superior orbicularis oculi muscle, selected from:

[0398] (i) the medial superior orbicularis oculi muscle (e.g., in the preseptal or orbital portion of the muscle, preferably the orbital portion);

[0399] (ii) supraorbital orbicularis oculi;

[0400] (iii) the lateral superior orbicularis oculi muscle (e.g., in the preseptal or orbital portion of the muscle, preferably the preseptal portion);

[0401] (iv) lateral orbital orbicularis oculi;

[0402] (v) medial superior tarsal preorbital orbicularis oculi muscle; and

[0403] (vi) lateral superior tarsal preorbital orbicularis oculi muscle; and / or

[0404] The unit dose is injected at up to two different injection sites in the inferior orbicularis oculi muscle, each selected from:

[0405] (i) the medial inferior orbicularis oculi muscle (e.g., in the preseptal or orbital portion of the muscle, preferably the preseptal portion); and

[0406] (ii) the lateral inferior orbicularis oculi muscle (e.g., in the preseptal or orbital portion of the muscle, preferably the preseptal portion); and / or

[0407] The unit dose is injected at up to two different injection sites, each selected from:

[0408] (i) two different injection sites in the corrugator supercilii muscle; and

[0409] (ii) one injection site in the procerus muscle;

[0410] wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A, wherein the total dose administered during the treatment period is greater than 24,000 pg and up to 82,500 pg (e.g., up to 75,000 pg) of the modified BoNT / A, and wherein the modified BoNT / A comprises a botulinum neurotoxin A (BoNT / A) light chain and a translocation domain (H N ) and the BoNT / B receptor binding domain (H C domain).

[0411] In one aspect, a method of treating atypical hemifacial spasm is provided, the method comprising administering a modified BoNT / A by intramuscular injection at multiple sites on the face of an individual, the method comprising:

[0412] a) administering a unit dose of a modified BoNT / A to the orbicularis oris muscle affected by hemifacial spasm (e.g., administering one unit dose of the modified BoNT / A to the upper orbicularis oris muscle and / or administering one unit dose to the lower orbicularis oris muscle affected by hemifacial spasm; preferably administering one unit dose of the modified BoNT / A to the upper orbicularis oris muscle and one unit dose to the lower orbicularis oris muscle affected by said hemifacial spasm); and

[0413] b) optionally, administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by said hemifacial spasm according to the following dosing regimen:

[0414] (x) administering a unit dose to the zygomatic major muscle;

[0415] (xi) administering a unit dose to the zygomaticus minor muscle;

[0416] (xii) administering up to five unit doses (preferably one unit dose) to the frontalis muscle;

[0417] (xiii) administering a unit dose to the mentalis muscle;

[0418] (xiv) administering a unit dose to the platysma muscle;

[0419] (xv) administering a unit dose to the buccinator muscle;

[0420] (xvi) administering up to two unit doses (preferably one unit dose) to the masseter muscle;

[0421] (xvii) administering a unit dose to the nasal muscle;

[0422] (xviii) administering a unit dose to the levator palpebrae superioris muscle; and / or

[0423] c) optionally, administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by said hemifacial spasm according to the following dosing regimen:

[0424] The unit dose is injected at each of up to six different injection sites in the superior orbicularis oculi muscle, selected from:

[0425] (i) the medial superior orbicularis oculi muscle (e.g., in the preseptal or orbital portion of the muscle, preferably the preseptal portion);

[0426] (ii) supraorbital orbicularis oculi;

[0427] (iii) the lateral superior orbicularis oculi muscle (e.g., in the preseptal or orbital portion of the muscle, preferably the orbital portion);

[0428] (iv) lateral orbital orbicularis oculi;

[0429] (v) medial superior tarsal preorbital orbicularis oculi muscle; and

[0430] (vi) lateral superior tarsal preorbital orbicularis oculi muscle; and / or

[0431] The unit dose is injected at up to two different injection sites in the inferior orbicularis oculi muscle, each selected from:

[0432] (i) the medial inferior orbicularis oculi muscle (e.g., in the preseptal or orbital portion of the muscle, preferably the preseptal portion); and

[0433] (ii) the lateral inferior orbicularis oculi muscle (e.g., in the preseptal or orbital portion of the muscle, preferably the preseptal portion); and / or

[0434] The unit dose is injected at up to two different injection sites, each selected from:

[0435] (i) two different injection sites in the corrugator supercilii muscle; and

[0436] (ii) a part of the procerus muscle;

[0437] wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A, wherein the total dose administered during the treatment period is greater than 24,000 pg and up to 82,500 pg (e.g., up to 75,000 pg) of the modified BoNT / A, and wherein the modified BoNT / A comprises a botulinum neurotoxin A (BoNT / A) light chain and a translocation domain (H N ) and the BoNT / B receptor binding domain (H C domain).

[0438] In one aspect, there is provided a use of a modified botulinum neurotoxin A (BoNT / A) in the preparation of a medicament for treating atypical hemifacial spasm, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of an individual, the treatment comprising:

[0439] a) administering a unit dose of a modified BoNT / A to the orbicularis oris muscle affected by hemifacial spasm (e.g., administering one unit dose of the modified BoNT / A to the upper orbicularis oris muscle and / or administering one unit dose to the lower orbicularis oris muscle affected by hemifacial spasm; preferably administering one unit dose of the modified BoNT / A to the upper orbicularis oris muscle and one unit dose to the lower orbicularis oris muscle affected by said hemifacial spasm); and

[0440] b) optionally, administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by said hemifacial spasm according to the following dosing regimen:

[0441] (i) administering a unit dose to the zygomaticus major muscle;

[0442] (ii) administering a unit dose to the zygomaticus minor muscle;

[0443] (iii) administering up to five unit doses (preferably one unit dose) to the frontalis muscle;

[0444] (iv) administering a unit dose to the mentalis muscle;

[0445] (v) administering a unit dose to the platysma muscle;

[0446] (vi) administering a unit dose to the buccinator muscle;

[0447] (vii) administering up to two unit doses (preferably one unit dose) to the masseter muscle;

[0448] (viii) administering a unit dose to the nasal muscle;

[0449] (ix) administering a unit dose to the levator palpebrae superioris muscle; and / or

[0450] c) optionally, administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by said hemifacial spasm according to the following dosing regimen:

[0451] The unit dose is injected at each of up to six different injection sites in the superior orbicularis oculi muscle, selected from:

[0452] (i) the medial superior orbicularis oculi muscle (e.g., in the preseptal or orbital portion of the muscle, preferably the preseptal portion);

[0453] (ii) supraorbital orbicularis oculi;

[0454] (iii) the lateral superior orbicularis oculi muscle (e.g., in the preseptal or orbital portion of the muscle, preferably the preseptal portion);

[0455] (iv) lateral orbital orbicularis oculi;

[0456] (v) medial superior tarsal preorbital orbicularis oculi muscle; and

[0457] (vi) lateral superior tarsal preorbital orbicularis oculi muscle; and / or

[0458] The unit dose is injected at up to two different injection sites in the inferior orbicularis oculi muscle, each selected from:

[0459] (i) the medial inferior orbicularis oculi muscle (e.g., in the preseptal or orbital portion of the muscle, preferably the preseptal portion); and

[0460] (ii) the lateral inferior orbicularis oculi muscle (e.g., in the preseptal or orbital portion of the muscle, preferably the preseptal portion); and / or

[0461] The unit dose is injected at up to two different injection sites, each selected from:

[0462] (i) two different injection sites in the corrugator supercilii muscle; and

[0463] (ii) one injection site in the procerus muscle;

[0464] wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A, wherein the total dose administered during the treatment period is greater than 24,000 pg and up to 82,500 pg (e.g., up to 75,000 pg) of the modified BoNT / A, and wherein the modified BoNT / A comprises a botulinum neurotoxin A (BoNT / A) light chain and a translocation domain (HN ) and the BoNT / B receptor binding domain (H C domain).

[0465] In another aspect, provided is a modified botulinum neurotoxin A (BoNT / A) for use in a method of treating atypical hemifacial spasm, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of an individual, the method comprising:

[0466] a) administering a unit dose of a modified BoNT / A to the orbicularis oris muscle affected by said hemifacial spasm (e.g., administering one unit dose of the modified BoNT / A to the upper orbicularis oris muscle and / or administering one unit dose to the lower orbicularis oris muscle affected by said hemifacial spasm; preferably administering one unit dose of the modified BoNT / A to the upper orbicularis oris muscle and one unit dose to the lower orbicularis oris muscle affected by said hemifacial spasm); and

[0467] b) optionally, administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by said hemifacial spasm according to the following dosing regimen:

[0468] (i) administering a unit dose to the zygomaticus major muscle;

[0469] (ii) administering a unit dose to the zygomaticus major muscle;

[0470] (iii) administering up to five unit doses (preferably one unit dose) to the frontalis muscle;

[0471] (iv) administering a unit dose to the mentalis muscle;

[0472] (v) administering a unit dose to the platysma muscle;

[0473] (vi) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle;

[0474] (vii) administering a unit dose to the buccinator muscle;

[0475] (viii) administering up to two unit doses (preferably one unit dose) to the masseter muscle;

[0476] (ix) administering a unit dose to the procerus muscle;

[0477] (x) administering a unit dose to the nasal muscle;

[0478] (xi) administering one unit dose to the lateral superior orbicularis oculi muscle;

[0479] (xii) administering one unit dose to the medial superior orbicularis oculi muscle;

[0480] (xiii) administering a unit dose to the lateral inferior orbicularis oculi muscle; and / or

[0481] (xiv) administering a unit dose to the levator palpebrae superioris muscle;

[0482] wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A,

[0483] wherein the total dose administered during the treatment period is greater than 24,000 pg (e.g., preferably greater than 24,100 pg; more preferably greater than 35,000 pg) and at most 82,500 pg (e.g., at most 75,000 pg) of the modified BoNT / A, and

[0484] The modified BoNT / A comprises a BoNT / A light chain and a translocation domain (HN) and a BoNT / B receptor binding domain (HC domain).

[0485] In a related aspect, the present invention provides a modified botulinum neurotoxin A (BoNT / A) for use in a method of treating atypical hemifacial spasm in an individual for a duration of treatment greater than the duration of treatment with an unmodified BoNT / A (e.g., SEQ ID NO: 2 [e.g., a di-chain form of SEQ ID NO: 2]), wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of the individual, the method comprising:

[0486] a) administering a unit dose of a modified BoNT / A to the orbicularis oris muscle affected by said hemifacial spasm (e.g., administering one unit dose of the modified BoNT / A to the upper orbicularis oris muscle and / or administering one unit dose to the lower orbicularis oris muscle affected by said hemifacial spasm; preferably administering one unit dose of the modified BoNT / A to the upper orbicularis oris muscle and one unit dose to the lower orbicularis oris muscle affected by said hemifacial spasm); and

[0487] b) optionally, administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by said hemifacial spasm according to the following dosing regimen:

[0488] (i) administering a unit dose to the zygomaticus major muscle;

[0489] (ii) administering a unit dose to the zygomaticus major muscle;

[0490] (iii) administering up to five unit doses (preferably one unit dose) to the frontalis muscle;

[0491] (iv) administering a unit dose to the mentalis muscle;

[0492] (v) administering a unit dose to the platysma muscle;

[0493] (vi) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle;

[0494] (vii) administering a unit dose to the buccinator muscle;

[0495] (viii) administering up to two unit doses (preferably one unit dose) to the masseter muscle;

[0496] (ix) administering a unit dose to the procerus muscle;

[0497] (x) administering a unit dose to the nasal muscle;

[0498] (xi) administering one unit dose to the lateral superior orbicularis oculi muscle;

[0499] (xii) administering one unit dose to the medial superior orbicularis oculi muscle;

[0500] (xiii) administering a unit dose to the lateral inferior orbicularis oculi muscle; and / or

[0501] (xiv) administering a unit dose to the levator palpebrae superioris muscle;

[0502] wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A,

[0503] wherein the total dose administered during the treatment period is greater than 24,000 pg (e.g., preferably greater than 24,100 pg; more preferably greater than 35,000 pg) and at most 82,500 pg (e.g., at most 75,000 pg) of the modified BoNT / A, and

[0504] The modified BoNT / A comprises a BoNT / A light chain and a translocation domain (HN) and a BoNT / B receptor binding domain (HC domain).

[0505] In a related aspect, the present invention provides a method of treating atypical hemifacial spasm in an individual, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of the individual, the method comprising:

[0506] a) administering a unit dose of a modified BoNT / A to the orbicularis oris muscle affected by hemifacial spasm (e.g., administering one unit dose of the modified BoNT / A to the upper orbicularis oris muscle and / or administering one unit dose to the lower orbicularis oris muscle affected by hemifacial spasm; preferably administering one unit dose of the modified BoNT / A to the upper orbicularis oris muscle and one unit dose to the lower orbicularis oris muscle affected by said hemifacial spasm); and

[0507] b) optionally, administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by said hemifacial spasm according to the following dosing regimen:

[0508] (i) administering a unit dose to the zygomaticus major muscle;

[0509] (ii) administering a unit dose to the zygomaticus major muscle;

[0510] (iii) administering up to five unit doses (preferably one unit dose) to the frontalis muscle;

[0511] (iv) administering a unit dose to the mentalis muscle;

[0512] (v) administering a unit dose to the platysma muscle;

[0513] (vi) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle;

[0514] (vii) administering a unit dose to the buccinator muscle;

[0515] (viii) administering up to two unit doses (preferably one unit dose) to the masseter muscle;

[0516] (ix) administering a unit dose to the procerus muscle;

[0517] (x) administering a unit dose to the nasal muscle;

[0518] (xi) administering one unit dose to the lateral superior orbicularis oculi muscle;

[0519] (xii) administering one unit dose to the medial superior orbicularis oculi muscle;

[0520] (xiii) administering a unit dose to the lateral inferior orbicularis oculi muscle; and / or

[0521] (xiv) administering a unit dose to the levator palpebrae superioris muscle;

[0522] wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A,

[0523] wherein the total dose administered during the treatment period is greater than 24,000 pg (e.g., preferably greater than 24,100 pg; more preferably greater than 35,000 pg) and at most 82,500 pg (e.g., at most 75,000 pg) of the modified BoNT / A, and

[0524] The modified BoNT / A comprises a BoNT / A light chain and a translocation domain (HN) and a BoNT / B receptor binding domain (HC domain).

[0525] In a related aspect, the invention provides a method of treating atypical hemifacial spasm in an individual for a duration of treatment that is longer than the duration of treatment with an unmodified BoNT / A (e.g., SEQ ID NO: 2 [e.g., a di-chain form of SEQ ID NO: 2]), wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of the individual, the method comprising:

[0526] a) administering a unit dose of a modified BoNT / A to the orbicularis oris muscle affected by hemifacial spasm (e.g., administering one unit dose of the modified BoNT / A to the upper orbicularis oris muscle and / or administering one unit dose to the lower orbicularis oris muscle affected by hemifacial spasm; preferably administering one unit dose of the modified BoNT / A to the upper orbicularis oris muscle and one unit dose to the lower orbicularis oris muscle affected by said hemifacial spasm); and

[0527] b) optionally, administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by said hemifacial spasm according to the following dosing regimen:

[0528] (i) administering a unit dose to the zygomaticus major muscle;

[0529] (ii) administering a unit dose to the zygomaticus major muscle;

[0530] (iii) administering up to five unit doses (preferably one unit dose) to the frontalis muscle;

[0531] (iv) administering a unit dose to the mentalis muscle;

[0532] (v) administering a unit dose to the platysma muscle;

[0533] (vi) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle;

[0534] (vii) administering a unit dose to the buccinator muscle;

[0535] (viii) administering up to two unit doses (preferably one unit dose) to the masseter muscle;

[0536] (ix) administering a unit dose to the procerus muscle;

[0537] (x) administering a unit dose to the nasal muscle;

[0538] (xi) administering one unit dose to the lateral superior orbicularis oculi muscle;

[0539] (xii) administering one unit dose to the medial superior orbicularis oculi muscle;

[0540] (xiii) administering a unit dose to the lateral inferior orbicularis oculi muscle; and / or

[0541] (xiv) administering a unit dose to the levator palpebrae superioris muscle;

[0542] wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A,

[0543] wherein the total dose administered during the treatment period is greater than 24,000 pg (e.g., preferably greater than 24,100 pg; more preferably greater than 35,000 pg) and at most 82,500 pg (e.g., at most 75,000 pg) of the modified BoNT / A, and

[0544] The modified BoNT / A comprises a BoNT / A light chain and a translocation domain (HN) and a BoNT / B receptor binding domain (HC domain).

[0545] In one aspect, the present invention provides a use of a modified botulinum neurotoxin A (BoNT / A) in the preparation of a medicament for treating atypical hemifacial spasm in an individual, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of the individual, comprising:

[0546] a) administering a unit dose of a modified BoNT / A to the orbicularis oris muscle affected by hemifacial spasm (e.g., administering one unit dose of the modified BoNT / A to the upper orbicularis oris muscle and / or administering one unit dose to the lower orbicularis oris muscle affected by hemifacial spasm; preferably administering one unit dose of the modified BoNT / A to the upper orbicularis oris muscle and one unit dose to the lower orbicularis oris muscle affected by said hemifacial spasm); and

[0547] b) optionally, administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by said hemifacial spasm according to the following dosing regimen:

[0548] (i) administering a unit dose to the zygomaticus major muscle;

[0549] (ii) administering a unit dose to the zygomaticus major muscle;

[0550] (iii) administering up to five unit doses (preferably one unit dose) to the frontalis muscle;

[0551] (iv) administering a unit dose to the mentalis muscle;

[0552] (v) administering a unit dose to the platysma muscle;

[0553] (vi) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle;

[0554] (vii) administering a unit dose to the buccinator muscle;

[0555] (viii) administering up to two unit doses (preferably one unit dose) to the masseter muscle;

[0556] (ix) administering a unit dose to the procerus muscle;

[0557] (x) administering a unit dose to the nasal muscle;

[0558] (xi) administering one unit dose to the lateral superior orbicularis oculi muscle;

[0559] (xii) administering one unit dose to the medial superior orbicularis oculi muscle;

[0560] (xiii) administering a unit dose to the lateral inferior orbicularis oculi muscle; and / or

[0561] (xiv) administering a unit dose to the levator palpebrae superioris muscle;

[0562] wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A,

[0563] wherein the total dose administered during the treatment period is greater than 24,000 pg (e.g., preferably greater than 24,100 pg; more preferably greater than 35,000 pg) and at most 82,500 pg (e.g., at most 75,000 pg) of the modified BoNT / A, and

[0564] The modified BoNT / A comprises a BoNT / A light chain and a translocation domain (HN) and a BoNT / B receptor binding domain (HC domain).

[0565] In one aspect, the present invention provides a use of a modified botulinum neurotoxin A (BoNT / A) for the preparation of a medicament for treating atypical hemifacial spasm in an individual for a longer duration of treatment than the duration of treatment with an unmodified BoNT / A (e.g., SEQ ID NO: 2 [e.g., a di-chain form of SEQ ID NO: 2]), wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of the individual, comprising:

[0566] a) administering a unit dose of a modified BoNT / A to the orbicularis oris muscle affected by hemifacial spasm (e.g., administering one unit dose of the modified BoNT / A to the upper orbicularis oris muscle and / or administering one unit dose to the lower orbicularis oris muscle affected by hemifacial spasm; preferably administering one unit dose of the modified BoNT / A to the upper orbicularis oris muscle and one unit dose to the lower orbicularis oris muscle affected by said hemifacial spasm); and

[0567] b) optionally, administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by said hemifacial spasm according to the following dosing regimen:

[0568] (i) administering a unit dose to the zygomaticus major muscle;

[0569] (ii) administering a unit dose to the zygomaticus major muscle;

[0570] (iii) administering up to five unit doses (preferably one unit dose) to the frontalis muscle;

[0571] (iv) administering a unit dose to the mentalis muscle;

[0572] (v) administering a unit dose to the platysma muscle;

[0573] (vi) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle;

[0574] (vii) administering a unit dose to the buccinator muscle;

[0575] (viii) administering up to two unit doses (preferably one unit dose) to the masseter muscle;

[0576] (ix) administering a unit dose to the procerus muscle;

[0577] (x) administering a unit dose to the nasal muscle;

[0578] (xi) administering one unit dose to the lateral superior orbicularis oculi muscle;

[0579] (xii) administering one unit dose to the medial superior orbicularis oculi muscle;

[0580] (xiii) administering a unit dose to the lateral inferior orbicularis oculi muscle; and / or

[0581] (xiv) administering a unit dose to the levator palpebrae superioris muscle;

[0582] wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A,

[0583] wherein the total dose administered during the treatment period is greater than 24,000 pg (e.g., preferably greater than 24,100 pg; more preferably greater than 35,000 pg) and at most 82,500 pg (e.g., at most 75,000 pg) of the modified BoNT / A, and

[0584] The modified BoNT / A comprises a BoNT / A light chain and a translocation domain (HN) and a BoNT / B receptor binding domain (HC domain).

[0585] Throughout this disclosure, reference to a total dose of greater than 24,000 pg of modified BoNT / A administered during a treatment period may mean a total dose of greater than 24,100 pg of modified BoNT / A administered during a treatment period. More preferably, reference to a total dose of greater than 24,000 pg of modified BoNT / A administered during a treatment period may mean a total dose of greater than 35,000 pg of modified BoNT / A administered during a treatment period.

[0586] The term "typical hemifacial spasm" may be used interchangeably with the term "hemifacial spasm" in this disclosure.

[0587] The term "treating the duration of blepharospasm in an individual longer than the duration of treatment with an unmodified BoNT / A" may refer to a reduction in one or more symptoms of the disorder in an individual for a longer period of time (e.g., 6-9 months) following administration of a modified BoNT / A of the present invention compared to administration of an unmodified BoNT / A. The reduction may be determined by comparison to an equivalent control individual treated with an unmodified BoNT / A exhibiting equivalent symptoms. An individual treated with a modified BoNT / A according to the present invention may exhibit an improvement of at least 5%, 10%, 25%, or 50% in the equivalent one or more symptoms when compared to the severity of the one or more symptoms prior to treatment with the modified BoNT / A, for a period of time that is substantially the same (e.g., the same) as the severity of the one or more symptoms in the control individual prior to treatment with the unmodified BoNT / A. The unmodified BoNT / A is preferably SEQ ID NO: 2 in a double-stranded form.

[0588] The term "treating a subject for a duration of typical hemifacial spasm longer than the duration of treatment with unmodified BoNT / A" may refer to a reduction in one or more symptoms of the disorder in the subject for a longer period of time (e.g., 6-9 months) following administration of a modified BoNT / A of the present invention compared to administration of an unmodified BoNT / A. The reduction may be determined by comparison to an equivalent control subject treated with an unmodified BoNT / A exhibiting equivalent symptoms. The subject treated with a modified BoNT / A according to the present invention may exhibit at least a 5%, 10%, 25%, or 50% improvement in the equivalent symptom or symptoms when compared to the severity of the one or more symptoms prior to treatment with the modified BoNT / A, over a period of time in which the severity of the one or more symptoms in the control subject is substantially the same (e.g., the same) as prior to treatment with the unmodified BoNT / A.

[0589] The term "the duration of atypical hemifacial spasm in a subject is longer than the duration of treatment with an unmodified BoNT / A" may refer to a reduction in one or more symptoms of the disorder in a subject for a longer period of time (e.g., 6-9 months) following administration of a modified BoNT / A of the present invention compared to administration of an unmodified BoNT / A. The reduction may be determined by comparison to an equivalent control subject treated with an unmodified BoNT / A exhibiting equivalent symptoms. A subject treated with a modified BoNT / A according to the present invention may exhibit at least a 5%, 10%, 25%, or 50% improvement in the equivalent symptom or symptoms when compared to the severity of the one or more symptoms prior to treatment with the modified BoNT / A, over a period of time in which the severity of the one or more symptoms in the control subject is substantially the same (e.g., the same) as prior to treatment with the unmodified BoNT / A.

[0590] The unit dose can be at least 240.4 pg, 500 pg, 1,000 pg, 2,000 pg, 3,000 pg, or 4,000 pg, such as at least 1,000 pg of the modified BoNT / A.

[0591] The unit dose can be at least 240.4 pg, 500 pg, 1,000 pg, 2,000 pg, 3,000 pg, 4,000 pg, 5,000 pg, 6000 pg, or 7,000 pg, preferably at least 4,000 pg of the modified BoNT / A.

[0592] In one embodiment, the upper limit of the unit dose of the present invention can be determined based on the total dose administered during the treatment period and the number of muscles and / or their sites to which the modified BoNT / A is administered. For example, the upper limit of the unit dose can be 9,375 pg in the following case: wherein the total dose administered during the treatment of blepharospasm is up to 75,000 pg of the modified BoNT / A, and the administration includes: (i) administering a (single) unit dose to the lateral superior orbicularis oculi muscle near a first eye of the individual; (ii) administering a (single) unit dose to the medial superior orbicularis oculi muscle near the first eye; (iii) administering a (single) unit dose to the lateral inferior orbicularis oculi muscle near only the first eye; (iv) administering two unit doses to the frontalis muscle near only the first eye; (v) administering two unit doses to the corrugator supercilii muscle near only the first eye; and (vi) administering a (single) unit dose to the procerus muscle (e.g., eight unit doses at multiple sites). If the additional administrations include: (i) administration of a (single) unit dose to the lateral superior orbicularis oculi muscle near the subject's second eye; (ii) administration of a (single) unit dose to the medial superior orbicularis oculi muscle near the second eye; (iii) administration of a (single) unit dose to the lateral inferior orbicularis oculi muscle near the second eye; (iv) administration of two unit doses to the frontalis muscle near the second eye; and (v) administration of two unit doses to the corrugator supercilii muscle near the second eye (e.g., an additional seven unit doses, bringing the total number of unit doses to 15), the upper limit may be 5,000 pg.

[0593] The unit dose can be 240 pg to 8,000 pg of a modified BoNT / A, wherein the modified BoNT / A comprises a BoNT / A light chain and a translocation domain and a BoNT / B receptor binding domain (H Cdomain). The upper limit of the unit dose range can be 7,500, 7,000, 6,500, 6,000, 5,500, 5,000, 4,800, 4,500, 4,000, 3,500, 3,000, 2,500, 2,400, 2,000, 1,500, or 1,250 pg of a modified BoNT / A. The upper limit of the unit dose range can be 5,500, 5,000, or 4,800 pg of a modified BoNT / A. A preferred unit dose range can have an upper limit of 5,000 pg of a modified BoNT / A. The lower end of the unit dose range can be 300, 400, 500, 600, 700, 800, 900, 1,000, 1,500, 2,000, 2,500, 3,000, 3,500, 4,000, 4,500, or 5,000 pg of modified BoNT / A, with a preferred lower end being 1,000 pg. The unit dose can be 1,000 pg to 6,000 pg, 1,000 pg to 5,500 pg, 1,000 pg to 5,000 pg, or 1,000 pg to 4,500 pg of modified BoNT / A. The unit dose can be 1,000 pg to 4,800 pg, 1,000 pg to 4,000 pg, 1,000 pg to 2,400 pg, or 1,000 pg to 2,000 pg.

[0594] The unit dose can be 1,500-5,000 pg of modified BoNT / A, preferably 2,000-4,500 pg of modified BoNT / A. Examples of suitable unit doses include about 2,500 pg (e.g., 2,000 pg ± 10%) of modified BoNT / A; and about 4,000 pg (e.g., 4,000 pg ± 10%) of modified BoNT / A. Such unit doses are particularly suitable for treating blepharospasm (whether bilateral or unilateral).

[0595] When carrying out the treatment regimen of the invention, the total dose administered can be greater than 24,000 pg (e.g., preferably greater than 24,100 pg; more preferably greater than 35,000 pg) of modified BoNT / A. In other words, the total amount of modified BoNT / A administered in a given treatment period can be greater than 24,000 pg. The total dose can be up to 82,500, 80,000, 75,000, 70,000, 65,000, 60,000, 55,000, 50,000, 45,000, 40,000, 35,000, 30,000, or 25,000 pg. The total dose may be at least 24,500, 25,000, 30,000, 35,000, 40,000, 45,000, 50,000, 55,000, 60,000, 65,000, or 70,000 pg. Preferably, the total dose may be at least 30,000 pg of modified BoNT / A. The total dose may be greater than 24,000 pg to 70,000 pg, preferably 30,000 pg to 60,000 pg.

[0596] The total dose may be greater than 35,000 pg to 70,000 pg.

[0597] The total dose can be 25,000 pg to 50,000 pg of modified BoNT / A (e.g., 25,000 pg to 50,000 pg). Examples of suitable ranges for total doses include 25,000 pg to 35,000 pg of modified BoNT / A; and 45,000 pg to 50,000 pg of modified BoNT / A. Examples of suitable total doses include about 30,000 pg (e.g., 30,000 pg ± 10%) and about 48,000 pg (e.g., 48,000 pg ± 10%) of modified d BoNT / A. Such unit doses are particularly suitable for treating blepharospasm (whether bilateral or unilateral).

[0598] Thus, a unit dose can be at least 240 pg of modified BoNT / A, while the total dose administered when following a treatment regimen of the invention can be greater than 24,000 pg and up to 82,500 pg of modified BoNT / A. A unit dose can be at least 240 pg of modified BoNT / A, while the total dose administered when following a treatment regimen of the invention can be greater than 35000 pg and up to 82,500 pg of modified BoNT / A.

[0599] In a preferred embodiment, the unit dose can be at least 240 pg of modified BoNT / A, while the total dose administered when following the treatment regimen of the invention can be greater than 24,000 pg and up to 75,000 pg of modified BoNT / A. The unit dose can be at least 240 pg of modified BoNT / A, while the total dose administered when following the treatment regimen of the invention can be greater than 35000 pg and up to 75,000 pg of modified BoNT / A.

[0600] In another preferred embodiment, the unit dose may be up to 5,000 pg of modified BoNT / A, while the total dose administered when following a treatment regimen of the invention may be greater than 24,000 pg and up to 75,000 pg of modified BoNT / A. The unit dose may be up to 5,000 pg of modified BoNT / A, while the total dose administered when following a treatment regimen of the invention may be greater than 35,000 pg and up to 75,000 pg of modified BoNT / A.

[0601] In another preferred embodiment, the unit dose may be 2,000 ng to 4,500 pg of modified BoNT / A, and the total dose administered when carrying out the treatment regimen of the present invention may be 25,000 pg to 50,000 pg of modified BoNT / A. Such a regimen may be particularly useful for treating blepharospasm (whether bilateral or unilateral). For example, a suitable dosage regimen includes:

[0602] - A unit dose of about 2,500 pg (e.g., 2,000 pg ± 10%) of a modified BoNT / A and a total dose of about 30,000 pg (e.g., 30,000 pg ± 10%) of a modified BoNT / A.

[0603] - A unit dose of about 4,000 pg (e.g., 4,000 pg ± 10%) of a modified BoNT / A and a total dose of about 48,000 pg (e.g., 48,000 pg ± 10%) of a modified BoNT / A.

[0604] In the case of unilateral conditions (e.g., affecting one side of the face, such as unilateral blepharospasm of one eye), the total dose may refer to the total dose applied to the side of the face affected by the condition. In the case of bilateral conditions (e.g., affecting both sides of the face, such as unilateral blepharospasm of both eyes), the total dose may refer to the total dose applied to both sides of the face. Preferably, 50% of the total dose is applied to each side of the face (e.g., for bilateral blepharospasm, to each eye).

[0605] In one aspect, provided is a modified botulinum neurotoxin A (BoNT / A) for use in a method of treating blepharospasm in an individual, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of the individual, the method comprising:

[0606] a) administering a unit dose of a modified BoNT / A to the lateral superior orbicularis oculi muscle (preferably the lateral superior preseptal orbicularis oculi muscle) proximal to a first eye of the individual;

[0607] b) administering a unit dose of the modified BoNT / A to the medial superior orbicularis oculi muscle (preferably the medial superior preseptal orbicularis oculi muscle) proximal to a first eye of the individual; and

[0608] c) administering a unit dose of the modified BoNT / A to the lateral inferior orbicularis oculi muscle (preferably the lateral inferior preseptal orbicularis oculi muscle) proximal to the first eye of the individual;

[0609] wherein the unit dose of the modified BoNT / A is at least 10 units (U) of the modified BoNT / A, wherein 1 unit corresponds to the calculated median lethal dose (LD50) in mice. 50 ), wherein the total dose administered during the treatment period is greater than 998 U and up to 3,432 U (e.g., up to 3,120 U) of the modified BoNT / A, and wherein the modified BoNT / A comprises a BoNT / A light chain and a translocation domain and a BoNT / B receptor binding domain (H C domain).

[0610] In a related aspect, the present invention provides a modified botulinum neurotoxin A (BoNT / A) for use in a method of treating blepharospasm in an individual for a duration of treatment that is longer than the duration of treatment with an unmodified BoNT / A (e.g., SEQ ID NO: 2 [e.g., a di-chain form of SEQ ID NO: 2]), wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of the individual, the method comprising: a) administering a unit dose of the modified BoNT / A to a lateral superior orbicularis oculi muscle (preferably a lateral superior preseptal orbicularis oculi muscle) proximal to a first eye of the individual;

[0611] b) administering a unit dose of the modified BoNT / A to the medial superior orbicularis oculi muscle (preferably the medial superior preseptal orbicularis oculi muscle) proximal to a first eye of the individual; and

[0612] c) administering a unit dose of the modified BoNT / A to the lateral inferior orbicularis oculi muscle (preferably the lateral inferior preseptal orbicularis oculi muscle) proximal to the first eye of the individual;

[0613] wherein the unit dose of the modified BoNT / A is at least 10 units (U) of the modified BoNT / A, wherein 1 unit is the amount of the modified BoNT / A corresponding to a calculated median lethal dose (LD50) in mice,

[0614] wherein the total dose administered during the treatment period is greater than 998 U and up to 3,432 U (e.g., up to 3,120 U) of the modified BoNT / A, and

[0615] The modified BoNT / A comprises a BoNT / A light chain and a translocation domain and a BoNT / B receptor binding domain (HC domain).

[0616] In a related aspect, the present invention provides a method of treating blepharospasm in an individual, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of the individual, the method comprising:

[0617] a) administering a unit dose of a modified BoNT / A to the lateral superior orbicularis oculi muscle (preferably the lateral superior preseptal orbicularis oculi muscle) proximal to a first eye of the individual;

[0618] b) administering a unit dose of the modified BoNT / A to the medial superior orbicularis oculi muscle (preferably the medial superior preseptal orbicularis oculi muscle) proximal to a first eye of the individual; and

[0619] c) administering a unit dose of the modified BoNT / A to the lateral inferior orbicularis oculi muscle (preferably the lateral inferior preseptal orbicularis oculi muscle) proximal to the first eye of the individual;

[0620] wherein the unit dose of the modified BoNT / A is at least 10 units (U) of the modified BoNT / A, wherein 1 unit is the amount of the modified BoNT / A corresponding to a calculated median lethal dose (LD50) in mice,

[0621] wherein the total dose administered during the treatment period is greater than 998 U and up to 3,432 U (e.g., up to 3,120 U) of the modified BoNT / A, and

[0622] The modified BoNT / A comprises a BoNT / A light chain and a translocation domain and a BoNT / B receptor binding domain (HC domain).

[0623] In a related aspect, the invention provides a method of treating blepharospasm in an individual for a duration of treatment that is longer than the duration of treatment with an unmodified BoNT / A (e.g., SEQ ID NO: 2 [e.g., a di-chain form of SEQ ID NO: 2]), wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of the individual, the method comprising:

[0624] a) administering a unit dose of a modified BoNT / A to the lateral superior orbicularis oculi muscle (preferably the lateral superior preseptal orbicularis oculi muscle) proximal to a first eye of the individual;

[0625] b) administering a unit dose of the modified BoNT / A to the medial superior orbicularis oculi muscle (preferably the medial superior preseptal orbicularis oculi muscle) proximal to a first eye of the individual; and

[0626] c) administering a unit dose of the modified BoNT / A to the lateral inferior orbicularis oculi muscle (preferably the lateral inferior preseptal orbicularis oculi muscle) proximal to the first eye of the individual;

[0627] wherein the unit dose of the modified BoNT / A is at least 10 units (U) of the modified BoNT / A, wherein 1 unit is the amount of the modified BoNT / A corresponding to a calculated median lethal dose (LD50) in mice,

[0628] wherein the total dose administered during the treatment period is greater than 998 U and up to 3,432 U (e.g., up to 3,120 U) of the modified BoNT / A, and

[0629] The modified BoNT / A comprises a BoNT / A light chain and a translocation domain and a BoNT / B receptor binding domain (HC domain).

[0630] In one aspect, the present invention provides a use of a modified botulinum neurotoxin A (BoNT / A) in the preparation of a medicament for treating blepharospasm in an individual, comprising:

[0631] a) administering a unit dose of a modified BoNT / A to the lateral superior orbicularis oculi muscle (preferably the lateral superior preseptal orbicularis oculi muscle) proximal to a first eye of the individual;

[0632] b) administering a unit dose of the modified BoNT / A to the medial superior orbicularis oculi muscle (preferably the medial superior preseptal orbicularis oculi muscle) proximal to a first eye of the individual; and

[0633] c) administering a unit dose of the modified BoNT / A to the lateral inferior orbicularis oculi muscle (preferably the lateral inferior preseptal orbicularis oculi muscle) proximal to the first eye of the individual;

[0634] wherein the unit dose of the modified BoNT / A is at least 10 units (U) of the modified BoNT / A, wherein 1 unit is the amount of the modified BoNT / A corresponding to a calculated median lethal dose (LD50) in mice,

[0635] wherein the total dose administered during the treatment period is greater than 998 U and up to 3,432 U (e.g., up to 3,120 U) of the modified BoNT / A, and

[0636] The modified BoNT / A comprises a BoNT / A light chain and a translocation domain and a BoNT / B receptor binding domain (HC domain).

[0637] In one aspect, the present invention provides a use of a modified botulinum neurotoxin A (BoNT / A) in the preparation of a medicament for treating blepharospasm in an individual for a treatment duration longer than that of an unmodified BoNT / A (e.g., SEQ ID NO: 2 [e.g., a di-chain form of SEQ ID NO: 2]), comprising: a) administering a unit dose of the modified BoNT / A to a lateral superior orbicularis oculi muscle (preferably a lateral superior preseptal orbicularis oculi muscle) proximal to a first eye of the individual;

[0638] b) administering a unit dose of the modified BoNT / A to the medial superior orbicularis oculi muscle (preferably the medial superior preseptal orbicularis oculi muscle) proximal to a first eye of the individual; and

[0639] c) administering a unit dose of the modified BoNT / A to the lateral inferior orbicularis oculi muscle (preferably the medial superior septal preorbicularis oculi muscle) proximal to the first eye of the individual,

[0640] wherein the unit dose of the modified BoNT / A is at least 10 units (U) of the modified BoNT / A, wherein 1 unit is the amount of the modified BoNT / A corresponding to a calculated median lethal dose (LD50) in mice,

[0641] wherein the total dose administered during the treatment period is greater than 998 U and up to 3,432 U (e.g., up to 3,120 U) of the modified BoNT / A, and

[0642] The modified BoNT / A comprises a BoNT / A light chain and a translocation domain and a BoNT / B receptor binding domain (HC domain).

[0643] In another aspect, provided is a modified botulinum neurotoxin A (BoNT / A) for use in a method of treating classic hemifacial spasm, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of an individual, the method comprising:

[0644] a) administering a unit dose of a modified BoNT / A to the lateral superior orbicularis oculi muscle (preferably the lateral superior preseptal orbicularis oculi muscle) proximal to the eye affected by hemifacial spasm;

[0645] b) administering a unit dose of the modified BoNT / A to the medial superior orbicularis oculi muscle (preferably the medial superior preseptal orbicularis oculi muscle) proximal to the eye affected by hemifacial spasm;

[0646] c) administering a unit dose of the modified BoNT / A to the lateral inferior orbicularis oculi muscle (preferably the lateral inferior preseptal orbicularis oculi muscle) proximal to the eye affected by hemifacial spasm; and

[0647] d) administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by the hemifacial spasm according to the following dosing regimen:

[0648] (i) administering one unit dose to the superior orbicularis oris muscle;

[0649] (ii) administering one unit dose to the inferior orbicularis oris muscle;

[0650] (iii) administering a unit dose to the zygomaticus major muscle;

[0651] (iv) administering a unit dose to the zygomaticus minor muscle;

[0652] (v) administering up to five unit doses (preferably one unit dose) to the frontalis muscle;

[0653] (vi) administering a unit dose to the mentalis muscle;

[0654] (vii) administering a unit dose to the platysma muscle;

[0655] (viii) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle;

[0656] (ix) administering a unit dose to the buccinator muscle;

[0657] (x) administering up to two unit doses (preferably one unit dose) to the masseter muscle;

[0658] (xi) administering a unit dose to the procerus muscle;

[0659] (xii) administering a unit dose to the nasal muscle; and / or

[0660] (xiii) administering one unit dose to the levator palpebrae superioris muscle;

[0661] wherein the unit dose of the modified BoNT / A is at least 10 units (U) of the modified BoNT / A, wherein 1 unit is the amount of the modified BoNT / A corresponding to a calculated median lethal dose (LD50) in mice,

[0662] wherein the total dose administered during the treatment period is greater than 998 U and up to 3,432 U (e.g., up to 3,120 U) of the modified BoNT / A, and

[0663] The modified BoNT / A comprises a BoNT / A light chain and a translocation domain and a BoNT / B receptor binding domain (HC domain).

[0664] In a related aspect, the present invention provides a modified botulinum neurotoxin A (BoNT / A) for use in a method of treating classic hemifacial spasm in an individual for a duration of treatment greater than the duration of treatment with an unmodified BoNT / A (e.g., SEQ ID NO: 2 [e.g., a di-chain form of SEQ ID NO: 2]), wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of the individual, the method comprising:

[0665] a) administering a unit dose of a modified BoNT / A to the lateral superior orbicularis oculi muscle (preferably the lateral superior preseptal orbicularis oculi muscle) proximal to the eye affected by hemifacial spasm;

[0666] b) administering a unit dose of the modified BoNT / A to the medial superior orbicularis oculi muscle (preferably the medial superior preseptal orbicularis oculi muscle) proximal to the eye affected by hemifacial spasm;

[0667] c) administering a unit dose of the modified BoNT / A to the lateral inferior orbicularis oculi muscle (preferably the lateral inferior preseptal orbicularis oculi muscle) proximal to the eye affected by hemifacial spasm; and

[0668] d) administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by said hemifacial spasm according to the following dosing regimen:

[0669] (i) administering one unit dose to the superior orbicularis oris muscle;

[0670] (ii) administering one unit dose to the inferior orbicularis oris muscle;

[0671] (iii) administering a unit dose to the zygomaticus major muscle;

[0672] (iv) administering a unit dose to the zygomaticus minor muscle;

[0673] (v) administering up to five unit doses (preferably one unit dose) to the frontalis muscle;

[0674] (vi) administering a unit dose to the mentalis muscle;

[0675] (vii) administering a unit dose to the platysma muscle;

[0676] (viii) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle;

[0677] (ix) administering a unit dose to the buccinator muscle;

[0678] (x) administering up to two unit doses (preferably one unit dose) to the masseter muscle;

[0679] (xi) administering a unit dose to the procerus muscle;

[0680] (xii) administering a unit dose to the nasal muscle; and / or

[0681] (xiii) administering one unit dose to the levator palpebrae superioris muscle;

[0682] wherein the unit dose of the modified BoNT / A is at least 10 units (U) of the modified BoNT / A, wherein 1 unit is the amount of the modified BoNT / A corresponding to a calculated median lethal dose (LD50) in mice,

[0683] wherein the total dose administered during the treatment period is greater than 998 U and up to 3,432 U (e.g., up to 3,120 U) of the modified BoNT / A, and

[0684] The modified BoNT / A comprises a BoNT / A light chain and a translocation domain and a BoNT / B receptor binding domain (HC domain).

[0685] In a related aspect, the present invention provides a method of treating classic hemifacial spasm in an individual, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of the individual, the method comprising:

[0686] a) administering a unit dose of a modified BoNT / A to the lateral superior orbicularis oculi muscle (preferably the lateral superior preseptal orbicularis oculi muscle) proximal to the eye affected by hemifacial spasm;

[0687] b) administering a unit dose of the modified BoNT / A to the medial superior orbicularis oculi muscle (preferably the medial superior preseptal orbicularis oculi muscle) proximal to the eye affected by hemifacial spasm;

[0688] c) administering a unit dose of the modified BoNT / A to the lateral inferior orbicularis oculi muscle (preferably the lateral inferior preseptal orbicularis oculi muscle) proximal to the eye affected by hemifacial spasm; and

[0689] d) administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by said hemifacial spasm according to the following dosing regimen:

[0690] (i) administering one unit dose to the superior orbicularis oris muscle;

[0691] (ii) administering one unit dose to the inferior orbicularis oris muscle;

[0692] (iii) administering a unit dose to the zygomaticus major muscle;

[0693] (iv) administering a unit dose to the zygomaticus minor muscle;

[0694] (v) administering up to five unit doses (preferably one unit dose) to the frontalis muscle;

[0695] (vi) administering a unit dose to the mentalis muscle;

[0696] (vii) administering a unit dose to the platysma muscle;

[0697] (viii) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle;

[0698] (ix) administering a unit dose to the buccinator muscle;

[0699] (x) administering up to two unit doses (preferably one unit dose) to the masseter muscle;

[0700] (xi) administering a unit dose to the procerus muscle;

[0701] (xii) administering a unit dose to the nasal muscle; and / or

[0702] (xiii) administering one unit dose to the levator palpebrae superioris muscle;

[0703] wherein the unit dose of the modified BoNT / A is at least 10 units (U) of the modified BoNT / A, wherein 1 unit is the amount of the modified BoNT / A corresponding to a calculated median lethal dose (LD50) in mice,

[0704] wherein the total dose administered during the treatment period is greater than 998 U and up to 3,432 U (e.g., up to 3,120 U) of the modified BoNT / A, and

[0705] The modified BoNT / A comprises a BoNT / A light chain and a translocation domain and a BoNT / B receptor binding domain (HC domain).

[0706] In a related aspect, the present invention provides a method of treating classic hemifacial spasm in an individual for a duration of treatment that is longer than the duration of treatment with an unmodified BoNT / A (e.g., SEQ ID NO: 2 [e.g., a di-chain form of SEQ ID NO: 2]), wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of the individual, the method comprising:

[0707] a) administering a unit dose of a modified BoNT / A to the lateral superior orbicularis oculi muscle (preferably the lateral superior preseptal orbicularis oculi muscle) proximal to the eye affected by hemifacial spasm;

[0708] b) administering a unit dose of the modified BoNT / A to the medial superior orbicularis oculi muscle (preferably the medial superior preseptal orbicularis oculi muscle) proximal to the eye affected by hemifacial spasm;

[0709] c) administering a unit dose of the modified BoNT / A to the lateral inferior orbicularis oculi muscle (preferably the lateral inferior preseptal orbicularis oculi muscle) proximal to the eye affected by hemifacial spasm; and

[0710] d) administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by said hemifacial spasm according to the following dosing regimen:

[0711] (i) administering one unit dose to the superior orbicularis oris muscle;

[0712] (ii) administering one unit dose to the inferior orbicularis oris muscle;

[0713] (iii) administering a unit dose to the zygomaticus major muscle;

[0714] (iv) administering a unit dose to the zygomaticus minor muscle;

[0715] (v) administering up to five unit doses (preferably one unit dose) to the frontalis muscle;

[0716] (vi) administering a unit dose to the mentalis muscle;

[0717] (vii) administering a unit dose to the platysma muscle;

[0718] (viii) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle;

[0719] (ix) administering a unit dose to the buccinator muscle;

[0720] (x) administering up to two unit doses (preferably one unit dose) to the masseter muscle;

[0721] (xi) administering a unit dose to the procerus muscle;

[0722] (xii) administering a unit dose to the nasal muscle; and / or

[0723] (xiii) administering one unit dose to the levator palpebrae superioris muscle;

[0724] wherein the unit dose of the modified BoNT / A is at least 10 units (U) of the modified BoNT / A, wherein 1 unit is the amount of the modified BoNT / A corresponding to a calculated median lethal dose (LD50) in mice,

[0725] wherein the total dose administered during the treatment period is greater than 998 U and up to 3,432 U (e.g., up to 3,120 U) of the modified BoNT / A, and

[0726] The modified BoNT / A comprises a BoNT / A light chain and a translocation domain and a BoNT / B receptor binding domain (HC domain).

[0727] In one aspect, the present invention provides a use of a modified botulinum neurotoxin A (BoNT / A) in the preparation of a medicament for treating classic hemifacial spasm in an individual, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of the individual, comprising:

[0728] a) administering a unit dose of a modified BoNT / A to the lateral superior orbicularis oculi muscle (preferably the lateral superior preseptal orbicularis oculi muscle) proximal to the eye affected by hemifacial spasm;

[0729] b) administering a unit dose of the modified BoNT / A to the medial superior orbicularis oculi muscle (preferably the medial superior preseptal orbicularis oculi muscle) proximal to the eye affected by hemifacial spasm;

[0730] c) administering a unit dose of the modified BoNT / A to the lateral inferior orbicularis oculi muscle (preferably the lateral inferior preseptal orbicularis oculi muscle) proximal to the eye affected by hemifacial spasm; and

[0731] d) administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by said hemifacial spasm according to the following dosing regimen:

[0732] (i) administering one unit dose to the superior orbicularis oris muscle;

[0733] (ii) administering one unit dose to the inferior orbicularis oris muscle;

[0734] (iii) administering a unit dose to the zygomaticus major muscle;

[0735] (iv) administering a unit dose to the zygomaticus minor muscle;

[0736] (v) administering up to five unit doses (preferably one unit dose) to the frontalis muscle;

[0737] (vi) administering a unit dose to the mentalis muscle;

[0738] (vii) administering a unit dose to the platysma muscle;

[0739] (viii) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle;

[0740] (ix) administering a unit dose to the buccinator muscle;

[0741] (x) administering up to two unit doses (preferably one unit dose) to the masseter muscle;

[0742] (xi) administering a unit dose to the procerus muscle;

[0743] (xii) administering a unit dose to the nasal muscle; and / or

[0744] (xiii) administering one unit dose to the levator palpebrae superioris muscle;

[0745] wherein the unit dose of the modified BoNT / A is at least 10 units (U) of the modified BoNT / A, wherein 1 unit is the amount of the modified BoNT / A corresponding to a calculated median lethal dose (LD50) in mice,

[0746] wherein the total dose administered during the treatment period is greater than 998 U and up to 3,432 U (e.g., up to 3,120 U) of the modified BoNT / A, and

[0747] The modified BoNT / A comprises a BoNT / A light chain and a translocation domain and a BoNT / B receptor binding domain (HC domain).

[0748] In one aspect, the present invention provides a use of a modified botulinum neurotoxin A (BoNT / A) for the preparation of a medicament for treating classic hemifacial spasm in an individual for a longer duration of treatment than the duration of treatment with an unmodified BoNT / A (e.g., SEQ ID NO: 2 [e.g., a di-chain form of SEQ ID NO: 2]), wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of the individual, comprising:

[0749] a) administering a unit dose of a modified BoNT / A to the lateral superior orbicularis oculi muscle (preferably the lateral superior preseptal orbicularis oculi muscle) proximal to the eye affected by hemifacial spasm;

[0750] b) administering a unit dose of the modified BoNT / A to the medial superior orbicularis oculi muscle (preferably the medial superior preseptal orbicularis oculi muscle) proximal to the eye affected by hemifacial spasm;

[0751] c) administering a unit dose of the modified BoNT / A to the lateral inferior orbicularis oculi muscle (preferably the lateral inferior preseptal orbicularis oculi muscle) proximal to the eye affected by hemifacial spasm; and

[0752] d) administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by said hemifacial spasm according to the following dosing regimen:

[0753] (i) administering one unit dose to the superior orbicularis oris muscle;

[0754] (ii) administering one unit dose to the inferior orbicularis oris muscle;

[0755] (iii) administering a unit dose to the zygomaticus major muscle;

[0756] (iv) administering a unit dose to the zygomaticus minor muscle;

[0757] (v) administering up to five unit doses (preferably one unit dose) to the frontalis muscle;

[0758] (vi) administering a unit dose to the mentalis muscle;

[0759] (vii) administering a unit dose to the platysma muscle;

[0760] (viii) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle;

[0761] (ix) administering a unit dose to the buccinator muscle;

[0762] (x) administering up to two unit doses (preferably one unit dose) to the masseter muscle;

[0763] (xi) administering a unit dose to the procerus muscle;

[0764] (xii) administering a unit dose to the nasal muscle; and / or

[0765] (xiii) administering one unit dose to the levator palpebrae superioris muscle;

[0766] wherein the unit dose of the modified BoNT / A is at least 10 units (U) of the modified BoNT / A, wherein 1 unit is the amount of the modified BoNT / A corresponding to a calculated median lethal dose (LD50) in mice,

[0767] wherein the total dose administered during the treatment period is greater than 998 U and up to 3,432 U (e.g., up to 3,120 U) of the modified BoNT / A, and

[0768] The modified BoNT / A comprises a BoNT / A light chain and a translocation domain and a BoNT / B receptor binding domain (HC domain).

[0769] In another aspect, provided is a modified botulinum neurotoxin A (BoNT / A) for use in a method of treating atypical hemifacial spasm, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of an individual, the method comprising:

[0770] a) administering a unit dose of a modified BoNT / A to the orbicularis oris muscle affected by hemifacial spasm (e.g., administering one unit dose of the modified BoNT / A to the superior orbicularis oris muscle and / or administering one unit dose to the inferior orbicularis oris muscle affected by hemifacial spasm; preferably administering one unit dose of the modified BoNT / A to the orbicul); and

[0771] b) optionally, administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by said hemifacial spasm according to the following dosing regimen:

[0772] (i) administering a unit dose to the zygomaticus major muscle;

[0773] (ii) administering a unit dose to the zygomaticus major muscle;

[0774] (iii) administering up to five unit doses (preferably one unit dose) to the frontalis muscle;

[0775] (iv) administering a unit dose to the mentalis muscle;

[0776] (v) administering a unit dose to the platysma muscle;

[0777] (vi) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle;

[0778] (vii) administering a unit dose to the buccinator muscle;

[0779] (viii) administering up to two unit doses (preferably one unit dose) to the masseter muscle;

[0780] (ix) administering a unit dose to the procerus muscle;

[0781] (x) administering a unit dose to the nasal muscle;

[0782] (xi) administering one unit dose to the lateral superior orbicularis oculi muscle;

[0783] (xii) administering one unit dose to the medial superior orbicularis oculi muscle;

[0784] (xiii) administering a unit dose to the lateral inferior orbicularis oculi muscle; and / or

[0785] (xiv) administering a unit dose to the levator palpebrae superioris muscle;

[0786] wherein the unit dose of the modified BoNT / A is at least 10 units (U) of the modified BoNT / A, wherein 1 unit is the amount of the modified BoNT / A corresponding to a calculated median lethal dose (LD50) in mice,

[0787] wherein the total dose administered during the treatment period is greater than 998 U and up to 3,432 U (e.g., up to 3,120 U) of the modified BoNT / A, and

[0788] The modified BoNT / A comprises a BoNT / A light chain and a translocation domain and a BoNT / B receptor binding domain (HC domain).

[0789] In a related aspect, the present invention provides a modified botulinum neurotoxin A (BoNT / A) for use in a method of treating atypical hemifacial spasm in an individual for a duration of treatment greater than the duration of treatment with an unmodified BoNT / A (e.g., SEQ ID NO: 2 [e.g., a di-chain form of SEQ ID NO: 2]), wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of the individual, the method comprising:

[0790] a) administering a unit dose of a modified BoNT / A to the orbicularis oris muscle affected by hemifacial spasm (e.g., administering one unit dose of the modified BoNT / A to the superior orbicularis oris muscle and / or administering one unit dose to the inferior orbicularis oris muscle affected by hemifacial spasm; preferably administering one unit dose of the modified BoNT / A to the orbicul); and

[0791] b) optionally, administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by said hemifacial spasm according to the following dosing regimen:

[0792] (i) administering a unit dose to the zygomaticus major muscle;

[0793] (ii) administering a unit dose to the zygomaticus major muscle;

[0794] (iii) administering up to five unit doses (preferably one unit dose) to the frontalis muscle;

[0795] (iv) administering a unit dose to the mentalis muscle;

[0796] (v) administering a unit dose to the platysma muscle;

[0797] (vi) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle;

[0798] (vii) administering a unit dose to the buccinator muscle;

[0799] (viii) administering up to two unit doses (preferably one unit dose) to the masseter muscle;

[0800] (ix) administering a unit dose to the procerus muscle;

[0801] (x) administering a unit dose to the nasal muscle;

[0802] (xi) administering one unit dose to the lateral superior orbicularis oculi muscle;

[0803] (xii) administering one unit dose to the medial superior orbicularis oculi muscle;

[0804] (xiii) administering a unit dose to the lateral inferior orbicularis oculi muscle; and / or

[0805] (xiv) administering a unit dose to the levator palpebrae superioris muscle;

[0806] wherein the unit dose of the modified BoNT / A is at least 10 units (U) of the modified BoNT / A, wherein 1 unit is the amount of the modified BoNT / A corresponding to a calculated median lethal dose (LD50) in mice,

[0807] wherein the total dose administered during the treatment period is greater than 998 U and up to 3,432 U (e.g., up to 3,120 U) of the modified BoNT / A, and

[0808] The modified BoNT / A comprises a BoNT / A light chain and a translocation domain and a BoNT / B receptor binding domain (HC domain).

[0809] In a related aspect, the present invention provides a method of treating atypical hemifacial spasm in an individual, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of the individual, the method comprising:

[0810] a) administering a unit dose of a modified BoNT / A to the orbicularis oris muscle affected by hemifacial spasm (e.g., administering one unit dose of the modified BoNT / A to the superior orbicularis oris muscle and / or administering one unit dose to the inferior orbicularis oris muscle affected by hemifacial spasm; preferably administering one unit dose of the modified BoNT / A to the orbicul); and

[0811] b) optionally, administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by the hemifacial spasm according to the following dosing regimen:

[0812] (i) administering a unit dose to the zygomaticus major muscle;

[0813] (ii) administering a unit dose to the zygomaticus major muscle;

[0814] (iii) administering up to five unit doses (preferably one unit dose) to the frontalis muscle;

[0815] (iv) administering a unit dose to the mentalis muscle;

[0816] (v) administering a unit dose to the platysma muscle;

[0817] (vi) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle;

[0818] (vii) administering a unit dose to the buccinator muscle;

[0819] (viii) administering up to two unit doses (preferably one unit dose) to the masseter muscle;

[0820] (ix) administering a unit dose to the procerus muscle;

[0821] (x) administering a unit dose to the nasal muscle;

[0822] (xi) administering one unit dose to the lateral superior orbicularis oculi muscle;

[0823] (xii) administering one unit dose to the medial superior orbicularis oculi muscle;

[0824] (xiii) administering a unit dose to the lateral inferior orbicularis oculi muscle; and / or

[0825] (xiv) administering a unit dose to the levator palpebrae superioris muscle;

[0826] wherein the unit dose of the modified BoNT / A is at least 10 units (U) of the modified BoNT / A, wherein 1 unit is the amount of the modified BoNT / A corresponding to a calculated median lethal dose (LD50) in mice,

[0827] wherein the total dose administered during the treatment period is greater than 998 U and up to 3,432 U (e.g., up to 3,120 U) of the modified BoNT / A, and

[0828] The modified BoNT / A comprises a BoNT / A light chain and a translocation domain and a BoNT / B receptor binding domain (HC domain).

[0829] In a related aspect, the invention provides a method of treating atypical hemifacial spasm in an individual for a duration of treatment that is longer than the duration of treatment with an unmodified BoNT / A (e.g., SEQ ID NO: 2 [e.g., a di-chain form of SEQ ID NO: 2]), wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of the individual, the method comprising:

[0830] a) administering a unit dose of a modified BoNT / A to the orbicularis oris muscle affected by hemifacial spasm (e.g., administering one unit dose of the modified BoNT / A to the superior orbicularis oris muscle and / or administering one unit dose to the inferior orbicularis oris muscle affected by hemifacial spasm; preferably administering one unit dose to the orbicul); and

[0831] b) optionally, administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by said hemifacial spasm according to the following dosing regimen:

[0832] (i) administering a unit dose to the zygomaticus major muscle;

[0833] (ii) administering a unit dose to the zygomaticus major muscle;

[0834] (iii) administering up to five unit doses (preferably one unit dose) to the frontalis muscle;

[0835] (iv) administering a unit dose to the mentalis muscle;

[0836] (v) administering a unit dose to the platysma muscle;

[0837] (vi) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle;

[0838] (vii) administering a unit dose to the buccinator muscle;

[0839] (viii) administering up to two unit doses (preferably one unit dose) to the masseter muscle;

[0840] (ix) administering a unit dose to the procerus muscle;

[0841] (x) administering a unit dose to the nasal muscle;

[0842] (xi) administering one unit dose to the lateral superior orbicularis oculi muscle;

[0843] (xii) administering one unit dose to the medial superior orbicularis oculi muscle;

[0844] (xiii) administering a unit dose to the lateral inferior orbicularis oculi muscle; and / or

[0845] (xiv) administering a unit dose to the levator palpebrae superioris muscle;

[0846] wherein the unit dose of the modified BoNT / A is at least 10 units (U) of the modified BoNT / A, wherein 1 unit is the amount of the modified BoNT / A corresponding to a calculated median lethal dose (LD50) in mice,

[0847] wherein the total dose administered during the treatment period is greater than 998 U and up to 3,432 U (e.g., up to 3,120 U) of the modified BoNT / A, and

[0848] The modified BoNT / A comprises a BoNT / A light chain and a translocation domain and a BoNT / B receptor binding domain (HC domain).

[0849] In one aspect, the present invention provides a use of a modified botulinum neurotoxin A (BoNT / A) in the preparation of a medicament for treating atypical hemifacial spasm in an individual, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of the individual, comprising:

[0850] a) administering a unit dose of a modified BoNT / A to the orbicularis oris muscle affected by hemifacial spasm (e.g., administering one unit dose of the modified BoNT / A to the superior orbicularis oris muscle and / or administering one unit dose to the inferior orbicularis oris muscle affected by hemifacial spasm; preferably administering one unit dose of the modified BoNT / A to the orbicul); and

[0851] b) optionally, administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by said hemifacial spasm according to the following dosing regimen:

[0852] (i) administering a unit dose to the zygomaticus major muscle;

[0853] (ii) administering a unit dose to the zygomaticus major muscle;

[0854] (iii) administering up to five unit doses (preferably one unit dose) to the frontalis muscle;

[0855] (iv) administering a unit dose to the mentalis muscle;

[0856] (v) administering a unit dose to the platysma muscle;

[0857] (vi) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle;

[0858] (vii) administering a unit dose to the buccinator muscle;

[0859] (viii) administering up to two unit doses (preferably one unit dose) to the masseter muscle;

[0860] (ix) administering a unit dose to the procerus muscle;

[0861] (x) administering a unit dose to the nasal muscle;

[0862] (xi) administering one unit dose to the lateral superior orbicularis oculi muscle;

[0863] (xii) administering one unit dose to the medial superior orbicularis oculi muscle;

[0864] (xiii) administering a unit dose to the lateral inferior orbicularis oculi muscle; and / or

[0865] (xiv) administering a unit dose to the levator palpebrae superioris muscle;

[0866] wherein the unit dose of the modified BoNT / A is at least 10 units (U) of the modified BoNT / A, wherein 1 unit is the amount of the modified BoNT / A corresponding to a calculated median lethal dose (LD50) in mice,

[0867] wherein the total dose administered during the treatment period is greater than 998 U and up to 3,432 U (e.g., up to 3,120 U) of the modified BoNT / A, and

[0868] The modified BoNT / A comprises a BoNT / A light chain and a translocation domain and a BoNT / B receptor binding domain (HC domain).

[0869] In one aspect, the present invention provides a use of a modified botulinum neurotoxin A (BoNT / A) for the preparation of a medicament for treating atypical hemifacial spasm in an individual for a longer duration of treatment than the duration of treatment with an unmodified BoNT / A (e.g., SEQ ID NO: 2 [e.g., a di-chain form of SEQ ID NO: 2]), wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of the individual, comprising:

[0870] a) administering a unit dose of a modified BoNT / A to the orbicularis oris muscle affected by hemifacial spasm (e.g., administering one unit dose of the modified BoNT / A to the superior orbicularis oris muscle and / or administering one unit dose to the inferior orbicularis oris muscle affected by hemifacial spasm; preferably administering one unit dose of the modified BoNT / A to the orbicul); and

[0871] b) optionally, administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by said hemifacial spasm according to the following dosing regimen:

[0872] (i) administering a unit dose to the zygomaticus major muscle;

[0873] (ii) administering a unit dose to the zygomaticus major muscle;

[0874] (iii) administering up to five unit doses (preferably one unit dose) to the frontalis muscle;

[0875] (iv) administering a unit dose to the mentalis muscle;

[0876] (v) administering a unit dose to the platysma muscle;

[0877] (vi) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle;

[0878] (vii) administering a unit dose to the buccinator muscle;

[0879] (viii) administering up to two unit doses (preferably one unit dose) to the masseter muscle;

[0880] (ix) administering a unit dose to the procerus muscle;

[0881] (x) administering a unit dose to the nasal muscle;

[0882] (xi) administering one unit dose to the lateral superior orbicularis oculi muscle;

[0883] (xii) administering one unit dose to the medial superior orbicularis oculi muscle;

[0884] (xiii) administering a unit dose to the lateral inferior orbicularis oculi muscle; and / or

[0885] (xiv) administering a unit dose to the levator palpebrae superioris muscle;

[0886] wherein the unit dose of the modified BoNT / A is at least 10 units (U) of the modified BoNT / A, wherein 1 unit is the amount of the modified BoNT / A corresponding to a calculated median lethal dose (LD50) in mice,

[0887] wherein the total dose administered during the treatment period is greater than 998 U and up to 3,432 U (e.g., up to 3,120 U) of the modified BoNT / A, and

[0888] The modified BoNT / A comprises a BoNT / A light chain and a translocation domain and a BoNT / B receptor binding domain (HC domain).

[0889] The unit dose can be at least 21 U, 42 U, 83 U, 125 U, or 166 U, preferably at least 42 U, wherein the modified BoNT / A comprises a BoNT / A light chain and a translocation domain and a BoNT / B receptor binding domain (H C domain).

[0890] The unit dose can be 10 U to 332.7 U of a modified BoNT / A, wherein the modified BoNT / A comprises a BoNT / A light chain and a translocation domain and a BoNT / B receptor binding domain (HC domain). The upper limit of the unit dose range can be 312, 291, 270, 250, 229, 208, 199.6, 187, 166.3, 146, 125, 104, 99.8, 89.17, 62, or 52 U of a modified BoNT / A. The lower limit of the unit dose range can be 12, 17, 21, 25, 29, 33, 37, 42, 62, 83, 104, 125, 146, 166, 187, or 208 U of a modified BoNT / A, with a preferred lower limit being 42 U. The unit dose can be from 42 U to 199.6 U, from 42 U to 166.3 U, from 42 U to 99.8 U, or from 42 U to 83.17 U.

[0891] The unit dose can be 62.4-208 U of modified BoNT / A, preferably 83.2 to 187.2 U of modified BoNT / A. Examples of suitable unit doses include about 104 U (e.g., 104 U ± 10%) of modified BoNT / A; and about 166.4 U (e.g., 166.4 U ± 10%) of modified BoNT / A. Such unit doses are particularly suitable for treating blepharospasm (whether bilateral or unilateral).

[0892] When carrying out the treatment regimen of the present invention, the total dose administered can be greater than 998 U of modified BoNT / A. In other words, the total amount of modified BoNT / A administered in a given treatment period can be greater than 998 U. The total dose can be at most 3430 U, 3326 U, 3119 U, 2911 U, 2703 U, 2495 U, 2287 U, 2079 U, 1871 U, 1663 U, 1455 U, 1247 U, or 1040 U. The total dose can be at least 1019 U, 1040 U, ​​1247 U, 1455 U, 1663 U, 1871 U, 2079 U, 2287 U, 2495 U, 2703 U, or 2911 U. Preferably, the total dose can be at least 125 U of modified BoNT / A. The total dose may be greater than 998U to 2911U, preferably 1247U to 2495U.

[0893] The total dose can be 1,040 U to 2080 U of the modified BoNT / A. Examples of suitable ranges of total doses include 1,040 U to 1456 U of the modified BoNT / A; and 1871.9 U to 2079.9 U of the modified BoNT / A. Examples of suitable total doses include about 1247.9 U (e.g., 1247.9 U ± 10%) of the modified BoNT / A; and about 1996.7 U (e.g., 1996.7 U ± 10%) of the modified BoNT / A. Such unit doses are particularly suitable for treating blepharospasm (whether bilateral or unilateral).

[0894] Thus, the unit dose may be at least 10 U of the modified BoNT / A, while the total dose administered when following a treatment regimen of the invention may be greater than 998 U and up to 3430 U of the modified BoNT / A. In a preferred embodiment, the unit dose may be at least 10 U of the modified BoNT / A, while the total dose administered when following a treatment regimen of the invention may be greater than 998 U and up to 3119 U of the modified BoNT / A. In another preferred embodiment, the unit dose may be up to 208 U of the modified BoNT / A, while the total dose administered when following a treatment regimen of the invention may be greater than 998 U and up to 3119 U of the modified BoNT / A.

[0895] In another preferred embodiment, the unit dose may be 83.2 U to 187.2 U of modified BoNT / A, and the total dose administered when carrying out the treatment regimen of the present invention may be 1039.9 U to 2079.9 U of modified BoNT / A. Such a regimen may be particularly useful for treating blepharospasm (whether bilateral or unilateral). For example, a suitable dosage regimen includes:

[0896] - a unit dose of about 104 U (e.g., 104 U ± 10%) of a modified BoNT / A and a total dose of about 1247.9 U (e.g., 1247.9 U ± 10%) of a modified BoNT / A;

[0897] - A unit dose of about 166.4 U (e.g., 166.4 U ± 10%) of the modified BoNT / A and a total dose of about 1996.7 U (e.g., 1996.7 U ± 10%) of the modified BoNT / A.

[0898] In the case of unilateral conditions (e.g., affecting one side of the face, such as unilateral blepharospasm of one eye), the total dose may refer to the total dose applied to the side of the face affected by the condition. In the case of bilateral conditions (e.g., affecting both sides of the face, such as unilateral blepharospasm of both eyes), the total dose may refer to the total dose applied to both sides of the face. Preferably, 50% of the total dose is applied to each side of the face (e.g., for bilateral blepharospasm, to each eye).

[0899] Suitable disorders affecting eyelid muscles (e.g., affecting two or more eyelid muscles) include blepharospasm and facial spasm (e.g., hemifacial spasm). Preferably, the disorder affecting the eyelid muscles of an individual is blepharospasm. Therefore, the present invention may be directed to the treatment of blepharospasm and / or facial spasm (e.g., hemifacial spasm), preferably directed to the treatment of blepharospasm.

[0900] The present invention is based on the surprising results of dose escalation studies demonstrating that high doses of Clostridial neurotoxin therapy (eg, greater than 24,000 pg and up to 82,500 pg) can be used to treat these disorders without exceeding acceptable levels of toxicity (see Examples).

[0901] The disorder affecting the eyelid muscles of an individual may be an eyelid muscle disorder. The cause of the disorder may be a nerve-related disorder (eg, a VIIth nerve disorder).

[0902] The modified BoNT / A can be administered to any muscle affected by the disorder (e.g., an affected eyelid muscle). The affected muscle may contribute to (e.g., cause) one or more symptoms of the disorder (e.g., blepharospasm and / or facial spasm, such as hemifacial spasm).

[0903] In one embodiment (preferably embodiments directed to treating blepharospasm), only a single unit dose of the modified BoNT / A is administered to at least each of the following groups: the lateral superior orbicularis oculi muscle proximal to the subject's first eye (e.g., the lateral pretarsal orbicularis oculi muscle of the upper eyelid); the medial superior orbicularis oculi muscle proximal to the subject's first eye (e.g., the medial pretarsal orbicularis oculi muscle of the upper eyelid); and the lateral inferior orbicularis oculi muscle proximal to the subject's first eye (e.g., the lateral pretarsal orbicularis oculi muscle of the lower eyelid). Preferably, a single unit is administered per injection site, which in this embodiment may correspond to administration at three injection sites. Thus, three unit doses may be administered according to the methods described above, however, other muscles and / or sites thereof may be treated according to the present invention, meaning that the total number of unit doses administered may be greater than three.

[0904] In one embodiment (preferably one directed to treating blepharospasm), where the disorder affects eyelid muscles proximal to both eyes of an individual (e.g., bilateral blepharospasm), a single unit dose of a modified BoNT / A is administered only to at least each of the following groups: the lateral superior orbicularis oculi muscle proximal to a first eye of the individual; the medial superior orbicularis oculi muscle proximal to the first eye of the individual; the lateral inferior orbicularis oculi muscle proximal to the first eye of the individual; the lateral superior orbicularis oculi muscle proximal to the second eye of the individual; the medial superior orbicularis oculi muscle proximal to the second eye of the individual; and the lateral inferior orbicularis oculi muscle proximal to the second eye of the individual. Preferably, a single unit is administered per injection site, which in this embodiment may correspond to administration at six injection sites. Thus, six unit doses may be administered according to the methods described above, however, other muscles and / or sites thereof may be treated according to the present invention, meaning that the total number of unit doses administered may be greater than six.

[0905] The terms "first eye" and "second eye" may refer to the left eye or the right eye. These terms are used merely to distinguish the two eyes from each other. In other words, if the first eye is the left eye, the second eye will be the right eye, and vice versa. Referring to the "first eye" does not mean that the muscles and / or parts thereof close to the "second eye" always need to be treated. For example, the "first eye" may be referred to in the context of a unilateral disorder (e.g., unilateral blepharospasm), in which the muscles and / or parts thereof close to the second eye are not affected and, therefore, are not treated.

[0906] The term "proximal" means that the muscle and / or part thereof referred to is closest to the eye. For example, if the first eye is the individual's left eye, then the muscle and / or part thereof proximal to the first eye is the muscle and / or part thereof that is closer to the left eye than to the individual's right eye.

[0907] The modified BoNT / A can be administered to one or more other muscles and / or sites thereof. When administered to other muscles and / or sites thereof, it is preferred to set an upper limit on the unit dose to ensure that the total amount of modified BoNT / A administered does not exceed the total dose to be administered during the treatment period as defined herein.

[0908] The additional muscles and / or parts thereof treated can be one or more (e.g., at least two, three, four, five, six, seven, eight, nine, ten, eleven or twelve, or all) selected from the following: the medial inferior orbicularis oculi, the orbicularis oris (e.g., the superior orbicularis oris and / or the inferior orbicularis oris); the zygomaticus (e.g., the zygomaticus major); the nasalis; the mentalis; the platysma; the frontalis; the corrugator supercilii; the buccinator; the masseter; the procerus; and the lateral canthus. The additional muscles and / or parts thereof treated can be one or more (e.g., at least two, three, four, five, six, seven, eight, nine, ten, eleven or twelve, or all muscles and / or parts) selected from the following: medial inferior orbicularis oculi, superior orbicularis oris, inferior orbicularis oris, zygomaticus major, zygomaticus minor, frontalis, mentalis, platysma, corrugator supercilii, buccinator, masseter, procerus, nasalis and levator palpebrae superioris. The additional muscles and / or parts thereof treated can be one or more (e.g., at least two, three, four, five, six, seven, eight, nine, ten, eleven or twelve, or all muscles and / or parts) selected from the following: orbicularis oris superior, orbicularis oris inferior, zygomaticus major, zygomaticus minor, frontalis, mentalis, platysma, corrugator supercilii, buccinator, masseter, procerus, nasalis and levator palpebrae superioris.

[0909] Where muscles are listed for administration according to the treatment of the invention, the invention may also include administration to additional muscles which are not listed.

[0910] The muscles and / or parts thereof near one or both eyes can be treated as needed. At least a single unit dose can be administered to the muscles and / or parts thereof, for example two or more (e.g. three or more, four or more or five or more) unit doses can be administered.

[0911] The modified BoNT / A can also be administered to the medial inferior orbicularis oculi muscle (e.g., the medial pretarsal orbicularis oculi muscle of the lower eyelid). In one embodiment, only a single unit dose can be administered to the medial inferior orbicularis oculi muscle. The medial inferior orbicularis oculi muscle near one or both eyes can be treated as desired.

[0912] The modified BoNT / A can also be administered to the frontalis muscle. In one embodiment, at least a single unit dose can be administered only to the frontalis muscle, for example, two or more, three or more, four or more, or five or more unit doses can be administered. The frontalis muscle near one or both eyes can be treated as desired.

[0913] The modified BoNT / A can also be administered to the corrugator supercilii muscle. In one embodiment, at least a single unit dose can be administered only to the corrugator supercilii muscle, for example, two or more, three or more, four or more, or five or more unit doses can be administered. The corrugator supercilii muscle near one or both eyes can be treated as desired.

[0914] When treating hemifacial spasm, one or more (e.g., at least two, three, four, five, six, seven, eight, nine, ten or eleven or all) additional muscles and / or parts thereof may be treated, wherein the one or more muscles and / or parts thereof are selected from: the orbicularis oris (e.g., the superior orbicularis oris and / or the inferior orbicularis oris); the zygomaticus (e.g., the zygomaticus major); the nasalis; the mentalis; the platysma; the frontalis; the corrugator supercilii; the buccinator; the masseter; the procerus; and the lateral canthus. When treating hemifacial spasm, one or more (e.g., at least two, three, four, five, six, seven, eight, nine, ten or eleven or all) additional muscles and / or parts thereof may be treated, wherein the one or more muscles and / or parts thereof are selected from: the orbicularis oris (e.g., the superior orbicularis oris and / or the inferior orbicularis oris); the zygomaticus (e.g., the zygomaticus major and / or the zygomaticus minor); the nasalis; the mentalis; the platysma; the frontalis; the corrugator supercilii; the buccinator; the masseter; the procerus; and the levator palpebrae superioris.

[0915] Preferably, one or more (eg at least two, three or four or all) additional muscles and / or sites are selected from the group consisting of: corrugator supercilii, frontalis, zygomaticus, buccinator and masseter.

[0916] In the case where the facial spasm is bilateral, the modified BoNT / A can be administered to any muscle and / or site thereof on both sides of the face of the individual. When the facial spasm is hemifacial spasm, the modified BoNT / A can be administered to any muscle and / or site thereof on the affected side of the face of the individual. At least a single unit dose can be administered to the muscle and / or site thereof, for example, two or more (e.g., three or more, four or more, or five or more) unit doses can be administered.

[0917] The frontalis muscle may be the venter frontalis muscle.

[0918] The corrugator muscle may be the corrugator supercilii muscle.

[0919] In any aspect or embodiment of the invention directed to treating blepharospasm, it is particularly preferred that the modified BoNT / A is administered by intramuscular injection to each of the following sites:

[0920] a) Lateral superior orbicularis oculi muscle;

[0921] b) medial superior orbicularis oculi muscle; and

[0922] c) Lateral inferior orbicularis oculi muscle.

[0923] The (three) areas outlined directly in the above paragraph may be referred to as the "minimal" areas in the treatment of blepharospasm.

[0924] In other words, in any aspect or embodiment of the invention directed to treating blepharospasm, it is particularly preferred that the modified BoNT / A is administered by intramuscular injection to each of the following muscles:

[0925] a) the lateral superior orbicularis oculi muscle affected by said blepharospasm;

[0926] b) the medial superior orbicularis oculi muscle affected by said blepharospasm; and

[0927] c) The lateral inferior orbicularis oculi muscle affected by said blepharospasm.

[0928] In other words, in any aspect or embodiment of the invention directed to treating blepharospasm, it is particularly preferred that the modified BoNT / A is administered by intramuscular injection to each of the following muscles:

[0929] a) each lateral superior orbicularis oculi muscle affected by said blepharospasm;

[0930] b) each medial superior orbicularis oculi muscle affected by said blepharospasm; and

[0931] c) Each lateral inferior orbicularis oculi muscle affected by said blepharospasm.

[0932] For example, in the treatment of blepharospasm, it is particularly preferred that the method comprises:

[0933] a) administering up to two unit doses of a modified BoNT / A to the lateral superior orbicularis oculi muscle proximal to a first eye of the individual;

[0934] b) administering a unit dose of the modified BoNT / A to the inner superior orbicularis oculi muscle proximal to the first eye of the individual; and

[0935] c) administering a unit dose of the modified BoNT / A to the lateral inferior orbicularis oculi muscle proximal to the subject's first eye.

[0936] In other words, in treating blepharospasm, it is particularly preferred that the method comprises:

[0937] a) Administering up to two unit doses of the modified BoNT / A to each lateral superior orbicularis oculi muscle affected by the blepharospasm.

[0938] b) administering a unit dose of the modified BoNT / A to each medial superior orbicularis oculi muscle affected by said blepharospasm; and

[0939] c) applying a unit dose of the modified BoNT / A to each lateral inferior orbicularis oculi muscle affected by said blepharospasm.

[0940] For example, in the treatment of blepharospasm, it is particularly preferred that the method comprises:

[0941] a) administering two unit doses of a modified BoNT / A to the lateral superior orbicularis oculi muscle proximal to a first eye of the individual;

[0942] b) administering a single unit dose of the modified BoNT / A to the inner superior orbicularis oculi muscle proximal to the first eye of the individual; and

[0943] c) administering a single unit dose of the modified BoNT / A to the lateral inferior orbicularis oculi muscle proximal to the subject's first eye.

[0944] In other words, in treating blepharospasm, it is particularly preferred that the method comprises:

[0945] a) Two unit doses of modified BoNT / A were administered to each lateral superior orbicularis oculi muscle affected by the blepharospasm.

[0946] b) administering a single unit dose of the modified BoNT / A to each medial superior orbicularis oculi muscle affected by said blepharospasm; and

[0947] c) administering a single unit dose of the modified BoNT / A to each lateral inferior orbicularis oculi muscle affected by the blepharospasm.

[0948] Reference to the "upper" orbicularis oculi muscle refers to the orbicularis oculi muscle of the upper eyelid. Similarly, reference to the "lower" orbicularis oculi muscle refers to the orbicularis oculi muscle of the lower eyelid.

[0949] The term "medial" (e.g., in the context of anatomy) is understood by those skilled in the art to mean toward the midline of the body. Similarly, the term "lateral" (e.g., in the context of anatomy) is understood by those skilled in the art to mean away from the midline of the body. Thus:

[0950] - "Lateral" superior orbicularis oculi refers to the portion of the orbicularis oculi muscle of the upper eyelid that is located away from the midline of the body (e.g., see Figure 8 positions (1) and (2));

[0951] - "Medial" superior orbicularis oculi refers to the portion of the orbicularis oculi muscle of the upper eyelid that is oriented toward the midline of the body (e.g., see Figure 8 position (2));

[0952] - "Lateral" inferior orbicularis oculi refers to the portion of the orbicularis oculi muscle of the lower eyelid that is located away from the midline of the body (e.g., see Figure 8 location (4)).

[0953] The term "lateral superior orbicularis oculi muscle" may be used synonymously with the term "external part of the orbicularis oculi muscle of the upper eyelid." The term "medial superior orbicularis oculi muscle" may be used synonymously with the term "inner part of the orbicularis oculi muscle of the upper eyelid." The term "lateral inferior orbicularis oculi muscle" may be used synonymously with the term "external part of the orbicularis oculi muscle of the lower eyelid."

[0954] The orbicularis oculi muscle consists of a "pretarsal portion" and a "preseptal portion" (both of which can be injected).

[0955] Thus, application to the lateral superior orbicularis oculi muscle may mean application to the lateral "pretarsal" superior orbicularis oculi muscle, or application to the lateral "preseptal" superior orbicularis oculi muscle.

[0956] Application to the medial superior orbicularis oculi muscle may mean application to the medial superior "pretarsal" orbicularis oculi muscle, or application to the medial superior "preseptal" orbicularis oculi muscle.

[0957] Application to the lateral inferior orbicularis oculi muscle may mean application to the lateral inferior "pretarsal" orbicularis oculi muscle, or application to the lateral inferior "preseptal" orbicularis oculi muscle.

[0958] When administered to the lateral superior orbicularis oculi muscle, it is preferred that the unit dose is administered to the preseptal portion (in other words, to the lateral "preseptal" superior orbicularis oculi muscle). When administered to the medial superior orbicularis oculi muscle, it is preferred that the unit dose is administered to the preseptal portion (in other words, to the medial superior "preseptal" orbicularis oculi muscle). When administered to the lateral inferior orbicularis oculi muscle, it is preferred that the unit dose is administered to the preseptal portion (in other words, to the lateral inferior "preseptal" orbicularis oculi muscle).

[0959] In any aspect or embodiment of the invention directed to treating blepharospasm, the invention can further comprise administering one or more unit doses of a modified BoNT / A to one or more other muscles affected by said blepharospasm according to the following dosing regimen:

[0960] (i) administering one unit dose to the superior orbicularis oris muscle;

[0961] (ii) administering one unit dose to the inferior orbicularis oris muscle;

[0962] (iii) administering a unit dose to the zygomaticus major muscle;

[0963] (iv) administering a unit dose to the zygomaticus minor muscle;

[0964] (v) administering up to five unit doses (preferably one unit dose) to the frontalis muscle;

[0965] (vi) administering a unit dose to the mentalis muscle;

[0966] (vii) administering a unit dose to the platysma muscle;

[0967] (viii) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle;

[0968] (ix) administering a unit dose to the buccinator muscle;

[0969] (x) administering up to two unit doses (preferably one unit dose) to the masseter muscle;

[0970] (xi) administering a unit dose to the procerus muscle;

[0971] (xii) administering a unit dose to the nasal muscle; and / or

[0972] (xiii) Administer one unit dose to the levator palpebrae superioris muscle.

[0973] In any aspect or embodiment of the invention directed to treating blepharospasm, the invention can further comprise administering one or more unit doses of a modified BoNT / A to one or more other muscles affected by said blepharospasm according to the following dosing regimen:

[0974] (i) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle;

[0975] (ii) administering up to five unit doses (preferably one unit dose) to the frontalis muscle;

[0976] and / or

[0977] (iii) administering a unit dose to the procerus muscle.

[0978] In other words, in any aspect or embodiment of the invention directed to treating blepharospasm, the invention can further comprise administering one or more unit doses of a modified BoNT / A to one or more other muscles affected by said blepharospasm according to the following dosing regimen:

[0979] (i) up to two unit doses (preferably one unit dose) per corrugator muscle (e.g., the corrugator muscle affected by said blepharospasm);

[0980] (ii) administering up to five unit doses (preferably one unit dose) to the frontalis muscle;

[0981] and / or

[0982] (iii) administering a unit dose to the procerus muscle.

[0983] In any aspect or embodiment of the invention directed to treating blepharospasm, the invention can further comprise administering one or more unit doses of a modified BoNT / A to one or more other muscles affected by said blepharospasm according to the following dosing regimen:

[0984] (i) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle; or administering one unit dose to the procerus supercilii muscle; and / or

[0985] (ii) administering up to five unit doses (preferably one unit dose) to the frontalis muscle.

[0986] In other words, in any aspect or embodiment of the invention directed to treating blepharospasm, the invention can further comprise administering one or more unit doses of a modified BoNT / A to one or more other muscles affected by said blepharospasm according to the following dosing regimen:

[0987] (i) up to two unit doses (preferably one unit dose) per corrugator supercilii muscle (e.g., the corrugator supercilii muscle affected by said blepharospasm); or one unit dose is administered to the procerus supercilii muscle; and / or

[0988] (ii) administering up to five unit doses (preferably one unit dose) to the frontalis muscle.

[0989] In any aspect or embodiment of the invention directed to treating blepharospasm, the invention can further comprise administering one or more unit doses of a modified BoNT / A to one or more other muscles affected by said blepharospasm according to the following dosing regimen:

[0990] (i) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle, and / or administering one unit dose to the procerus supercilii muscle; and optionally

[0991] (ii) administering up to five unit doses (preferably one unit dose) to the frontalis muscle.

[0992] In other words, in any aspect or embodiment of the invention directed to treating blepharospasm, the invention can further comprise administering one or more unit doses of a modified BoNT / A to one or more other muscles affected by said blepharospasm according to the following dosing regimen:

[0993] (i) up to two unit doses (preferably one unit dose) per corrugator supercilii muscle (e.g., the corrugator supercilii muscle affected by said blepharospasm), and / or one unit dose to the procerus supercilii muscle; and optionally

[0994] (ii) administering up to five unit doses (preferably one unit dose) to the frontalis muscle.

[0995] In any aspect or embodiment of the invention directed to treating blepharospasm, the invention can further comprise administering the modified BoNT / A to other muscles affected by said blepharospasm according to the following dosing regimen:

[0996] (i) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle;

[0997] (ii) administering up to five unit doses (preferably one unit dose) to the frontalis muscle;

[0998] and

[0999] (iii) administering a unit dose to the procerus muscle.

[1000] In other words, in any aspect or embodiment of the invention directed to treating blepharospasm, the invention can further comprise administering the modified BoNT / A to other muscles affected by said blepharospasm according to the following dosing regimen:

[1001] (i) up to two unit doses (preferably one unit dose) per corrugator muscle (e.g., the corrugator muscle affected by said blepharospasm);

[1002] (ii) administering up to five unit doses (preferably one unit dose) to the frontalis muscle;

[1003] and

[1004] (iii) administering a unit dose to the procerus muscle.

[1005] In any aspect or embodiment of the invention directed to treating blepharospasm, the invention can further comprise administering the modified BoNT / A to other muscles affected by said blepharospasm according to the following dosing regimen:

[1006] (i) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle; or administering one unit dose to the procerus supercilii muscle; and

[1007] (ii) administering up to five unit doses (preferably one unit dose) to the frontalis muscle.

[1008] In other words, in any aspect or embodiment of the invention directed to treating blepharospasm, the invention can further comprise administering the modified BoNT / A to other muscles affected by said blepharospasm according to the following dosing regimen:

[1009] (i) up to two unit doses (preferably one unit dose) per corrugator supercilii muscle (e.g., the corrugator supercilii muscle affected by said blepharospasm); or one unit dose to the procerus supercilii muscle; and

[1010] (ii) administering up to five unit doses (preferably one unit dose) to the frontalis muscle.

[1011] In any aspect or embodiment of the invention directed to treating blepharospasm, the invention can further comprise administering one or more unit doses of a modified BoNT / A to one or more other muscles affected by said blepharospasm according to the following dosing regimen:

[1012] (i) administering a unit dose to the corrugator supercilii muscle;

[1013] (ii) administering two unit doses to the frontalis muscle (e.g., one unit dose for each affected eye); and / or

[1014] (iii) administering a unit dose to the procerus muscle.

[1015] In other words, in any aspect or embodiment of the invention directed to treating blepharospasm, the invention can further comprise administering one or more unit doses of a modified BoNT / A to one or more other muscles affected by said blepharospasm according to the following dosing regimen:

[1016] (i) one unit dose per corrugator muscle (e.g., the corrugator muscle affected by the blepharospasm);

[1017] (ii) administering two unit doses to the frontalis muscle (e.g., one unit dose for each affected eye); and / or

[1018] (iii) administering a unit dose to the procerus muscle.

[1019] In any aspect or embodiment of the invention directed to treating blepharospasm, the invention can further comprise administering one or more unit doses of a modified BoNT / A to one or more other muscles affected by said blepharospasm according to the following dosing regimen:

[1020] (i) administering a unit dose to the corrugator supercilii muscle, or administering a unit dose to the procerus supercilii muscle; and / or

[1021] (ii) Two unit doses are administered to the frontalis muscle (eg, one unit dose for each affected eye).

[1022] In other words, in any aspect or embodiment of the invention directed to treating blepharospasm, the invention can further comprise administering one or more unit doses of a modified BoNT / A to one or more other muscles affected by said blepharospasm according to the following dosing regimen:

[1023] (i) one unit dose per corrugator supercilii muscle (e.g., the corrugator supercilii muscle affected by said blepharospasm), or one unit dose administered to the procerus supercilii muscle; and / or

[1024] (ii) Two unit doses were administered to the frontalis muscle.

[1025] In any aspect or embodiment of the invention directed to treating blepharospasm, the invention can further comprise administering the modified BoNT / A to other muscles affected by said blepharospasm according to the following dosing regimen:

[1026] (i) administering a unit dose to the corrugator supercilii muscle;

[1027] (ii) administering two unit doses to the frontalis muscle (e.g., one unit dose for each affected eye); and

[1028] (iii) administering a unit dose to the procerus muscle.

[1029] In other words, in any aspect or embodiment of the invention directed to treating blepharospasm, the invention can further comprise administering the modified BoNT / A to other muscles affected by said blepharospasm according to the following dosing regimen:

[1030] (i) one unit dose per corrugator muscle (e.g., the corrugator muscle affected by the blepharospasm);

[1031] (ii) administering two unit doses to the frontalis muscle (e.g., one unit dose for each affected eye); and

[1032] (iii) administering a unit dose to the procerus muscle.

[1033] In any aspect or embodiment of the invention directed to treating blepharospasm, the invention can further comprise administering the modified BoNT / A to other muscles affected by said blepharospasm according to the following dosing regimen:

[1034] (i) administering one unit dose to the corrugator supercilii muscle, or administering one unit dose to the procerus supercilii muscle; and

[1035] (ii) Two unit doses are administered to the frontalis muscle (eg, one unit dose for each affected eye).

[1036] In other words, in any aspect or embodiment of the invention directed to treating blepharospasm, the invention can further comprise administering the modified BoNT / A to other muscles affected by said blepharospasm according to the following dosing regimen:

[1037] (i) one unit dose per corrugator muscle (e.g., the corrugator muscle affected by said blepharospasm), or one unit dose administered to the procerus muscle; and

[1038] (ii) Two unit doses were administered to the frontalis muscle.

[1039] In any aspect or embodiment of the invention directed to treating blepharospasm, the invention can further comprise administering one unit dose to the superior orbicularis oris muscle; and optionally administering one or more unit doses of a modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, or 12 or more) other muscles affected by said blepharospasm according to the following dosing regimen:

[1040] (i) one unit dose is administered to the orbicularis oris inferior muscle; (ii) one unit dose is administered to the zygomaticus major muscle; (iii) one unit dose is administered to the zygomaticus minor muscle; (iv) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (v) one unit dose is administered to the mentalis muscle; (vi) one unit dose is administered to the platysma muscle; (vii) up to two unit doses are administered to the corrugator supercilii muscle (preferably one unit dose); (viii) one unit dose is administered to the buccinator muscle; (ix) up to two unit doses are administered to the masseter muscle (preferably one unit dose); (x) one unit dose is administered to the procerus muscle; (x). One unit dose is administered to the nasalis muscle; and / or (xii) one unit dose is administered to the levator palpebrae superioris muscle.

[1041] In any aspect or embodiment of the invention directed to treating blepharospasm, the invention can further comprise administering one unit dose to the inferior orbicularis oris muscle; and optionally administering one or more unit doses of a modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, or 12 or more) other muscles affected by said blepharospasm according to the following dosing regimen:

[1042] (i) one unit dose is administered to the orbicularis oris superior muscle; (ii) one unit dose is administered to the zygomaticus major muscle; (iii) one unit dose is administered to the zygomaticus minor muscle; (iv) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (v) one unit dose is administered to the mentalis muscle; (vi) one unit dose is administered to the platysma muscle; (vii) up to two unit doses are administered to the corrugator supercilii muscle (preferably one unit dose); (viii) one unit dose is administered to the buccinator muscle; (ix) up to two unit doses are administered to the masseter muscle (preferably one unit dose); (x) one unit dose is administered to the procerus muscle; (x) one unit dose is administered to the nasalis muscle; and / or (xii) one unit dose is administered to the levator palpebrae superioris muscle.

[1043] In any aspect or embodiment of the invention directed to treating blepharospasm, the invention can further comprise administering one unit dose to the zygomaticus major muscle; and optionally administering one or more unit doses of a modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, or 12 or more) other muscles affected by said blepharospasm according to the following dosing regimen:

[1044] (i) one unit dose is administered to the inferior orbicularis oris muscle; (ii) one unit dose is administered to the superior orbicularis oris muscle; (iii) one unit dose is administered to the zygomaticus minor muscle; (iv) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (v) one unit dose is administered to the mentalis muscle; (vi) one unit dose is administered to the platysma muscle; (vii) up to two unit doses are administered to the corrugator supercilii muscle (preferably one unit dose); (viii) one unit dose is administered to the buccinator muscle; (ix) up to two unit doses are administered to the masseter muscle (preferably one unit dose); (x) one unit dose is administered to the procerus muscle; (x) one unit dose is administered to the nasalis muscle; and / or (xii) one unit dose is administered to the levator palpebrae superioris muscle.

[1045] In any aspect or embodiment of the invention directed to treating blepharospasm, the invention can further comprise administering one unit dose to the zygomaticus minor muscle; and optionally administering one or more unit doses of a modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, or 12 or more) other muscles affected by said blepharospasm according to the following dosing regimen:

[1046] (i) one unit dose is administered to the inferior orbicularis oris muscle; (ii) one unit dose is administered to the zygomatic major muscle; (iii) one unit dose is administered to the superior orbicularis oris muscle; (iv) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (v) one unit dose is administered to the mentalis muscle; (vi) one unit dose is administered to the platysma muscle; (vii) up to two unit doses are administered to the corrugator supercilii muscle (preferably one unit dose); (viii) one unit dose is administered to the buccinator muscle; (ix) up to two unit doses are administered to the masseter muscle (preferably one unit dose); (x) one unit dose is administered to the procerus muscle; (x) one unit dose is administered to the nasalis muscle; and / or (xii) one unit dose is administered to the levator palpebrae superioris muscle.

[1047] In any aspect or embodiment of the invention directed to treating blepharospasm, the invention can further comprise administering up to five unit doses (preferably one unit dose; more preferably two unit doses; most preferably three unit doses) to the frontalis muscle; and optionally administering one or more unit doses of the modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, or 12 or more) other muscles affected by said blepharospasm according to the following dosing regimen:

[1048] (i) one unit dose is administered to the inferior orbicularis oris muscle; (ii) one unit dose is administered to the zygomatic major muscle; (iii) one unit dose is administered to the zygomatic minor muscle; (iv) one unit dose is administered to the superior orbicularis oris muscle; (v) one unit dose is administered to the mentalis muscle; (vi) one unit dose is administered to the platysma muscle; (vii) up to two unit doses (preferably one unit dose) are administered to the corrugator supercilii muscle; (viii) one unit dose is administered to the buccinator muscle; (ix) up to two unit doses (preferably one unit dose) are administered to the masseter muscle; (x) one unit dose is administered to the procerus muscle; (x) one unit dose is administered to the nasalis muscle; and / or (xii) one unit dose is administered to the levator palpebrae superioris muscle.

[1049] In any aspect or embodiment of the invention directed to treating blepharospasm, the invention can further comprise administering one unit dose to the mentalis muscle; and optionally administering one or more unit doses of a modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, or 12 or more) other muscles affected by said blepharospasm according to the following dosing regimen:

[1050] (i) one unit dose is administered to the inferior orbicularis oris muscle; (ii) one unit dose is administered to the zygomatic major muscle; (iii) one unit dose is administered to the zygomatic minor muscle; (iv) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (v) one unit dose is administered to the superior orbicularis oris muscle; (vi) one unit dose is administered to the platysma muscle; (vii) up to two unit doses are administered to the corrugator supercilii muscle (preferably one unit dose); (viii) one unit dose is administered to the buccinator muscle; (ix) up to two unit doses are administered to the masseter muscle (preferably one unit dose); (x) one unit dose is administered to the procerus muscle; (x). One unit dose is administered to the nasalis muscle; and / or (xii) one unit dose is administered to the levator palpebrae superioris muscle.

[1051] In any aspect or embodiment of the invention directed to treating blepharospasm, the invention can further comprise administering one unit dose to the platysma muscle; and optionally administering one or more unit doses of a modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, or 12 or more) other muscles affected by said blepharospasm according to the following dosing regimen:

[1052] (i) one unit dose is administered to the inferior orbicularis oris muscle; (ii) one unit dose is administered to the zygomatic major muscle; (iii) one unit dose is administered to the zygomatic minor muscle; (iv) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (v) one unit dose is administered to the mentalis muscle; (vi) one unit dose is administered to the superior orbicularis oris muscle; (vii) up to two unit doses are administered to the corrugator supercilii muscle (preferably one unit dose); (viii) one unit dose is administered to the buccinator muscle; (ix) up to two unit doses are administered to the masseter muscle (preferably one unit dose); (x) one unit dose is administered to the procerus muscle; (x) one unit dose is administered to the nasalis muscle; and / or (xii) one unit dose is administered to the levator palpebrae superioris muscle.

[1053] In any aspect or embodiment of the invention directed to treating blepharospasm, the invention can further comprise administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle; and optionally administering one or more unit doses of a modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, or 12 or more) of the other muscles affected by said blepharospasm according to the following dosing regimen:

[1054] (i) one unit dose is administered to the inferior orbicularis oris muscle; (ii) one unit dose is administered to the zygomaticus major muscle; (iii) one unit dose is administered to the zygomaticus minor muscle; (iv) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (v) one unit dose is administered to the mentalis muscle; (vi) one unit dose is administered to the platysma muscle; (vii) one unit dose is administered to the superior orbicularis oris muscle; (viii) one unit dose is administered to the buccinator muscle; (ix) up to two unit doses are administered to the masseter muscle (preferably one unit dose); (x) one unit dose is administered to the procerus procerus muscle; (x). One unit dose is administered to the nasalis muscle; and / or (xii) one unit dose is administered to the levator palpebrae superioris muscle.

[1055] In any aspect or embodiment of the invention directed to treating blepharospasm, the invention can further comprise administering one unit dose to the buccinator muscle; and optionally administering one or more unit doses of a modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, or 12 or more) other muscles affected by said blepharospasm according to the following dosing regimen:

[1056] (i) one unit dose is administered to the inferior orbicularis oris muscle; (ii) one unit dose is administered to the zygomatic major muscle; (iii) one unit dose is administered to the zygomatic minor muscle; (iv) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (v) one unit dose is administered to the mentalis muscle; (vi) one unit dose is administered to the platysma muscle; (vii) up to two unit doses are administered to the corrugator supercilii muscle (preferably one unit dose); (viii) one unit dose is administered to the superior orbicularis oris muscle; (ix) up to two unit doses are administered to the masseter muscle (preferably one unit dose); (x) one unit dose is administered to the procerus muscle; (x). One unit dose is administered to the nasalis muscle; and / or (xii) one unit dose is administered to the levator palpebrae superioris muscle.

[1057] In any aspect or embodiment of the invention directed to treating blepharospasm, the invention can further comprise administering up to two unit doses (preferably one unit dose) to the masseter muscle; and optionally administering one or more unit doses of the modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, or 12 or more) other muscles affected by said blepharospasm according to the following dosing regimen:

[1058] (i) one unit dose is administered to the inferior orbicularis oris muscle; (ii) one unit dose is administered to the zygomaticus major muscle; (iii) one unit dose is administered to the zygomaticus minor muscle; (iv) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (v) one unit dose is administered to the mentalis muscle; (vi) one unit dose is administered to the platysma muscle; (vii) up to two unit doses are administered to the corrugator supercilii muscle (preferably one unit dose); (viii) one unit dose is administered to the buccinator muscle; (ix) one unit dose is administered to the superior orbicularis oris muscle; (x) one unit dose is administered to the procerus procerus muscle; (x) one unit dose is administered to the nasalis muscle; and / or (xii) one unit dose is administered to the levator palpebrae superioris muscle.

[1059] In any aspect or embodiment of the invention directed to treating blepharospasm, the invention can further comprise administering one unit dose to the procerus muscle; and optionally administering one or more unit doses of a modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, or 12 or more) other muscles affected by said blepharospasm according to the following dosing regimen:

[1060] (i) one unit dose is administered to the inferior orbicularis oris muscle; (ii) one unit dose is administered to the zygomatic major muscle; (iii) one unit dose is administered to the zygomatic minor muscle; (iv) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (v) one unit dose is administered to the mentalis muscle; (vi) one unit dose is administered to the platysma muscle; (vii) up to two unit doses are administered to the corrugator supercilii muscle (preferably one unit dose); (viii) one unit dose is administered to the buccinator muscle; (ix) up to two unit doses are administered to the masseter muscle (preferably one unit dose); (x) one unit dose is administered to the superior orbicularis oris muscle; (x) one unit dose is administered to the nasalis muscle; and / or (xii) one unit dose is administered to the levator palpebrae superioris muscle.

[1061] In any aspect or embodiment of the invention directed to treating blepharospasm, the invention can further comprise administering one unit dose to a nasal muscle; and optionally administering one or more unit doses of a modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, or 12 or more) other muscles affected by said blepharospasm according to the following dosing regimen:

[1062] (i) one unit dose is administered to the inferior orbicularis oris muscle; (ii) one unit dose is administered to the zygomatic major muscle; (iii) one unit dose is administered to the zygomatic minor muscle; (iv) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (v) one unit dose is administered to the mentalis muscle; (vi) one unit dose is administered to the platysma muscle; (vii) up to two unit doses are administered to the corrugator supercilii muscle (preferably one unit dose); (viii) one unit dose is administered to the buccinator muscle; (ix) up to two unit doses are administered to the masseter muscle (preferably one unit dose); (x) one unit dose is administered to the procerus procerus muscle; (x) one unit dose is administered to the superior orbicularis oris muscle; and / or (xii) one unit dose is administered to the levator palpebrae superioris muscle.

[1063] In any aspect or embodiment of the invention directed to treating blepharospasm, the invention can further comprise administering one unit dose to the levator palpebrae superioris muscle; and optionally administering one or more unit doses of a modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, or 12 or more) other muscles affected by said blepharospasm according to the following dosing regimen:

[1064] (i) one unit dose is administered to the inferior orbicularis oris muscle; (ii) one unit dose is administered to the zygomatic major muscle; (iii) one unit dose is administered to the zygomatic minor muscle; (iv) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (v) one unit dose is administered to the mentalis muscle; (vi) one unit dose is administered to the platysma muscle; (vii) up to two unit doses are administered to the corrugator supercilii muscle (preferably one unit dose); (viii) one unit dose is administered to the buccinator muscle; (ix) up to two unit doses are administered to the masseter muscle (preferably one unit dose); (x) one unit dose is administered to the procerus muscle; (x) one unit dose is administered to the nasalis muscle; and / or (xii) one unit dose is administered to the superior orbicularis oris muscle.

[1065] As described above, in aspects of the invention directed to treating classic hemifacial spasm, the invention can include administering one or more unit doses of a modified BoNT / A to one or more other muscles affected by said classic hemifacial spasm according to the following dosing regimen: (i) one unit dose to the superior orbicularis oris muscle; (ii) one unit dose to the inferior orbicularis oris muscle; (iii) one unit dose to the zygomaticus major muscle; (iv) one unit dose to the zygomaticus minor muscle; (v) up to five unit doses (preferably one unit dose) to the frontalis muscle; (vi) one unit dose to the mentalis muscle; (vii) one unit dose to the platysma muscle; (viii) up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle; (ix) one unit dose to the buccinator muscle; (x) up to two unit doses (preferably one unit dose) to the masseter muscle; (xi) one unit dose to the procerus muscle; (xii) one unit dose to the nasalis muscle; and / or (xiii) one unit dose to the levator palpebrae superioris muscle.

[1066] In any aspect or embodiment of the invention directed to treating classic hemifacial spasm, the invention can further comprise: (i) administering one unit dose to the superior orbicularis oris muscle affected by said classic hemifacial spasm; and optionally administering one or more unit doses of the modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, or 12 or more) other muscles affected by said classic hemifacial spasm according to the following dosing regimen:

[1067] (ii) one unit dose is administered to the orbicularis oris inferior muscle; (iii) one unit dose is administered to the zygomaticus major muscle; (iv) one unit dose is administered to the zygomaticus minor muscle; (v) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (vi) one unit dose is administered to the mentalis muscle; (vii) one unit dose is administered to the platysma muscle; (viii) up to two unit doses are administered to the corrugator supercilii muscle (preferably one unit dose); (ix) one unit dose is administered to the buccinator muscle; (x) up to two unit doses are administered to the masseter muscle (preferably one unit dose); (xi) one unit dose is administered to the procerus muscle; (xii) one unit dose is administered to the nasalis muscle; and / or (xiii) one unit dose is administered to the levator palpebrae superioris muscle.

[1068] In any aspect or embodiment of the invention directed to treating classic hemifacial spasm, the invention can further comprise administering one unit dose to the inferior orbicularis oris muscle affected by said classic hemifacial spasm; and optionally administering one or more unit doses of a modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, or 12 or more) other muscles affected by said classic hemifacial spasm according to the following dosing regimen:

[1069] (i) one unit dose is administered to the orbicularis oris superior muscle; (ii) one unit dose is administered to the zygomaticus major muscle; (iii) one unit dose is administered to the zygomaticus minor muscle; (iv) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (v) one unit dose is administered to the mentalis muscle; (vi) one unit dose is administered to the platysma muscle; (vii) up to two unit doses are administered to the corrugator supercilii muscle (preferably one unit dose); (iix) one unit dose is administered to the buccinator muscle; (ix) up to two unit doses are administered to the masseter muscle (preferably one unit dose); (x) one unit dose is administered to the procerus muscle; (xi) one unit dose is administered to the nasalis muscle; and / or (xii) one unit dose is administered to the levator palpebrae superioris muscle.

[1070] In any aspect or embodiment of the invention directed to treating classic hemifacial spasm, the invention can further comprise: administering one unit dose to the zygomatic major muscle affected by said classic hemifacial spasm; and optionally administering one or more unit doses of the modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, or 12 or more) other muscles affected by said classic hemifacial spasm according to the following dosing regimen:

[1071] (i) one unit dose is administered to the superior orbicularis oris muscle; (ii) one unit dose is administered to the zygomaticus minor muscle; (iii) the inferior orbicularis oris muscle; (iv) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (v) one unit dose is administered to the mentalis muscle; (vi) one unit dose is administered to the platysma muscle; (vii) up to two unit doses are administered to the corrugator supercilii muscle (preferably one unit dose); (iix) one unit dose is administered to the buccinator muscle; (ix) up to two unit doses are administered to the masseter muscle (preferably one unit dose); (x) one unit dose is administered to the procerus muscle; (xi) one unit dose is administered to the nasalis muscle; and / or (xii) one unit dose is administered to the levator palpebrae superioris muscle.

[1072] In any aspect or embodiment of the invention directed to treating classic hemifacial spasm, the invention can further comprise: administering one unit dose to the zygomaticus minor muscle affected by said classic hemifacial spasm; and optionally administering one or more unit doses of the modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, or 12 or more) other muscles affected by said classic hemifacial spasm according to the following dosing regimen:

[1073] (i) one unit dose is administered to the superior orbicularis oris muscle; (ii) one unit dose is administered to the zygomatic major muscle; (iii) one unit dose is administered to the inferior orbicularis oris muscle; (iv) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (v) one unit dose is administered to the mentalis muscle; (vi) one unit dose is administered to the platysma muscle; (vii) up to two unit doses are administered to the corrugator supercilii muscle (preferably one unit dose); (iix) one unit dose is administered to the buccinator muscle; (ix) up to two unit doses are administered to the masseter muscle (preferably one unit dose); (x) one unit dose is administered to the procerus muscle; (xi) one unit dose is administered to the nasalis muscle; and / or (xii) one unit dose is administered to the levator palpebrae superioris muscle.

[1074] In any aspect or embodiment of the invention directed to treating classic hemifacial spasm, the invention can further comprise: administering up to five unit doses (preferably one unit dose) to the frontalis muscle affected by said classic hemifacial spasm; and optionally administering one or more unit doses of the modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, or 12 or more) of the other muscles affected by said classic hemifacial spasm according to the following dosing regimen:

[1075] (i) one unit dose is administered to the superior orbicularis oris muscle; (ii) one unit dose is administered to the zygomaticus major muscle; (iii) one unit dose is administered to the zygomaticus minor muscle; (iv) one unit dose is administered to the inferior orbicularis oris muscle; (v) one unit dose is administered to the mentalis muscle; (vi) one unit dose is administered to the platysma muscle; (vii) up to two unit doses (preferably one unit dose) are administered to the corrugator supercilii muscle; (iix) one unit dose is administered to the buccinator muscle; (ix) up to two unit doses (preferably one unit dose) are administered to the masseter muscle; (x) one unit dose is administered to the procerus muscle; (xi) one unit dose is administered to the nasalis muscle; and / or (xii) one unit dose is administered to the levator palpebrae superioris muscle.

[1076] In any aspect or embodiment of the invention directed to treating classic hemifacial spasm, the invention can further comprise: administering one unit dose to the mentalis muscle affected by said classic hemifacial spasm; and optionally administering one or more unit doses of the modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, or 12 or more) other muscles affected by said classic hemifacial spasm according to the following dosing regimen:

[1077] (i) one unit dose is administered to the superior orbicularis oris muscle; (ii) one unit dose is administered to the zygomaticus major muscle; (iii) one unit dose is administered to the zygomaticus minor muscle; (iv) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (v) one unit dose is administered to the inferior orbicularis oris muscle; (vi) one unit dose is administered to the platysma muscle; (vii) up to two unit doses are administered to the corrugator supercilii muscle (preferably one unit dose); (iix) one unit dose is administered to the buccinator muscle; (ix) up to two unit doses are administered to the masseter muscle (preferably one unit dose); (x) one unit dose is administered to the procerus muscle; (xi) one unit dose is administered to the nasalis muscle; and / or (xii) one unit dose is administered to the levator palpebrae superioris muscle.

[1078] In any aspect or embodiment of the invention directed to treating classic hemifacial spasm, the invention can further comprise: administering one unit dose to the platysma muscle affected by said classic hemifacial spasm; and optionally administering one or more unit doses of the modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, or 12 or more) other muscles affected by said classic hemifacial spasm according to the following dosing regimen:

[1079] (i) one unit dose is administered to the superior orbicularis oris muscle; (ii) one unit dose is administered to the zygomaticus major muscle; (iii) one unit dose is administered to the zygomaticus minor muscle; (iv) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (v) one unit dose is administered to the mentalis muscle; (vi) one unit dose is administered to the inferior orbicularis oris muscle; (vii) up to two unit doses are administered to the corrugator supercilii muscle (preferably one unit dose); (iix) one unit dose is administered to the buccinator muscle; (ix) up to two unit doses are administered to the masseter muscle (preferably one unit dose); (x) one unit dose is administered to the procerus muscle; (xi) one unit dose is administered to the nasalis muscle; and / or (xii) one unit dose is administered to the levator palpebrae superioris muscle.

[1080] In any aspect or embodiment of the invention directed to treating classic hemifacial spasm, the invention can further comprise: administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle affected by said classic hemifacial spasm; and optionally administering one or more unit doses of the modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, or 12 or more) of the other muscles affected by said classic hemifacial spasm according to the following dosing regimen:

[1081] (i) one unit dose is administered to the superior orbicularis oris muscle; (ii) one unit dose is administered to the zygomaticus major muscle; (iii) one unit dose is administered to the zygomaticus minor muscle; (iv) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (v) one unit dose is administered to the mentalis muscle; (vi) one unit dose is administered to the platysma muscle; (vii) one unit dose is administered to the inferior orbicularis oris muscle; (iix) one unit dose is administered to the buccinator muscle; (ix) up to two unit doses are administered to the masseter muscle (preferably one unit dose); (x) one unit dose is administered to the procerus muscle; (xi) one unit dose is administered to the nasalis muscle; and / or (xii) one unit dose is administered to the levator palpebrae superioris muscle.

[1082] In any aspect or embodiment of the invention directed to treating classic hemifacial spasm, the invention can further comprise: administering one unit dose to the buccinator muscle affected by said classic hemifacial spasm; and optionally administering one or more unit doses of the modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, or 12 or more) other muscles affected by said classic hemifacial spasm according to the following dosing regimen:

[1083] (i) one unit dose is administered to the superior orbicularis oris; (ii) one unit dose is administered to the zygomaticus major; (iii) one unit dose is administered to the zygomaticus minor; (iv) up to five unit doses are administered to the frontalis (preferably one unit dose); (v) one unit dose is administered to the mentalis; (vi) one unit dose is administered to the platysma; (vii) up to two unit doses are administered to the corrugator supercilii (preferably one unit dose); (iix) one unit dose is administered to the inferior orbicularis oris; (ix) up to two unit doses are administered to the masseter; (x) one unit dose is administered to the procerus; (xi) one unit dose is administered to the nasalis; and / or (xii) one unit dose is administered to the levator palpebrae superioris.

[1084] In any aspect or embodiment of the invention directed to treating classic hemifacial spasm, the invention can further comprise: administering up to two unit doses (preferably one unit dose) to the masseter muscle affected by said classic hemifacial spasm; and optionally administering one or more unit doses of the modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, or 12 or more) of the other muscles affected by said classic hemifacial spasm according to the following dosing regimen:

[1085] (i) one unit dose is administered to the superior orbicularis oris; (ii) one unit dose is administered to the zygomaticus major; (iii) one unit dose is administered to the zygomaticus minor; (iv) up to five unit doses are administered to the frontalis (preferably one unit dose); (v) one unit dose is administered to the mentalis; (vi) one unit dose is administered to the platysma; (vii) up to two unit doses are administered to the corrugator supercilii (preferably one unit dose); (iix) one unit dose is administered to the buccinator; (ix) one unit dose is administered to the inferior orbicularis oris; (x) one unit dose is administered to the procerus; (xi) one unit dose is administered to the nasalis; and / or (xii) one unit dose is administered to the levator palpebrae superioris.

[1086] In any aspect or embodiment of the invention directed to treating classic hemifacial spasm, the invention can further comprise: administering one unit dose to the procerus muscle affected by said classic hemifacial spasm; and optionally administering one or more unit doses of the modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, or 12 or more) other muscles affected by said classic hemifacial spasm according to the following dosing regimen:

[1087] (i) one unit dose is administered to the superior orbicularis oris muscle; (ii) one unit dose is administered to the zygomatic major muscle; (iii) one unit dose is administered to the zygomatic minor muscle; (iv) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (v) one unit dose is administered to the mentalis muscle; (vi) one unit dose is administered to the platysma muscle; (vii) up to two unit doses are administered to the corrugator supercilii muscle (preferably one unit dose); (iix) one unit dose is administered to the buccinator muscle; (ix) up to two unit doses are administered to the masseter muscle (preferably one unit dose); (x) one unit dose is administered to the inferior orbicularis oris muscle; (xi) one unit dose is administered to the nasalis muscle; and / or (xii) one unit dose is administered to the levator palpebrae superioris muscle.

[1088] In any aspect or embodiment of the invention directed to treating classic hemifacial spasm, the invention can further comprise: administering one unit dose to a nasal muscle affected by said classic hemifacial spasm; and optionally administering one or more unit doses of a modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, or 12 or more) other muscles affected by said classic hemifacial spasm according to the following dosing regimen:

[1089] (i) one unit dose is administered to the superior orbicularis oris muscle; (ii) one unit dose is administered to the zygomaticus major muscle; (iii) one unit dose is administered to the zygomaticus minor muscle; (iv) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (v) one unit dose is administered to the mentalis muscle; (vi) one unit dose is administered to the platysma muscle; (vii) up to two unit doses are administered to the corrugator supercilii muscle (preferably one unit dose); (iix) one unit dose is administered to the buccinator muscle; (ix) up to two unit doses are administered to the masseter muscle (preferably one unit dose); (x) one unit dose is administered to the procerus muscle; (xi) one unit dose is administered to the inferior orbicularis oris muscle; and / or (xii) one unit dose is administered to the levator palpebrae superioris muscle.

[1090] In any aspect or embodiment of the invention directed to treating classic hemifacial spasm, the invention can further comprise: administering one unit dose to the levator palpebrae superioris muscle affected by said classic hemifacial spasm; and optionally administering one or more unit doses of the modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, or 12 or more) other muscles affected by said classic hemifacial spasm according to the following dosing regimen:

[1091] (i) one unit dose is administered to the superior orbicularis oris muscle; (ii) one unit dose is administered to the zygomaticus major muscle; (iii) one unit dose is administered to the zygomaticus minor muscle; (iv) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (v) one unit dose is administered to the mentalis muscle; (vi) one unit dose is administered to the platysma muscle; (vii) up to two unit doses are administered to the corrugator supercilii muscle (preferably one unit dose); (iix) one unit dose is administered to the buccinator muscle; (ix) up to two unit doses are administered to the masseter muscle (preferably one unit dose); (x) one unit dose is administered to the procerus muscle; (xi) one unit dose is administered to the nasalis muscle; and / or (xii) one unit dose is administered to the inferior orbicularis oris muscle.

[1092] As described above, in aspects of the invention directed to treating atypical hemifacial spasm, the invention may include administering one or more unit doses of a modified BoNT / A to one or more other muscles affected by said atypical hemifacial spasm according to the following dosing regimen:

[1093] (i) one unit dose is administered to the zygomatic major muscle; (ii) one unit dose is administered to the zygomatic minor muscle; (iii) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (iv) one unit dose is administered to the mentalis muscle; (v) one unit dose is administered to the platysma muscle; (vi) up to two unit doses are administered to the corrugator supercilii muscle (preferably one unit dose); (vii) one unit dose is administered to the buccinator muscle; (viii) up to two unit doses are administered to the masseter muscle (preferably one unit dose); (ix) one unit dose is administered to the procerus muscle; (x) one unit dose is administered to the nasalis muscle; (xi) one unit dose is administered to the lateral superior orbicularis oculi muscle; (xii) one unit dose is administered to the medial superior orbicularis oculi muscle; (xiii) one unit dose is administered to the lateral inferior orbicularis oculi muscle; and / or (xiv) one unit dose is administered to the levator palpebrae superioris muscle.

[1094] In any aspect or embodiment of the invention directed to treating atypical hemifacial spasm, the invention can further comprise: (i) administering one unit dose to the zygomatic major muscle affected by said atypical hemifacial spasm; and optionally administering one or more unit doses of the modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, or 13 or more) additional muscles affected by said atypical hemifacial spasm according to the following dosing regimen:

[1095] (ii) one unit dose is administered to the zygomaticus minor; (iii) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (iv) one unit dose is administered to the mentalis muscle; (v) one unit dose is administered to the platysma muscle; (vi) up to two unit doses are administered to the corrugator supercilii muscle (preferably one unit dose); (vii) one unit dose is administered to the buccinator muscle; (viii) up to two unit doses are administered to the masseter muscle (preferably one unit dose); (ix) one unit dose is administered to the procerus muscle; (x) one unit dose is administered to the nasalis muscle; (xi) one unit dose is administered to the lateral superior orbicularis oculi muscle; (xii) one unit dose is administered to the medial superior orbicularis oculi muscle; (xiii) one unit dose is administered to the lateral inferior orbicularis oculi muscle; and / or (xiv) one unit dose is administered to the levator palpebrae superioris muscle.

[1096] In any aspect or embodiment of the invention directed to treating atypical hemifacial spasm, the invention can further comprise: (i) administering one unit dose to the zygomaticus minor muscle affected by said atypical hemifacial spasm; and optionally administering one or more unit doses of the modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, or 13 or more) additional muscles affected by said atypical hemifacial spasm according to the following dosing regimen:

[1097] (ii) one unit dose is administered to the zygomatic major muscle; (iii) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (iv) one unit dose is administered to the mentalis muscle; (v) one unit dose is administered to the platysma muscle; (vi) up to two unit doses are administered to the corrugator supercilii muscle (preferably one unit dose); (vii) one unit dose is administered to the buccinator muscle; (viii) up to two unit doses are administered to the masseter muscle (preferably one unit dose); (ix) one unit dose is administered to the procerus muscle; (x) one unit dose is administered to the nasalis muscle; (xi) one unit dose is administered to the lateral superior orbicularis oculi muscle; (xii) one unit dose is administered to the medial superior orbicularis oculi muscle; (xiii) one unit dose is administered to the lateral inferior orbicularis oculi muscle; and / or (xiv) one unit dose is administered to the levator palpebrae superioris muscle.

[1098] In any aspect or embodiment of the invention directed to treating atypical hemifacial spasm, the invention can further comprise: (i) administering up to five unit doses (preferably one unit dose) to the frontalis muscle; and optionally administering one or more unit doses of the modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, or 13 or more) other muscles affected by said atypical hemifacial spasm according to the following dosing regimen:

[1099] (ii) one unit dose is administered to the zygomaticus minor; (iii) one unit dose is administered to the zygomaticus major; (iv) one unit dose is administered to the mentalis muscle; (v) one unit dose is administered to the platysma muscle; (vi) up to two unit doses are administered to the corrugator supercilii muscle (preferably one unit dose); (vii) one unit dose is administered to the buccinator muscle; (viii) up to two unit doses are administered to the masseter muscle (preferably one unit dose); (ix) one unit dose is administered to the procerus muscle; (x) one unit dose is administered to the nasalis muscle; (xi) one unit dose is administered to the lateral superior orbicularis oculi muscle; (xii) one unit dose is administered to the medial superior orbicularis oculi muscle; (xiii) one unit dose is administered to the lateral inferior orbicularis oculi muscle; and / or (xiv) one unit dose is administered to the levator palpebrae superioris muscle.

[1100] In any aspect or embodiment of the invention directed to treating atypical hemifacial spasm, the invention can further comprise: (i) administering one unit dose to the mentalis muscle affected by said atypical hemifacial spasm; and optionally administering one or more unit doses of the modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, or 13 or more) other muscles affected by said atypical hemifacial spasm according to the following dosing regimen:

[1101] (ii) one unit dose is administered to the zygomaticus minor; (iii) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (iv) one unit dose is administered to the zygomaticus major muscle; (v) one unit dose is administered to the platysma muscle; (vi) up to two unit doses are administered to the corrugator supercilii muscle (preferably one unit dose); (vii) one unit dose is administered to the buccinator muscle; (viii) up to two unit doses are administered to the masseter muscle (preferably one unit dose); (ix) one unit dose is administered to the procerus muscle; (x) one unit dose is administered to the nasalis muscle; (xi) one unit dose is administered to the lateral superior orbicularis oculi muscle; (xii) one unit dose is administered to the medial superior orbicularis oculi muscle; (xiii) one unit dose is administered to the lateral inferior orbicularis oculi muscle; and / or (xiv) one unit dose is administered to the levator palpebrae superioris muscle.

[1102] In any aspect or embodiment of the invention directed to treating atypical hemifacial spasm, the invention can further comprise: (i) administering one unit dose to the platysma muscle affected by said atypical hemifacial spasm; and optionally administering one or more unit doses of the modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, or 13 or more) additional muscles affected by said atypical hemifacial spasm according to the following dosing regimen:

[1103] (ii) one unit dose is administered to the zygomaticus minor; (iii) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (iv) one unit dose is administered to the mentalis muscle; (v) one unit dose is administered to the zygomaticus major muscle; (vi) up to two unit doses are administered to the corrugator supercilii muscle (preferably one unit dose); (vii) one unit dose is administered to the buccinator muscle; (viii) up to two unit doses are administered to the masseter muscle (preferably one unit dose); (ix) one unit dose is administered to the procerus muscle; (x) one unit dose is administered to the nasalis muscle; (xi) one unit dose is administered to the lateral superior orbicularis oculi muscle; (xii) one unit dose is administered to the medial superior orbicularis oculi muscle; (xiii) one unit dose is administered to the lateral inferior orbicularis oculi muscle; and / or (xiv) one unit dose is administered to the levator palpebrae superioris muscle.

[1104] In any aspect or embodiment of the invention directed to treating atypical hemifacial spasm, the invention can further comprise: (i) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle affected by said atypical hemifacial spasm; and optionally administering one or more unit doses of the modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, or 13 or more) of the other muscles affected by said atypical hemifacial spasm according to the following dosing regimen:

[1105] (ii) one unit dose is administered to the zygomaticus minor; (iii) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (iv) one unit dose is administered to the mentalis muscle; (v) one unit dose is administered to the platysma muscle; (vi) one unit dose is administered to the zygomaticus major muscle; (vii) one unit dose is administered to the buccinator muscle; (viii) up to two unit doses are administered to the masseter muscle (preferably one unit dose); (ix) one unit dose is administered to the procerus muscle; (x) one unit dose is administered to the nasalis muscle; (xi) one unit dose is administered to the lateral superior orbicularis oculi muscle; (xii) one unit dose is administered to the medial superior orbicularis oculi muscle; (xiii) one unit dose is administered to the lateral inferior orbicularis oculi muscle; and / or (xiv) one unit dose is administered to the levator palpebrae superioris muscle.

[1106] In any aspect or embodiment of the invention directed to treating atypical hemifacial spasm, the invention can further comprise: (i) administering one unit dose to the buccinator muscle affected by said atypical hemifacial spasm; and optionally administering one or more unit doses of the modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, or 13 or more) additional muscles affected by said atypical hemifacial spasm according to the following dosing regimen:

[1107] (ii) one unit dose is administered to the zygomaticus minor; (iii) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (iv) one unit dose is administered to the mentalis muscle; (v) one unit dose is administered to the platysma muscle; (vi) up to two unit doses are administered to the corrugator supercilii muscle (preferably one unit dose); (vii) one unit dose is administered to the zygomaticus major muscle; (viii) up to two unit doses are administered to the masseter muscle (preferably one unit dose); (ix) one unit dose is administered to the procerus muscle; (x) one unit dose is administered to the nasalis muscle; (xi) one unit dose is administered to the lateral superior orbicularis oculi muscle; (xii) one unit dose is administered to the medial superior orbicularis oculi muscle; (xiii) one unit dose is administered to the lateral inferior orbicularis oculi muscle; and / or (xiv) one unit dose is administered to the levator palpebrae superioris muscle.

[1108] In any aspect or embodiment of the invention directed to treating atypical hemifacial spasm, the invention can further comprise: (i) administering up to two unit doses (preferably one unit dose) to the masseter muscle affected by said atypical hemifacial spasm; and optionally administering one or more unit doses of the modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, or 13 or more) of the other muscles affected by said atypical hemifacial spasm according to the following dosing regimen:

[1109] (ii) one unit dose is administered to the zygomaticus minor; (iii) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (iv) one unit dose is administered to the mentalis muscle; (v) one unit dose is administered to the platysma muscle; (vi) up to two unit doses are administered to the corrugator supercilii muscle (preferably one unit dose); (vii) one unit dose is administered to the buccinator muscle; (viii) one unit dose is administered to the zygomaticus major muscle; (ix) one unit dose is administered to the procerus muscle; (x) one unit dose is administered to the nasalis muscle; (xi) one unit dose is administered to the lateral superior orbicularis oculi muscle; (xii) one unit dose is administered to the medial superior orbicularis oculi muscle; (xiii) one unit dose is administered to the lateral inferior orbicularis oculi muscle; and / or (xiv) one unit dose is administered to the levator palpebrae superioris muscle.

[1110] In any aspect or embodiment of the invention directed to treating atypical hemifacial spasm, the invention can further comprise: (i) administering one unit dose to the procerus muscle affected by said atypical hemifacial spasm; and optionally administering one or more unit doses of the modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, or 13 or more) additional muscles affected by said atypical hemifacial spasm according to the following dosing regimen:

[1111] (ii) one unit dose is administered to the zygomaticus minor; (iii) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (iv) one unit dose is administered to the mentalis muscle; (v) one unit dose is administered to the platysma muscle; (vi) up to two unit doses are administered to the corrugator supercilii muscle (preferably one unit dose); (vii) one unit dose is administered to the buccinator muscle; (viii) up to two unit doses are administered to the masseter muscle (preferably one unit dose); (ix) one unit dose is administered to the zygomaticus major muscle; (x) one unit dose is administered to the nasalis muscle; (xi) one unit dose is administered to the lateral superior orbicularis oculi muscle; (xii) one unit dose is administered to the medial superior orbicularis oculi muscle; (xiii) one unit dose is administered to the lateral inferior orbicularis oculi muscle; and / or (xiv) one unit dose is administered to the levator palpebrae superioris muscle.

[1112] In any aspect or embodiment of the invention directed to treating atypical hemifacial spasm, the invention can further comprise: (i) administering one unit dose to a nasal muscle affected by said atypical hemifacial spasm; and optionally administering one or more unit doses of a modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, or 13 or more) additional muscles affected by said atypical hemifacial spasm according to the following dosing regimen:

[1113] (ii) one unit dose is administered to the zygomaticus minor; (iii) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (iv) one unit dose is administered to the mentalis muscle; (v) one unit dose is administered to the platysma muscle; (vi) up to two unit doses are administered to the corrugator supercilii muscle (preferably one unit dose); (vii) one unit dose is administered to the buccinator muscle; (viii) up to two unit doses are administered to the masseter muscle (preferably one unit dose); (ix) one unit dose is administered to the procerus muscle; (x) one unit dose is administered to the zygomaticus major muscle; (xi) one unit dose is administered to the lateral superior orbicularis oculi muscle; (xii) one unit dose is administered to the medial superior orbicularis oculi muscle; (xiii) one unit dose is administered to the lateral inferior orbicularis oculi muscle; and / or (xiv) one unit dose is administered to the levator palpebrae superioris muscle.

[1114] In any aspect or embodiment of the invention directed to treating atypical hemifacial spasm, the invention can further comprise: (i) administering one unit dose to the lateral superior orbicularis oculi muscle affected by said atypical hemifacial spasm; and optionally administering one or more unit doses of the modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, or 13 or more) additional muscles affected by said atypical hemifacial spasm according to the following dosing regimen:

[1115] (ii) one unit dose is administered to the zygomaticus minor; (iii) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (iv) one unit dose is administered to the mentalis muscle; (v) one unit dose is administered to the platysma muscle; (vi) up to two unit doses are administered to the corrugator supercilii muscle (preferably one unit dose); (vii) one unit dose is administered to the buccinator muscle; (viii) up to two unit doses are administered to the masseter muscle (preferably one unit dose); (ix) one unit dose is administered to the procerus muscle; (x) one unit dose is administered to the nasalis muscle; (xi) one unit dose is administered to the zygomaticus major muscle; (xii) one unit dose is administered to the medial superior orbicularis oculi muscle; (xiii) one unit dose is administered to the lateral inferior orbicularis oculi muscle; and / or (xiv) one unit dose is administered to the levator palpebrae superioris muscle.

[1116] In any aspect or embodiment of the invention directed to treating atypical hemifacial spasm, the invention can further comprise: (i) administering one unit dose to the medial superior orbicularis oculi muscle affected by said atypical hemifacial spasm; and optionally administering one or more unit doses of the modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, or 13 or more) additional muscles affected by said atypical hemifacial spasm according to the following dosing regimen:

[1117] (ii) one unit dose is administered to the zygomaticus minor; (iii) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (iv) one unit dose is administered to the mentalis muscle; (v) one unit dose is administered to the platysma muscle; (vi) up to two unit doses are administered to the corrugator supercilii muscle (preferably one unit dose); (vii) one unit dose is administered to the buccinator muscle; (viii) up to two unit doses are administered to the masseter muscle (preferably one unit dose); (ix) one unit dose is administered to the procerus muscle; (x) one unit dose is administered to the nasalis muscle; (xi) one unit dose is administered to the lateral superior orbicularis oculi muscle; (xii) one unit dose is administered to the zygomaticus major muscle; (xiii) one unit dose is administered to the lateral inferior orbicularis oculi muscle; and / or (xiv) one unit dose is administered to the levator palpebrae superioris muscle.

[1118] In any aspect or embodiment of the invention directed to treating atypical hemifacial spasm, the invention can further comprise: (i) administering one unit dose to the lateral inferior orbicularis oculi muscle affected by said atypical hemifacial spasm; and optionally administering one or more unit doses of the modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, or 13 or more) additional muscles affected by said atypical hemifacial spasm according to the following dosing regimen:

[1119] (ii) one unit dose is administered to the zygomaticus minor; (iii) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (iv) one unit dose is administered to the mentalis muscle; (v) one unit dose is administered to the platysma muscle; (vi) up to two unit doses are administered to the corrugator supercilii muscle (preferably one unit dose); (vii) one unit dose is administered to the buccinator muscle; (viii) up to two unit doses are administered to the masseter muscle (preferably one unit dose); (ix) one unit dose is administered to the procerus muscle; (x) one unit dose is administered to the nasalis muscle; (xi) one unit dose is administered to the lateral superior orbicularis oculi muscle; (xii) one unit dose is administered to the medial superior orbicularis oculi muscle; (xiii) one unit dose is administered to the zygomaticus major muscle; and / or (xiv) one unit dose is administered to the levator palpebrae superioris muscle.

[1120] In any aspect or embodiment of the invention directed to treating atypical hemifacial spasm, the invention can further comprise: (i) administering one unit dose to the levator palpebrae superioris muscle affected by said atypical hemifacial spasm; and optionally administering one or more unit doses of the modified BoNT / A to one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, or 13 or more) other muscles affected by said atypical hemifacial spasm according to the following dosing regimen:

[1121] (ii) one unit dose is administered to the zygomatic minor muscle; (iii) up to five unit doses are administered to the frontalis muscle (preferably one unit dose); (iv) one unit dose is administered to the mentalis muscle; (v) one unit dose is administered to the platysma muscle; (vi) up to two unit doses are administered to the corrugator supercilii muscle (preferably one unit dose); (vii) one unit dose is administered to the buccinator muscle; (viii) up to two unit doses are administered to the masseter muscle (preferably one unit dose); (ix) one unit dose is administered to the procerus muscle; (x) one unit dose is administered to the nasalis muscle; (xi) one unit dose is administered to the lateral superior orbicularis oculi muscle; (xii) one unit dose is administered to the medial superior orbicularis oculi muscle; (xiii) one unit dose is administered to the lateral inferior orbicularis oculi muscle; and / or (xiv) one unit dose is administered to the zygomatic major muscle.

[1122] According to the present invention, the modified BoNT / A can be administered to the muscle and / or a site thereof by any suitable method.

[1123] As an alternative to intramuscular injection, the modified BoNT / A can be administered subcutaneously, for example, by subcutaneous injection. The subcutaneous injection can include injecting medially and / or laterally into the junction between the preseptal portion of the superior and / or inferior orbicularis oculi muscle and the orbit as desired.

[1124] Most preferably, the modified BoNT / A is administered intramuscularly, such as by intramuscular injection.

[1125] Electromyographic control / guidance may be employed to assist in administering a modified BoNT / A according to the present invention.

[1126] The term "unit dose" may include more than one unit dose. For example, the term "unit dose" may refer to at most two unit doses, at most three unit doses, at most four unit doses, or at most five unit doses. The term "unit dose" may also refer to a single unit dose.

[1127] A single unit dose may be administered to the affected muscle at one or more injection sites. When a single unit dose is administered at more than one injection site, the unit dose may be distributed (equally or unequally) between two or more injection sites. However, it is preferred that a single unit dose is administered per injection site.

[1128] The term "administering a single unit dose" refers to administering substantially all of a single unit dose. For example, a residual amount of a unit dose (e.g., up to 1%, 0.1%, or 0.01%) may remain in the vial in which the modified BoNT / A has been reconstituted. However, preferably, the entire single unit dose is administered (e.g., at one or more injection sites, preferably at each injection site). This definition applies similarly to administering two unit doses, three unit doses, etc.

[1129] The potency of the modified BoNT / A used in accordance with the present invention can be determined by mouse LD according to standard techniques. 50 In the test, 1 unit is defined as the amount corresponding to the calculated median lethal dose (LD50) in mice. 50 ) of the modified BoNT / A. Preferably, the amount corresponding to the calculated mouse median lethal intraperitoneal dose

[1130] When the modified BoNT / A used in the present invention is a BoNT / A light chain and translocation domain and a BoNT / B receptor binding domain (H C When the modified BoNT / A contains a modified BoNT / A having a glycosylated domain, the amount corresponding to 1 unit of the modified BoNT / A in the assay is preferably 24.04 pg.

[1131] The term "up to" when used in reference to a value (e.g., up to 82,500 pg) means up to and including the referenced value. Thus, as an example, reference to administering "up to 82,500 pg" of a modified BoNT / A includes administering 82,500 pg of the modified BoNT / A as well as administering less than 82,500 pg of the modified BoNT / A.

[1132] A unit dose can be expressed in terms of the amount of a modified BoNT / A, units of a modified BoNT / A, or a combination thereof.

[1133] The total number of unit doses administered may be up to 20, 15, 10, 5 or 3. The total number of unit doses administered may be at least 3, 5, 10 or 15. The total number of unit doses administered may be 3-20, 4-16 or 5-12. In one embodiment, 5 unit doses are administered. In one embodiment, 6 unit doses are administered. In one embodiment, 10 unit doses are administered. In one embodiment, 12 unit doses are administered. In one embodiment, 15 doses are administered. Preferably, a total of 12 unit doses are administered, particularly in the treatment of blepharospasm (more particularly bilateral blepharospasm).

[1134] The modified BoNT / A can be administered by intramuscular injection to a total of six, seven, eight, nine, ten, eleven, or twelve sites in a first eye of an individual. The modified BoNT / A can be administered by intramuscular injection to a total of six, seven, eight, nine, ten, or eleven sites in a first eye of an individual. Additionally or alternatively, the modified BoNT / A can be administered by intramuscular injection to a total of six, seven, eight, nine, ten, eleven, or twelve sites in a second eye of an individual. The modified BoNT / A can be administered by intramuscular injection to a total of six, seven, eight, nine, ten, or eleven sites in a second eye of an individual.

[1135] In a preferred embodiment, the modified BoNT / A is administered to a total of six sites in a first eye of the individual by intramuscular injection. Additionally or alternatively, the modified BoNT / A may preferably be administered to a total of six sites in a second eye of the individual by intramuscular injection.

[1136] In the case of treatment of blepharospasm (e.g. preferably bilateral blepharospasm), up to 12 unit doses are preferably administered at the following sites:

[1137] - two unit doses are administered to the lateral superior orbicularis oculi muscle of the affected eye (eg, two unit doses are administered to said site in each eye, for a total of four unit doses);

[1138] - administering one unit dose to the inner superior orbicularis oculi muscle of the affected eye (e.g., administering one unit dose to that site in each eye for a total of two unit doses);

[1139] - administering one unit dose to the lateral inferior orbicularis oculi muscle of the affected eye (e.g., administering one unit dose to that site in each eye for a total of two unit doses);

[1140] - Administer one unit dose to the procerus muscle;

[1141] - administering one unit dose to the corrugator supercilii muscle proximal to the affected eye (eg, administering one unit dose to that site in each eye for a total of two unit doses); and

[1142] - One unit dose is administered to the frontalis muscle proximal to the affected eye (eg, one unit dose is administered to said site in each eye, for a total of two unit doses).

[1143] For example, treatment may comprise a total of 12 unit dose injections at the aforementioned sites. Preferably, 12 unit dose injections are administered at the aforementioned sites (particularly for blepharospasm, more particularly of the bilateral type).

[1144] In the case of treatment of unilateral blepharospasm, up to 6 unit doses are preferably administered at the following sites:

[1145] -Administer two unit doses to the lateral superior orbicularis oculi muscle of the affected eye;

[1146] -Administer one unit dose to the medial superior orbicularis oculi muscle of the affected eye;

[1147] -Administer one unit dose to the lateral inferior orbicularis oculi muscle of the affected eye;

[1148] - Administer one unit dose to the procerus muscle;

[1149] - Administer one unit dose to the corrugator supercilii muscle near the affected eye; and

[1150] -Administer one unit dose into the frontalis muscle near the affected eye.

[1151] For example, treatment may include a total of 6 unit dose injections at the above sites.

[1152] Optionally, the unit dose may be administered to only one of the procerus and corrugator supercilii muscles (but not both).

[1153] Preferably, the above treatment regimen encompasses each of the following injection sites (eg, which may be referred to as "minimal" injection sites):

[1154] - two unit doses are administered to the lateral superior orbicularis oculi muscle of the affected eye (eg, two unit doses are administered to said site in each eye, for a total of four unit doses);

[1155] - administering one unit dose to the inner superior orbicularis oculi muscle of the affected eye (eg, administering one unit dose to that site in each eye for a total of two unit doses); and

[1156] - administering one unit dose to the lateral inferior orbicularis oculi muscle of the affected eye (e.g., administering one unit dose to that site in each eye for a total of two unit doses);

[1157] The "minimal" injection site may be sufficient to achieve treatment such that a total of four unit doses are administered per eye (e.g., a total of four unit doses are administered in the case of unilateral blepharospasm). Nevertheless, treatment may be extended to the procerus and / or corrugator supercilii (preferably the procerus or corrugator supercilii), adding an additional unit dose of the procerus and / or an additional unit dose of each corrugator supercilii in the treatment regimen. Additionally or alternatively, treatment may be extended to the frontalis muscle of the affected eye, adding an additional unit dose (for the frontalis) for each affected eye.

[1158] One skilled in the art will consider whether the individual has recently (or subsequently) received additional treatment with a clostridial neurotoxin (e.g., an unmodified BoNT), for example as part of a cosmetic treatment or treatment for a different indication. Using routine techniques in the art, one skilled in the art will adjust the present treatment regimen accordingly. Preferably, the present invention does not include treatment with other clostridial neurotoxins (e.g., BoNTs).

[1159] Compared with unmodified BoNT / A (e.g., The modified BoNT / A of the invention preferably has a longer duration of action than that of a modified BoNT / A of the invention, for example, the effect is an improvement in one or more symptoms of blepharospasm or hemifacial spasm, for example, an improvement of at least 5%, 10%, 25%, or 50% compared to the one or more symptoms before treatment. The duration of action can be at least 1.25-fold, 1.5-fold, 1.75-fold, 2.0-fold, or 2.25-fold or more. The duration of action of the modified BoNT / A can be between 6-9 months. For example, the duration of action can be at least: 4.5 months (from onset), 5.0 months, 5.5 months, 6 months, 6.5 months, 7.0 months, 7.5 months, 8.0 months, 8.5 months, or 9.0 months. In specific embodiments, the duration of action can be greater than 9.0 months.

[1160] Treatment can be repeated at appropriate time intervals after administration of the modified BoNT / A. Considering that the duration of action is approximately that of an unmodified BoNT / A (e.g., ), so the interval between subsequent administrations is longer than with unmodified BoNT / A (e.g., ) for a longer period of time than when the subject was treated. A modified BoNT / A according to the present invention can be re-administered to a subject at least 18, 20, 25, or 30 weeks after the previous administration. For example, a modified BoNT / A according to the present invention can be re-administered to a subject at least 18-45 weeks, preferably 20-35 weeks, after the previous administration.

[1161] As used herein, an "individual" may be a mammal, such as a human or other mammal. Preferably, an "individual" refers to a human individual. An "individual" is preferably an adult individual, i.e., an individual of at least 18 years old. The terms "individual" and "patient" are used synonymously herein. Preferably, the individual has been diagnosed with the facial dystonia (blepharospasm, typical hemifacial spasm, or atypical hemifacial spasm) of the present invention.

[1162] An individual treated in accordance with the present invention may be an individual who is not suitable for treatment with an unmodified BoNT / A (e.g., SEQ ID NO: 2). The individual may be an individual who has developed resistance to treatment with an unmodified BoNT / A. Resistance may arise due to an individual developing an immune response to a clostridial neurotoxin, including the development of anti-clostridial neurotoxin antibodies.

[1163] The terms "treat" or "treating" as used herein include preventive treatment (e.g., to prevent the onset of a disorder) as well as corrective treatment (treating an individual who already has a disorder). Preferably, "treat" or "treating" as used herein refers to corrective treatment. The terms "treat" or "treating" as used herein refer to a disorder and / or its symptoms.

[1164] BoNT / A is an example of a clostridial neurotoxin produced by Clostridia bacteria. Other examples of such clostridial neurotoxins include those produced by C. tetani (TeNT) and C. botulinum (BoNT) serotypes BG and X (see WO 2018 / 009903 A2), as well as those produced by C. baratii and C. butyricum. The neurotoxins have strong potency and specificity and can poison neurons and other cells to which they are delivered. Clostridial toxins are among the strongest toxins known. For example, the median lethal dose (LD50) of botulinum neurotoxin in mice is 1.5 50 mmol / l. 50) ranges from 0.5-5 ng / kg, depending on the serotype. Both tetanus toxin and botulinum toxin act by inhibiting the function of the affected neurons, particularly the release of neurotransmitters. Botulinum toxin acts at the neuromuscular junction and inhibits cholinergic transmission in the peripheral nervous system, while tetanus toxin acts on the central nervous system.

[1165] In nature, Clostridial neurotoxins, including BoNT / A, are synthesized as single-chain polypeptides that are modified post-translationally by proteolytic cleavage events to form two polypeptide chains linked together by disulfide bonds. Cleavage occurs at a specific cleavage site, often referred to as the activation site (e.g., the activation loop), which is located between the cysteine ​​residues that provide the interchain disulfide bond. It is this two-chain form that is the active form of the toxin. The two chains are referred to as: the heavy chain (H chain), which has a molecular weight of approximately 100 kDa; and the light chain (L chain), which has a molecular weight of approximately 50 kDa. The H chain contains an N-terminal translocation component (H N domain) and the C-terminal targeting component (H C domain). The cleavage site is located between the L chain and the translocation domain component. C After the domain binds to its target neuron and the bound toxin enters the cell via endocytosis, H N The domain translocates the L chain across the endosomal membrane and into the cytosol, and the L chain provides the protease function (also known as a non-cytotoxic protease).

[1166] Non-cytotoxic proteases act by proteolytic cleavage of intracellular transporters known as SNARE proteins, such as SNAP-25, VAMP or Syntaxin, see Gerald K (2002) "Cell and Molecular Biology" (4th edition) John Wiley & Sons, Inc. The acronym SNARE is derived from the term soluble NSF attachment receptor ( S oluble N SF A ttachment Re ceptor), where NSF refers to N-ethylmaleimide-sensitive factor ( N -ethylmaleimide- S ensitive FSNARE proteins are essential for intracellular vesicle fusion and are therefore essential for secretion of molecules from cells via vesicle transport. The protease function is a zinc-dependent endopeptidase activity and exhibits high substrate specificity for SNARE proteins. Therefore, once delivered to the desired target cells, the non-cytotoxic protease is able to inhibit cellular secretion of the target cells. The L-chain protease of Clostridial toxins is a non-cytotoxic protease that cleaves SNARE proteins.

[1167] Given the ubiquity of SNARE proteins, clostridial neurotoxins such as botulinum toxin have been successfully used in a wide range of therapeutic applications.

[1168] For further details on the genetic basis of toxin production in Clostridium botulinum and C. tetani, see Henderson et al., (1997) in The Clostridia: Molecular Biology and Pathogenesis, Academic press.

[1169] As described above, Clostridial neurotoxins are composed of two polypeptide chains: a heavy chain (H chain), which has a molecular weight of approximately 100 kDa; and a light chain (L chain), which has a molecular weight of approximately 50 kDa. The H chain contains a C-terminal targeting component (receptor binding domain or H C domain) and the N-terminal translocation component (H N domain).

[1170] Clostridial neurotoxin domains are described in more detail below.

[1171] Examples of L chain reference sequences include:

[1172] Botulinum neurotoxin type A: amino acid residues 1-448

[1173] Botulinum neurotoxin type B: amino acid residues 1-440

[1174] The reference sequences identified above should be considered guide sequences, as slight variations may occur depending on the subserotype. For example, US2007 / 0166332 (incorporated herein by reference in its entirety) cites a slightly different Clostridium sequence:

[1175] Botulinum neurotoxin type A: amino acid residues M1-K448

[1176] Botulinum neurotoxin type B: amino acid residues M1-K441

[1177] The translocation domain is a fragment of the H chain of a clostridial neurotoxin that corresponds approximately to the amino-terminal half of the H chain, or a domain that corresponds to this fragment in an intact H chain.

[1178] Examples of reference translocation domains include:

[1179] Botulinum neurotoxin type A -- amino acid residues (449-871)

[1180] Botulinum neurotoxin type B -- amino acid residues (441-858)

[1181] The reference sequences identified above should be considered guide sequences, as slight variations may occur depending on the subserotype. For example, US2007 / 0166332 (incorporated herein by reference) cites a slightly different Clostridium sequence:

[1182] Botulinum neurotoxin type A - amino acid residues (A449-K871)

[1183] Botulinum neurotoxin type B -- amino acid residues (A442-S858)

[1184] In the context of the present invention, various BoNT / AH comprising a translocation domain N Regions may be used in aspects of the invention. H from a BoNT / A heavy chain N The length of the region is about 410-430 amino acids and contains the translocation domain. Studies have shown that the H N The full length of the region is not necessary for the translocation activity of the translocation domain. Thus, aspects of this embodiment may include a BoNT / AH N A region comprising a translocation domain having a length of, for example, at least 350 amino acids, at least 375 amino acids, at least 400 amino acids, or at least 425 amino acids. Other aspects of this embodiment may include a BoNT / AH N A region comprising a translocation domain having a length of, for example, at most 350 amino acids, at most 375 amino acids, at most 400 amino acids, or at most 425 amino acids.

[1185] Terminology N Covers naturally occurring BoNT / AH N Portions, and modified BoNT / AHs having non-naturally occurring amino acid sequences and / or synthetic amino acid residues N Preferably, the modified BoNT / AH N Some still show the above translocation function.

[1186] Clostridial neurotoxin receptor binding domain (H C) Examples of reference sequences include:

[1187] BoNT / A-N872-L1296

[1188] BoNT / B-E859-E1291

[1189] Clostridial neurotoxins (e.g., BoNT) have a ~50 kDa H C The domain consists of two distinct structural features, called H CC and H CN domains, each typically ~25 kDa. The amino acid residues involved in receptor binding are thought to be located primarily in the H CC Domain. H of natural Clostridial neurotoxin C The domain may contain about 400-440 amino acid residues. This fact is confirmed by the following publications, each of which is incorporated herein by reference in its entirety: Umland TC (1997)) Nat. Struct. Biol. 4: 788-792; Herreros J (2000) Biochem. J. 347: 199-204; Halpern J (1993) J. Biol. Chem. 268: 15, pp. 11188-11192; Rummel A (2007) PNAS 104: 359-364; Lacey DB (1998) Nat. Struct. Biol. 5: 898-902; Knapp (1998) Am. Cryst. Assoc. Abstract Papers 25:90; Swaminathan and Eswaramoorthy (2000) Nat. Struct. Biol. 7:1751-1759; and Rummel A (2004) Mol. Microbiol. 51(3), 631-643.

[1190] (Reference)H CN Examples of domains include:

[1191] Botulinum neurotoxin type A -- amino acid residues (872-1110)

[1192] Botulinum neurotoxin type B -- amino acid residues (859-1097)

[1193] The above sequence positions may vary slightly depending on serotype / subtype, and (reference) H CN Other examples of domains include:

[1194] Botulinum neurotoxin type A -- amino acid residues (874-1110)

[1195] Botulinum neurotoxin type B -- amino acid residues (861-1097)

[1196] (Reference)H CC Examples of domains include:

[1197] Botulinum neurotoxin type A -- amino acid residues (Y1111-L1296)

[1198] Botulinum neurotoxin type B -- amino acid residues (Y1098-E1291)

[1199] L chain and H N The domains (optionally including a complete or partial activation loop, e.g., a complete activation loop when the modified BoNT / A is in single-chain form and a cleaved / partial activation loop when in double-chain form) may be collectively referred to as LH N domain. Therefore, LH N The domain may not further contain H C Structural domain.

[1200] WO 2017 / 191315 A1 (which is incorporated herein by reference) teaches modified BoNT / A and methods of preparing and manufacturing the same. Thus, the invention provides a method for preparing a modified BoNT / A comprising a botulinum neurotoxin A (BoNT / A) light chain and a translocation domain (BoNT / AH) N ) and the BoNT / B receptor binding domain (H C The modified BoNT / A having a 3D-domain (e.g., a 3D-domain) may be the one taught in WO 2017 / 191315 A1.

[1201] As used herein, the term "modified BoNT / A" or "chimeric clostridial neurotoxin" or "chimeric neurotoxin" refers to a neurotoxin comprising (preferably consisting of) a clostridial neurotoxin light chain and a translocation domain (H domain) from a first clostridial neurotoxin serotype. N domain) and a receptor binding domain from a second different Clostridial neurotoxin serotype (H C In particular, the modified BoNT / A used in the present invention comprises a botulinum neurotoxin A (BoNT / A) light chain and a translocation domain (H N domain) and the BoNT / B receptor binding domain (H C Domain). BoNT / A LH of modified BoNT / A N Domains and BoNT / BH C The domains are covalently linked. The modified BoNT / A of the present invention may be referred to as a chimeric botulinum neurotoxin. The modified BoNT / A is also referred to herein as a "BoNT / AB," "mrBoNT / AB," or a "BoNT / AB chimera."

[1202] L chain and H N The domains (optionally including a complete or partial activation loop, e.g., a complete activation loop when the modified BoNT / A is in single-chain form and a cleaved / partial activation loop when in double-chain form) may be collectively referred to as LH N domain. Therefore, LH N The domain does not further contain H C Structural domain.

[1203] The modified BoNT / A can consist essentially of a botulinum neurotoxin A (BoNT / A) light chain and a translocation domain (H N domain) and the BoNT / B receptor binding domain (H C domain).

[1204] As used herein, the term "consisting essentially of" means that the modified BoNT / A does not further comprise one or more amino acid residues that confer additional functionality to the polypeptide, e.g., when administered to an individual. In other words, "consisting essentially of" a botulinum neurotoxin A (BoNT / A) light chain and a translocation domain (H N domain) and the BoNT / B receptor binding domain (H C The polypeptide composed of a botulinum neurotoxin A (BoNT / A) light chain and a translocation domain (H N domain) and the BoNT / B receptor binding domain (H C The amino acid residues of the polypeptide (or domain) are the same), but the one or more additional amino acid residues do not confer additional functions to the polypeptide when, for example, administered to an individual. The additional functions may include enzymatic activity, binding activity and / or any physiological activity.

[1205] The modified BoNT / A may comprise a non-Clostridial neurotoxin sequence in addition to any Clostridial neurotoxin sequence, provided that the non-Clostridial neurotoxin sequence does not impair the ability of the modified BoNT / A to achieve its therapeutic effect. Preferably, the non-Clostridial neurotoxin sequence is not a non-Clostridial neurotoxin sequence that has catalytic activity, such as enzymatic activity. In one embodiment, the modified BoNT / A of the present invention does not comprise a non-Clostridial catalytically active domain. In one embodiment, the modified BoNT / A does not comprise an additional catalytically active domain. In one embodiment, the non-Clostridial sequence is not a sequence that binds to a cell receptor. In other words, in one embodiment, the non-Clostridial sequence is not a ligand for a cell receptor. The cell receptor may be a protein cell receptor, such as an integral membrane protein. Examples of cell receptors can be found in the IUPHAR Guide to Pharmacology Database, version 2019.4, at https: / / www.guidetopharmacology.org / download.jsp#db_reports. The non-Clostridial neurotoxin sequence may include a tag that facilitates purification, such as a His tag. In one embodiment, a modified BoNT / A of the invention does not comprise a label or a site for adding a label, such as a sortase acceptor or donor site.

[1206] Preferably, the modified BoNT / A may be composed of a botulinum neurotoxin A (BoNT / A) light chain and a translocation domain (H N domain) and the BoNT / B receptor binding domain (H C domain).

[1207] The modified BoNT / A comprises a light chain that is capable of exhibiting non-cytotoxic protease activity and is capable of cleaving SNARE proteins in the cytosol of target neurons. Cell-based in vivo assays can also be used to determine whether a Clostridial neurotoxin comprising an L chain and a functional cell binding and translocation domain has non-cytotoxic protease activity. Assays such as the toe abduction score (DAS) assay, the dorsal root ganglion (DRG) assay, the spinal cord neuron (SCN) assay, and the mouse phrenic nerve hemidiaphragm (PNHD) assay are routine assays in the art. Suitable assays for determining non-cytotoxic protease activity can be assays described in Aoki KR, Toxicon 39: 1815-1820; 2001 or Donald et al. (2018), Pharmacol Res Perspect, e00446, 1-14, which are incorporated herein by reference.

[1208] When administered to an individual, the modified BoNT / A is preferably in its active two-chain form, wherein the light chain and the heavy chain are linked together by a disulfide bond. When a BoNT / A (e.g., a modified BoNT / A) is defined herein by a polypeptide sequence (SEQ ID NO), the L chain portion of the sequence (SEQ ID NO) can constitute the first chain of the two-chain clostridial neurotoxin (e.g., a two-chain modified BoNT / A), and the H chain portion can constitute the first chain of the two-chain clostridial neurotoxin (e.g., a two-chain modified BoNT / A). N and H C The domains together may constitute the second chain of a two-chain clostridial neurotoxin (e.g., a two-chain modified BoNT / A), wherein the first chain and the second chain are linked together by a disulfide bond. It will be appreciated by those skilled in the art that a protease may cleave at one or more positions within the activation loop of a clostridial neurotoxin (e.g., a modified BoNT / A), preferably at two positions within the activation loop. When cleavage occurs at more than one position (preferably two positions) within the activation loop, a small fragment of the C-terminal L chain portion of the sequence may not be present in the two-chain clostridial neurotoxin sequence (e.g., a two-chain modified BoNT / A). In view of this, the sequence of a two-chain clostridial neurotoxin (e.g., a two-chain modified BoNT / A) may differ slightly from the sequence of a corresponding single-chain clostridial neurotoxin (e.g., a single-chain modified BoNT / A). The small fragment may be 1-15 amino acids. In particular, in one embodiment, when a single-chain modified BoNT / A is converted to a two-chain modified BoNT / A using Lys-C, the small fragment of the C-terminal L chain portion of the sequence that is absent may be SEQ ID NO: 9 or 10.

[1209] Most preferably, the modified BoNT / A for use in the present invention may include a BoNT / A light chain and a translocation domain (BoNT / ALH N domain) and BoNT / BH C Domain. BoNT / A LH N Domains and BoNT / BH C The modified BoNT / A is also referred to herein as a "BoNT / AB" or a "BoNT / AB chimera."

[1210] LH N The C-terminal amino acid residue of the domain may correspond to the LH that separates BoNT / A N and H C Domain 3 10 The first amino acid residue of the helix, and H C The N-terminal amino acid residue of the domain may correspond to the LH in the BoNT / B N and H C Domain 3 10 The second amino acid residue of the helix.

[1211] An example of a BoNT / A polypeptide sequence is provided as SEQ ID NO: 2 (eg, a double-chain form of SEQ ID NO: 2).

[1212] An example of a BoNT / B polypeptide sequence is provided as SEQ ID NO: 8 (UniProt Accession No. B1 INP5).

[1213] The article refers to "LH that separates BoNT / A N and H C Domain 3 10 The first amino acid residue of the helix is ​​the N and H C Domain 3 10 The N-terminal residue of the helix.

[1214] The article mentions "LH that separates BoNT / B N and H C Domain 3 10 The second amino acid residue of the helix is ​​the N and H C Domain 3 10 The amino acid residue following the N-terminal residue of the helix.

[1215] "3 10 A "helix" is a type of secondary structure found in proteins and peptides, along with α-helices, β-sheets, and reverse turns. 10 The amino acids in the helix are arranged in a right-handed helical structure, in which each complete turn is completed by three residues and ten atoms, separated by intramolecular hydrogen bonds between them. Each amino acid corresponds to a 120° turn in the helix (i.e., the helix has three residues per turn), and a translation along the helical axis is and has 10 atoms in a ring formed by hydrogen bonding. Most importantly, the NH group of the amino acid forms hydrogen bonds with the C=O groups of the amino acids of the first three residues; this repeated i+3→i hydrogen bonding defines the 3 10 Spiral. 3 10 A helix is ​​a standard concept in structural biology with which those skilled in the art are familiar.

[1216] This 3 10 The helix corresponds to the four residues that form the actual helix and two cap (or transition) residues, one at each end of the four residues. N and H C Domain 3 10 The "helix" is composed of these six residues.

[1217] By performing structural analysis and sequence alignment, the LH N and H C Domain 3 10 Spiral. This 3 10 The helix is ​​at its N-terminal end (i.e., at the end of LH N The C-terminal part of the domain) is surrounded by an α-helix and at its C-terminus (i.e., at the H C The N-terminal part of the domain) is surrounded by β-strands. 10 The first (N-terminal) residue of a helix (the cap or transition residue) also corresponds to the C-terminal residue of the alpha helix.

[1218] Separation of LH N and H C Domain 3 10 The helices can be determined, for example, from publicly available crystal structures of botulinum neurotoxins, such as 3BTA (http: / / www.rcsb.org / pdb / explore / explore.do?structureld=3BTA) and 1EPW (http: / / www.rcsb.org / pdb / explore / explore.do?structureld=1EPW) corresponding to botulinum neurotoxins A1 and B1, respectively.

[1219] Publicly available computer modeling and alignment tools can also be used to identify LH compartments in other neurotoxins. N and H C Domain 3 10The positions of the helices are determined by, for example, the homology modeling servers LOOPP (Learning, Observing and Outputting Protein Patterns, http: / / loopp.org), PHYRE (Protein Homology / analogY Recognition Engine, http: / / www.sbg.bio.ic.ac.uk / phyre2 / ) and Rosetta (https: / / www.rosettacommons.org / ), the protein superposition server SuperPose (http: / / wishart.biology.ualberta.ca / superpose / ), the alignment program Clustal Omega (http: / / www.clustal.org / omega / ), and many other tools / services listed on the Internet Resources for Molecular and Cell Biologists (http: / / molbiol-tools.ca / ). In particular, “H N / H CN “The region surrounding the junction can be highly conserved in structure, making it an ideal region for superimposing different serotypes.

[1220] For example, the following method can be used to determine the presence of this 3 10 The sequence of the spiral:

[1221] 1. The structural homology modeling tool LOOP (http: / / loopp.org) can be used to obtain predicted structures of other BoNT serotypes based on the BoNT / A1 crystal structure (3BTA.pdb);

[1222] 2. The structure (pdb) file thus obtained can be edited to include only H CN The N-terminus of the domain and the approximately 80 residues preceding it (which are H N domain), thereby retaining the highly conserved "H N / H CN "area;

[1223] 3. Protein overlay server SuperPose

[1224] ( http: / / wishart.biology.ualberta.ca / superpose / ) can be used to superimpose each serotype onto the 3BTA.pdb structure;

[1225] 4. You can check the superimposed pdb files to locate the H of BoNT / A1 C 3 at the beginning of the domain 10 helix, the corresponding residues in other serotypes could then be identified.

[1226] 5. Other BoNT serotype sequences can be aligned with Clustal Omega to check if the corresponding residues are correct.

[1227] The LH determined by this method N , H C and 3 10 An example of a helical domain is shown below:

[1228]

[1229]

[1230] Through structural analysis and sequence alignment, it was found that the LH N and H C Domain 3 10 The β-strand following the helix is ​​conserved in all botulinum and tetanus neurotoxins and is involved in the separation of LH N and H C Domain 3 10 Starting with the first residue of the helix, the beta strand begins at residue 8 (eg, residue 879 for BoNT / A1).

[1231] A BoNT / AB chimera can include H from BoNT / B C Domain covalently linked to LH from BoNT / A N domain, in which LH N The C-terminal amino acid residue of the domain corresponds to the H C The eighth amino acid residue from the N-terminus of the β-strand of the start (N-terminus) of the domain, and wherein H C The N-terminal amino acid residue of the domain corresponds to the H C The start (N-terminus) of the domain is the seventh amino acid residue from the N-terminus of the β-strand.

[1232] A BoNT / AB chimera can include H from BoNT / B C Domain covalently linked to LH from BoNT / A N domain, in which LH N The C-terminal amino acid residue of the domain corresponds to the LH N The C-terminal amino acid residue of the alpha helix at the end of the domain (C-terminus), and wherein HC The N-terminal amino acid residues of the domain correspond to the LH residues located immediately adjacent to the BoNT / B N The amino acid residue at the C-terminal end of the alpha helix at the end of the domain (C-terminus).

[1233] The rationale for the BoNT / AB chimera design process is to ensure that the secondary structure is as intact as possible, thereby minimizing any changes to the tertiary structure and the function of each domain. 10 The four central amino acid residues of the helix ensure the optimal conformation of the chimeric neurotoxins, thereby allowing the chimeric neurotoxins to fully exert their full function. In fact, surprisingly, only the 3 10 The first amino acid residue of the helix and the 3 10 The second amino acid residue after the helix not only allows for the generation of soluble and functional BoNT / AB chimeras, but further results in improved properties relative to other BoNT / AB chimeras, particularly increased potency, increased safety ratio, and / or longer duration of action (as well as increased safety ratio and / or duration of action when compared to an unmodified BoNT / A (e.g., SEQ ID NO: 2)).

[1234] BoNT / A light chain, BoNT / A translocation domain, and / or BoNT / BH C The domain can be a modified BoNT / A light chain, a BoNT / A translocation domain, and / or a BoNT / BH C Domains or derivatives thereof, including but not limited to those described below. Modified BoNT / A light chains, BoNT / A translocation domains, and / or BoNT / BH C The domain or derivative may contain one or more BoNT / A light chains, BoNT / A translocation domains, and / or BoNT / BH chains that are identical to the native (unmodified) forms. C The BoNT / A light chain, BoNT / A translocation domain, and / or BoNT / BH domain may contain one or more amino acids that are not present in the native (unmodified) form. C For example, relative to a native (unmodified) BoNT / A light chain, a BoNT / A translocation domain, and / or a BoNT / BH C Domain sequences, modified BoNT / A light chain, BoNT / A translocation domain, and / or BoNT / BH CThe domains may have modified amino acid sequences in one or more domains. Such modifications may modify aspects of their function, such as biological activity or persistence. Thus, in one embodiment, a BoNT / A light chain, a BoNT / A translocation domain, and / or a BoNT / BH C The domain is a modified BoNT / A light chain, BoNT / A translocation domain, and / or BoNT / BH C domain, or a modified BoNT / A light chain, BoNT / A translocation domain, and / or BoNT / BH C Derivatives of the domain.

[1235] Modified BoNT / BH C The domain may have one or more modifications that modify binding to target neural cells, such as when combined with native (unmodified) BoNT / BH C The domains provide higher or lower affinity binding when compared. BoNT / BH C Such modifications in the domain may include modifying H C The modification of a residue in a ganglioside binding site of a synaptotagmin domain or a residue in a protein (e.g., synaptotagmin) binding site, which alters binding to a ganglioside receptor and / or protein receptor of a target neural cell. Examples of such modified neurotoxins are described in WO 2006 / 027207 and WO 2006 / 114308, both of which are incorporated herein by reference in their entirety.

[1236] The modified light chain may have one or more modifications in its amino acid sequence, such as modifications in the substrate binding or catalytic domains, which may alter or modify the SNARE protein specificity of the modified light chain, preferably provided that the modification does not render the light chain catalytically inactive. Examples of such modified neurotoxins are described in WO 2010 / 120766 and US2011 / 0318385, both of which are incorporated herein by reference in their entirety.

[1237] LH from BoNT / A N The domain may correspond to amino acid residues 1 to 872 of SEQ ID NO: 2, or a polypeptide sequence having at least 70% sequence identity thereto. N The domain may correspond to amino acid residues 1 to 872 of SEQ ID NO: 2, or a polypeptide sequence having at least 80%, 90%, or 95% sequence identity thereto. Preferably, the LH from a BoNT / A N The domain corresponds to amino acid residues 1 to 872 of SEQ ID NO:2.

[1238] H from BoNT / B CThe domain may correspond to amino acid residues 860 to 1291 of SEQ ID NO:8, or a polypeptide sequence having at least 70% sequence identity thereto. C The domain may correspond to amino acid residues 860 to 1291 of SEQ ID NO:8, or a polypeptide sequence having at least 80%, 90%, or 95% sequence identity thereto. Preferably, the H from a BoNT / B C The domain corresponds to amino acid residues 860 to 1291 of SEQ ID NO:8.

[1239] Preferably, the BoNT / AB chimera comprises BoNT / A1 LH N Domains and BoNT / B1 H C More preferably, LH N The domain corresponds to amino acid residues 1 to 872 of BoNT / A1 (SEQ ID NO: 2), and H C The domain corresponds to amino acid residues 860 to 1291 of BoNT / B1 (SEQ ID NO: 8).

[1240] Most preferably, BoNT / BH C The domain also contains H CC At least one amino acid residue substitution, insertion, indel, or deletion in a subdomain that has the effect of increasing the binding affinity of the BoNT / B neurotoxin to human SytII compared to the native BoNT / B sequence. CC Suitable amino acid residue substitutions, insertions, indels or deletions in subdomains have been disclosed in WO 2013 / 180799 and WO 2016 / 154534 (both incorporated herein by reference).

[1241] BoNT / BH CC Suitable amino acid residue substitutions, insertions, indels or deletions in the subdomains may include substitution mutations selected from the group consisting of: V1118M; Y1183M; E1191M; E1191I; E1191Q; E1191T; S1199Y; S1199F; S1199L; S1201V; E1191C; E1191V; E1191L; E1191Y; S1199W; S1199E; S1199H; W1178Y; W1178Q; W1178A; W1178S; Y1183C; Y1183P and combinations thereof.

[1242] BoNT / BH CCSuitable amino acid residue substitutions, insertions, indels or deletions in the subdomains may also include a combination of two substitution mutations selected from the following: E1191M and S1199L; E1191M and S1199Y; E1191M and S1199F; E1191Q and S1199L; E1191Q and S1199Y; E1191Q and S1199F; E1191M and S1199W; E1191M and W1178Q; E1191C and S1199W; E1191C and S1199Y; E1191C and W1178Q; E1191Q and S1199W; E1191V and S1199W; E1191V and S1199Y; or E1191V and W1178Q.

[1243] BoNT / BH CC Suitable amino acid residue substitutions, insertions, indels or deletions in the subdomains may also include a combination of three substitution mutations, namely E1191M, S1199W and W1178Q.

[1244] Preferably, BoNT / BH CC The amino acid residue substitutions, insertions, indels, or deletions in the subdomain include a combination of two substitution mutations, which are E1191M and S1199Y. For example, such modifications are present in a modified BoNT / A (e.g., a BoNT / AB chimera) of SEQ ID NO: 5 and SEQ ID NO: 6. E1191M can correspond to position 1204 of SEQ ID NO: 6, and S1199Y can correspond to position 1212. Thus, SEQ ID NO: 6 can include 1204M and 1212Y.

[1245] The modification can be a modification when compared to an unmodified BoNT / B as set forth in SEQ ID NO:8, wherein the amino acid residue numbering is determined by alignment with SEQ ID NO:8. Since the presence of a methionine residue at position 1 of SEQ ID NO:8 (and SEQ ID NOs corresponding to the modified BoNT / A polypeptides described herein) is optional, one skilled in the art will take into account the presence / absence of the methionine residue when determining the amino acid residue numbering. For example, when SEQ ID NO:8 includes a methionine, the position numbering will be as defined above (e.g., E1191 will be E1191 of SEQ ID NO:8). Alternatively, when a methionine is absent in SEQ ID NO:8, the amino acid residue numbering should be modified by -1 (e.g., E1191 will be E1190 of SEQ ID NO:8). Thus, the initial methionine amino acid residue of the polypeptide sequence of the modified BoNT / A can be optional or absent. Similar considerations apply when a methionine at position 1 of other polypeptide sequences described herein is present / absent, and the skilled artisan will readily determine the correct amino acid residue numbering using routine techniques in the art.

[1246] The modified BoNT / A for use in the present invention can include a polypeptide sequence having at least 70% sequence identity to a polypeptide sequence selected from SEQ ID NOs: 3-7. For example, a polypeptide sequence having at least 80%, 90%, 95%, or 99.9% sequence identity to a polypeptide sequence selected from SEQ ID NOs: 3-7. Preferably, the modified BoNT / A for use in the present invention can include (more preferably consist of) a polypeptide sequence selected from SEQ ID NOs: 3-7.

[1247] Preferably, the modified BoNT / A comprises a polypeptide sequence having at least 70% sequence identity to SEQ ID NO: 6. For example, a polypeptide sequence having at least 80%, 90%, 95%, or 99.9% sequence identity to SEQ ID NO: 6. Most preferably, the modified BoNT / A for use in the present invention may comprise (more preferably consist of) SEQ ID NO: 6.

[1248] The term "deletion" as used herein refers to the removal of one or more amino acid residues of a polypeptide without replacing one or more amino acid residues at the site of the deletion. Thus, when one amino acid residue is deleted from a polypeptide sequence having x amino acid residues (for example), the resulting polypeptide has x-1 amino acid residues.

[1249] As used herein, the term "indel" refers to the deletion of one or more amino acid residues of a polypeptide, and the insertion of a different number of amino acid residues (more or fewer amino acid residues) than the number of amino acid residues deleted at the deletion site. Thus, for an indel in which two amino acid residues are deleted from a polypeptide sequence having x amino acid residues (for example), the resulting polypeptide has x-1 amino acid residues or x+≥1 amino acid residues. Insertions and deletions can be performed in any order, sequentially or simultaneously.

[1250] The term "substitution" as used herein refers to replacing one or more amino acid residues with the same number of amino acid residues at the same site. Thus, for a substitution of a polypeptide sequence having x amino acid residues (for example), the resulting polypeptide also has x amino acid residues. Preferably, the substitution is a substitution at a single amino acid position.

[1251] The term "insertion" as used herein refers to the addition of one or more amino acid residues of a polypeptide at an insertion site without deleting one or more amino acid residues of the polypeptide. Thus, when an amino acid residue has been inserted into a polypeptide sequence having x amino acid residues (for example), the resulting polypeptide has x+1 amino acid residues.

[1252] Methods for modifying proteins by substitution, insertion or deletion of amino acid residues are known in the art. For example, amino acid modifications can be introduced by modifying a DNA sequence encoding a BoNT / A (e.g., encoding an unmodified BoNT / A). This can be accomplished using standard molecular cloning techniques, such as by site-directed mutagenesis using a polymerase, where a short DNA strand (oligonucleotide) encoding the desired amino acid is substituted for the original coding sequence, or by inserting / deleting portions of the gene using a variety of enzymes (e.g., ligases and restriction endonucleases). Alternatively, the modified gene sequence can be chemically synthesized. Generally, the modification can be made by modifying a nucleic acid encoding a native clostridial neurotoxin (or a portion thereof) such that the modified BoNT / A (or a portion thereof) encoded by the nucleic acid comprises the modification. Alternatively, a nucleic acid encoding a modified clostridial neurotoxin (or a portion thereof) comprising the modification can be synthesized.

[1253] When the polypeptide sequence of the modified BoNT / A described herein comprises a tag, such as a His tag, for example, for purification, the tag is optional. Preferably, the tag is removed prior to use of the modified BoNT / A of the present invention.

[1254] As described above, the modified BoNT / A described herein have increased tissue retention properties, which also provide increased efficacy and / or duration of action, and can allow for increased dosage without any additional negative effects. One way these advantageous properties can be defined is in terms of the safety ratio of the modified BoNT / A. In this regard, the undesirable effects of clostridial toxins (caused by diffusion of the toxin from the site of administration) can be experimentally assessed by measuring the percent weight loss in relevant animal models (e.g., mice, where weight loss is detected within seven days of administration). Conversely, the desired on-target effects of neurotoxins can be experimentally evaluated by the toe abduction score (DAS) test (a measure of muscle paralysis). The DAS test can be performed by injecting 20 μL of clostridial neurotoxin formulated in gelatin phosphate buffer into the gastrocnemius / soleus complex of mice, followed by assessing the toe abduction score using the method of Aoki (Aoki KR, Toxicon 39: 1815-1820; 2001). In the DAS test, mice are briefly suspended by their tails to elicit a characteristic startle response in which the mice extend their hind limbs and abduct their hind toes. After injection of the clostridial neurotoxin, varying degrees of digital abduction are scored on a five-point scale (0 = normal to 4 = maximal reduction in digital abduction and leg extension).

[1255] The safety ratio of a neurotoxin, such as a modified BoNT / A of the present invention (or an unmodified BoNT / A for comparison) can then be expressed as the ratio between the amount of toxin required for a 10% decrease in body weight (measured at peak effect within the first seven days after administration to mice) and the amount of neurotoxin required for a DAS score of 2. Thus, a high safety ratio score is desirable and indicates that the neurotoxin is able to effectively paralyze the target muscle with few undesirable off-target effects. The safety ratio of the modified BoNT / A of the present invention is higher than the safety ratio of the equivalent unmodified (natural) BoNT / A.

[1256] A high safety ratio is particularly advantageous in treatment because it represents an increase in the therapeutic index. In other words, this means that reduced doses can be used and / or increased doses can be used without any additional (e.g., deleterious) effects compared to alternative clostridial neurotoxin therapeutics. The possibility of using higher doses of neurotoxins without additional effects is particularly advantageous because higher doses generally result in a longer duration of action of the neurotoxin.

[1257] The potency of a modified BoNT / A can be expressed as the minimum dose of the neurotoxin that results in a given DAS score when administered to the gastrocnemius / soleus complex of mice, e.g., a DAS score of 2 (ED 50dose) or a DAS score of 4. The potency of the modified BoNT / A can also be expressed as the EC in a cellular assay measuring SNARE cleavage by the neurotoxin. 50 Dose, e.g. EC in a cell-based assay measuring cleavage of SNAP25 by modified BoNT / A 50 dose.

[1258] The duration of action of a modified BoNT / A can be expressed as the time required to restore a DAS score of 0 following administration of a given dose of neurotoxin (e.g., the minimum dose of neurotoxin that results in a DAS score of 4) to the gastrocnemius / soleus complex of mice.

[1259] Thus, in one embodiment, the modified BoNT / A of the invention has a safety ratio greater than 7 (e.g., at least 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50), wherein the safety ratio is calculated as follows: - the toxin dose required for a 10% change in body weight (pg / mouse) divided by the DAS ED 50 (pg / mouse) [ED 50 =dose required to produce a DAS score of 2]. For example, the safety ratio of the modified BoNT / A is at least 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50.

[1260] In one embodiment, the modified BoNT / A of the invention has a safety ratio of at least 10. In one embodiment, the modified BoNT / A of the invention has a safety ratio of at least 15. Preferably, the modified BoNT / A has a safety ratio of at least 10 (e.g., a safety ratio of 10), more preferably at least 12 or 13 (e.g., 14-15).

[1261] The modified BoNT / A for use in the present invention may comprise a polypeptide sequence having at least 70% sequence identity to a polypeptide sequence selected from SEQ ID NOs: 3-7. For example, a polypeptide sequence having at least 80%, 90%, 95%, or 99.9% sequence identity to a polypeptide sequence selected from SEQ ID NOs: 3-7. Preferably, the modified BoNT / A for use in the present invention may comprise (more preferably consist of) a polypeptide sequence selected from SEQ ID NOs: 3-7. Among the modified BoNT / A, SEQ ID NO: 6 is preferred.

[1262] Thus, preferably, the modified BoNT / A comprises a polypeptide sequence having at least 70% sequence identity to a polypeptide sequence selected from SEQ ID NO: 6. More preferably, the polypeptide sequence has at least 80%, 90%, 95%, or 99.9% sequence identity to SEQ ID NO: 6. Most preferably, the modified BoNT / A for use in the present invention may comprise (more preferably consist of) SEQ ID NO: 6.

[1263] The double-chain modified BoNT / A of the present invention may include an L chain portion of a polypeptide sequence having at least 70%, 80%, 90%, 95%, 99.9% or 100% sequence identity to any one of SEQ ID NOs: 3-7, which constitutes the first chain of the double-chain modified BoNT / A, and may include an H chain portion of a polypeptide sequence having at least 70%, 80%, 90%, 95%, 99.9% or 100% sequence identity to any one of SEQ ID NOs: 3-7. N and H C The structural domains together constitute the second chain of the double-chain modified BoNT / A, wherein the first chain and the second chain are connected together by a disulfide bond.

[1264] When cleavage occurs at more than one position (preferably two positions) within the activation loop of a modified BoNT / A comprising a polypeptide sequence having at least 70%, 80%, 90%, 95%, 99.9%, or 100% sequence identity to any one of SEQ ID NOs: 3-7, then a small fragment of the C-terminal L chain portion of a sequence having at least 70%, 80%, 90%, 95%, 99.9%, or 100% sequence identity to any one of SEQ ID NOs: 3-7 may not be present in the two-chain modified BoNT / A. In view of this, the sequence of the two-chain modified BoNT / A (e.g., comprising a polypeptide sequence having at least 70%, 80%, 90%, 95%, 99.9%, or 100% sequence identity to any one of SEQ ID NOs: 3-7) can be slightly different from the corresponding single-chain modified BoNT / A, comprising a polypeptide sequence having at least 70%, 80%, 90%, 95%, 99.9%, or 100% sequence identity to any one of SEQ ID NOs: 3-7. The small fragment can be 1-15 amino acids. In particular, in one embodiment, when Lys-C is used to convert a single-chain modified BoNT / A into a two-chain clostridial neurotoxin, the small fragment of the C-terminal L chain portion of the sequence that is absent can be SEQ ID NO: 9 or 10.

[1265] Preferably, the double-chain modified BoNT / A of the present invention may include an L chain portion of a polypeptide sequence having at least 70%, 80%, 90%, 95%, 99.9% or 100% sequence identity to SEQ ID NO: 6, which constitutes the first chain of the double-chain modified BoNT / A, and may include an H chain portion of a polypeptide sequence having at least 70%, 80%, 90%, 95%, 99.9% or 100% sequence identity to SEQ ID NO: 6. N and H CThe structural domains together constitute the second chain of the two-chain modified BoNT / A, wherein the first chain and the second chain are linked together by a disulfide bond.

[1266] When cleavage occurs at more than one position (preferably two positions) within the activation loop of a modified BoNT / A comprising a polypeptide sequence having at least 70%, 80%, 90%, 95%, 99.9%, or 100% sequence identity to SEQ ID NO:6, then a small fragment of the C-terminal L chain portion of a sequence having at least 70%, 80%, 90%, 95%, 99.9%, or 100% sequence identity to SEQ ID NO:6 may not be present in the two-chain modified BoNT / A. In view of this, the sequence of the double-chain modified BoNT / A (e.g., comprising a polypeptide sequence having at least 70%, 80%, 90%, 95%, 99.9%, or 100% sequence identity to SEQ ID: 6) can be slightly different from the corresponding single-chain modified BoNT / A, the single-chain modified BoNT / A comprising a polypeptide sequence having at least 70%, 80%, 90%, 95%, 99.9%, or 100% sequence identity to SEQ ID: 6. The small fragment can be 1-15 amino acids. In particular, in one embodiment, when Lys-C is used to convert a single-chain modified BoNT / A into a double-chain modified BoNT / A, the small fragment of the L chain portion of the C-terminal portion of the sequence that is absent can be SEQ ID NO: 9 or 10.

[1267] In particularly preferred embodiments, the two-chain modified BoNT / A comprises (or consists of) a light chain comprising a polypeptide sequence having at least 70%, 80%, 90%, 95%, or 99.9% sequence identity to SEQ ID NO: 11 or 12 (preferably SEQ ID NO: 11), and a heavy chain comprising a polypeptide sequence having at least 70%, 80%, 90%, 95%, or 99.9% sequence identity to SEQ ID NO: 13, wherein the light chain and heavy chain are linked together by a disulfide bond. More preferably, the two-chain modified BoNT / A comprises (or consists of) a light chain comprising SEQ ID NO: 11 or 12 (preferably SEQ ID NO: 11), and a heavy chain comprising S...

Claims

1. A modified botulinum neurotoxin A (BoNT / A) for use in a method of treating blepharospasm in an individual, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of the individual, the method comprising: a) administering a unit dose of a modified BoNT / A to each of up to six different injection sites proximate to the superior orbicularis oculi muscle of a first eye of the individual, wherein the up to six different injection sites are selected from: i) medial superior orbital septum preorbicularis oculi muscle; ii) superior orbital orbicularis oculi; iii) lateral superior orbital septum preorbicularis oculi muscle; iv) lateral orbital orbicularis oculi; v) medial superior tarsal preorbital orbicularis oculi muscle; and vi) Lateral superior tarsal preorbital orbicularis oculi muscle; and / or b) administering a unit dose of a modified BoNT / A to up to two different injection sites proximate to the inferior orbicularis oculi muscle of a first eye of the individual, each injection site, wherein the up to two different injection sites are selected from: i) medial inferior orbicularis oculi muscle; and ii) Lateral inferior orbicularis oculi muscle; and / or c) administering a unit dose of the modified BoNT / A to up to two different injection sites selected from: i) two different injection sites on the corrugator supercilii muscle near the subject's first eye; and ii) an injection site on the procerus muscle close to the subject's first eye; wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A, wherein the total dose administered during the treatment period is greater than 24,000 pg and up to 82,500 pg (e.g., up to 75,000 pg) of the modified BoNT / A, and wherein the modified BoNT / A comprises a BoNT / A light chain and a translocation domain (H N ) and the BoNT / B receptor binding domain (H C domain).

2. A method of treating blepharospasm in an individual, the method comprising administering a modified botulinum neurotoxin A (BoNT / A) by intramuscular injection at multiple sites on the face of the individual, the method comprising: a) administering a unit dose of a modified BoNT / A to each of up to six different injection sites proximate to the superior orbicularis oculi muscle of a first eye of the individual, wherein the up to six different injection sites are selected from: i) medial superior orbital septum preorbicularis oculi muscle; ii) superior orbital orbicularis oculi; iii) lateral superior orbital septum preorbicularis oculi muscle; iv) lateral orbital orbicularis oculi; v) medial superior tarsal preorbital orbicularis oculi muscle; and vi) Lateral superior tarsal preorbital orbicularis oculi muscle; and / or b) administering a unit dose of a modified BoNT / A to up to two different injection sites proximate to the inferior orbicularis oculi muscle of a first eye of the individual, each injection site, wherein the up to two different injection sites are selected from: i) medial inferior orbicularis oculi muscle; and ii) Lateral inferior orbicularis oculi muscle; and / or c) administering a unit dose of the modified BoNT / A to up to two different injection sites selected from: i) two different injection sites on the corrugator supercilii muscle near the subject's first eye; and ii) an injection site on the procerus muscle close to the subject's first eye; wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A, wherein the total dose administered during the treatment period is greater than 24,000 pg and up to 82,500 pg (e.g., up to 75,000 pg) of the modified BoNT / A, and wherein the modified BoNT / A comprises a BoNT / A light chain and a translocation domain (H N ) and the BoNT / B receptor binding domain (H C domain).

3. Use of a modified botulinum neurotoxin A (BoNT / A) in the preparation of a medicament for treating classic hemifacial spasm, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of an individual, the treatment comprising: (a) administering a unit dose of a modified BoNT / A to each of up to six different injection sites proximate to the superior orbicularis oculi muscle of a first eye of the individual, wherein the up to six different injection sites are selected from: (i) medial superior orbital septum preorbicularis oculi muscle; (ii) supraorbital orbicularis oculi; (iii) lateral superior orbital septum preorbicularis oculi muscle; (iv) lateral orbital orbicularis oculi; (v) medial superior tarsal preorbital orbicularis oculi muscle; and (vi) lateral superior tarsal preorbital orbicularis oculi muscle; and / or (b) administering a unit dose of a modified BoNT / A to up to two different injection sites proximate to the inferior orbicularis oculi muscle of a first eye of the individual, each injection site, wherein the up to two different injection sites are selected from: (i) medial inferior orbicularis oculi muscle; and (ii) lateral inferior orbicularis oculi muscle; and / or (c) administering a unit dose of the modified BoNT / A to up to two different injection sites selected from: (i) two different injection sites on the corrugator supercilii muscle proximal to the subject's first eye; and (ii) an injection site on the procerus muscle proximal to the subject's first eye; wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A, wherein the total dose administered during the treatment period is greater than 24,000 pg and up to 82,500 pg (e.g., up to 75,000 pg) of the modified BoNT / A, and wherein the modified BoNT / A comprises a BoNT / A light chain and a translocation domain (H N ) and the BoNT / B receptor binding domain (H C domain).

4. The modified BoNT / A for use, method or use according to any one of the preceding claims, wherein the modified BoNT / A is administered by intramuscular injection at at least six different sites on the face of the individual.

5. The modified BoNT / A for use, method or use according to any one of the preceding claims, wherein the method for treating blepharospasm further comprises: (a) administering a unit dose of a modified BoNT / A to each of up to six different injection sites proximate to the superior orbicularis oculi muscle of a second eye of the individual, wherein the up to six different injection sites are selected from: (i) medial superior orbital septum preorbicularis oculi muscle; (ii) supraorbital orbicularis oculi; (iii) lateral superior orbital septum preorbicularis oculi muscle; (iv) lateral orbital orbicularis oculi; (v) medial superior tarsal preorbital orbicularis oculi muscle; and (vi) lateral superior tarsal preorbital orbicularis oculi muscle; and / or (b) administering a unit dose of a modified BoNT / A to up to two different injection sites proximate to the inferior orbicularis oculi muscle of a second eye of the individual, each injection site, wherein the up to two different injection sites are selected from: (i) medial inferior orbicularis oculi muscle; and (ii) lateral inferior orbicularis oculi muscle; and / or (c) administering a unit dose of the modified BoNT / A to up to two different injection sites selected from: (i) two different injection sites on the corrugator supercilii muscle near the subject's second eye; and (ii) an injection site on the procerus muscle near the subject's second eye.

6. The modified BoNT / A for use, method or use according to claim 5, wherein the modified BoNT / A is administered by intramuscular injection at at least six different sites in each eye of the individual.

7. The modified BoNT / A for use, method or use according to any one of the preceding claims, wherein the method comprises: (a) administering a unit dose of a modified BoNT / A to the lateral superior orbital septal preorbicularis oculi muscle proximal to a first eye of a subject; (b) administering a unit dose of the modified BoNT / A to the medial superior septal pre-orbicularis oculi muscle proximal to a first eye of the individual; and (c) administering a unit dose of the modified BoNT / A to the lateral inferior orbicularis oculi muscle (preferably the lateral inferior preseptal orbicularis oculi muscle) proximal to the first eye of the individual.

8. A modified botulinum neurotoxin A (BoNT / A) for use in a method of treating classic hemifacial spasm, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of an individual, the method comprising: (a) administering a unit dose of a modified BoNT / A to each of up to six different injection sites proximate to the superior orbicularis oculi muscle of a first eye of the individual, wherein the up to six different injection sites are selected from: (i) medial superior orbital septum preorbicularis oculi muscle; (ii) supraorbital orbicularis oculi; (iii) lateral superior orbital septum preorbicularis oculi muscle; (iv) lateral orbital orbicularis oculi; (v) medial superior tarsal preorbital orbicularis oculi muscle; and (vi) lateral superior tarsal preorbital orbicularis oculi muscle; and / or (b) administering a unit dose of a modified BoNT / A to up to two different injection sites proximate to the inferior orbicularis oculi muscle of a first eye of the individual, each injection site, wherein the up to two different injection sites are selected from: (i) medial inferior orbicularis oculi muscle; and (ii) lateral inferior orbicularis oculi muscle; and / or (c) administering a unit dose of the modified BoNT / A to up to two different injection sites selected from: (i) two different injection sites on the corrugator supercilii muscle proximal to the subject's first eye; and (ii) an injection site on the procerus muscle proximal to the subject's first eye; and / or (d) administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by the hemifacial spasm according to the following dosing regimen: (i) administering one unit dose to the superior orbicularis oris muscle; (ii) administering one unit dose to the inferior orbicularis oris muscle; (iii) administering a unit dose to the zygomaticus major muscle; (iv) administering a unit dose to the zygomaticus minor muscle; (v) administering up to five unit doses (preferably one unit dose) to the frontalis muscle; (vi) administering a unit dose to the mentalis muscle; (vii) administering a unit dose to the platysma muscle; (viii) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle; (ix) administering a unit dose to the buccinator muscle; (x) administering up to two unit doses (preferably one unit dose) to the masseter muscle; (xi) administering a unit dose to the procerus muscle; (xii) administering a unit dose to the nasal muscle; and / or (xiii) administering one unit dose to the levator palpebrae superioris muscle; wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A, wherein the total dose administered during the treatment period is greater than 24,000 pg and up to 82,500 pg (e.g., up to 75,000 pg) of the modified BoNT / A, and wherein the modified BoNT / A comprises a botulinum neurotoxin A (BoNT / A) light chain and a translocation domain (H N ) and the BoNT / B receptor binding domain (H C domain).

9. A method of treating classic hemifacial spasm, the method comprising administering a modified BoNT / A by intramuscular injection at multiple sites on the face of an individual, the method comprising: (a) administering a unit dose of a modified BoNT / A to each of up to six different injection sites proximate to the superior orbicularis oculi muscle of a first eye of the individual, wherein the up to six different injection sites are selected from: (i) medial superior orbital septum preorbicularis oculi muscle; (ii) supraorbital orbicularis oculi; (iii) lateral superior orbital septum preorbicularis oculi muscle; (iv) lateral orbital orbicularis oculi; (v) medial superior tarsal preorbital orbicularis oculi muscle; and (vi) lateral superior tarsal preorbital orbicularis oculi muscle; and / or (b) administering a unit dose of a modified BoNT / A to up to two different injection sites proximate to the inferior orbicularis oculi muscle of a first eye of the individual, each injection site, wherein the up to two different injection sites are selected from: (i) medial inferior orbicularis oculi muscle; and (ii) lateral inferior orbicularis oculi muscle; and / or (c) administering a unit dose of the modified BoNT / A to up to two different injection sites selected from: (i) two different injection sites on the corrugator supercilii muscle proximal to the subject's first eye; and (ii) an injection site on the procerus muscle proximal to the subject's first eye; and / or (d) administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by the hemifacial spasm according to the following dosing regimen: (i) administering one unit dose to the superior orbicularis oris muscle; (ii) administering one unit dose to the inferior orbicularis oris muscle; (iii) administering a unit dose to the zygomaticus major muscle; (iv) administering a unit dose to the zygomaticus minor muscle; (v) administering up to five unit doses (preferably one unit dose) to the frontalis muscle; (vi) administering a unit dose to the mentalis muscle; (vii) administering a unit dose to the platysma muscle; (viii) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle; (ix) administering a unit dose to the buccinator muscle; (x) administering up to two unit doses (preferably one unit dose) to the masseter muscle; (xi) administering a unit dose to the procerus muscle; (xii) administering a unit dose to the nasal muscle; and / or (xiii) administering one unit dose to the levator palpebrae superioris muscle; wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A, wherein the total dose administered during the treatment period is greater than 24,000 pg and up to 82,500 pg (e.g., up to 75,000 pg) of the modified BoNT / A, and wherein the modified BoNT / A comprises a botulinum neurotoxin A (BoNT / A) light chain and a translocation domain (H N ) and the BoNT / B receptor binding domain (H C domain).

10. Use of a modified botulinum neurotoxin A (BoNT / A) in the preparation of a medicament for treating classic hemifacial spasm, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of an individual, the treatment comprising: (a) administering a unit dose of a modified BoNT / A to each of up to six different injection sites proximate to the superior orbicularis oculi muscle of a first eye of the individual, wherein the up to six different injection sites are selected from: (i) medial superior orbital septum preorbicularis oculi muscle; (ii) supraorbital orbicularis oculi; (iii) lateral superior orbital septum preorbicularis oculi muscle; (iv) lateral orbital orbicularis oculi; (v) medial superior tarsal preorbital orbicularis oculi muscle; and (vi) lateral superior tarsal preorbital orbicularis oculi muscle; and / or (b) administering a unit dose of a modified BoNT / A to up to two different injection sites proximate to the inferior orbicularis oculi muscle of a first eye of the individual, each injection site, wherein the up to two different injection sites are selected from: (i) medial inferior orbicularis oculi muscle; and (ii) lateral inferior orbicularis oculi muscle; and / or (c) administering a unit dose of the modified BoNT / A to up to two different injection sites selected from: (i) two different injection sites on the corrugator supercilii muscle proximal to the subject's first eye; and (ii) an injection site on the procerus muscle proximal to the subject's first eye; and / or (d) administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by the hemifacial spasm according to the following dosing regimen: (i) administering one unit dose to the superior orbicularis oris muscle; (ii) administering one unit dose to the inferior orbicularis oris muscle; (iii) administering a unit dose to the zygomaticus major muscle; (iv) administering a unit dose to the zygomaticus minor muscle; (v) administering up to five unit doses (preferably one unit dose) to the frontalis muscle; (vi) administering a unit dose to the mentalis muscle; (vii) administering a unit dose to the platysma muscle; (viii) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle; (ix) administering a unit dose to the buccinator muscle; (x) administering up to two unit doses (preferably one unit dose) to the masseter muscle; (xi) administering a unit dose to the procerus muscle; (xii) administering a unit dose to the nasal muscle; and / or (xiii) administering one unit dose to the levator palpebrae superioris muscle; wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A, wherein the total dose administered during the treatment period is greater than 24,000 pg and up to 82,500 pg (e.g., up to 75,000 pg) of the modified BoNT / A, and wherein the modified BoNT / A comprises a botulinum neurotoxin A (BoNT / A) light chain and a translocation domain (H N ) and the BoNT / B receptor binding domain (H C domain).

11. The modified BoNT / A for use, method or use according to any one of the preceding claims, wherein the modified BoNT / A is administered by intramuscular injection at at least six different sites on the face of the individual.

12. The modified BoNT / A for use, method or use according to any one of the preceding claims, wherein the method comprises: (a) administering a unit dose of a modified BoNT / A to the lateral superior orbital septal preorbicularis oculi muscle proximal to a first eye of a subject; (b) administering a unit dose of the modified BoNT / A to the medial superior septal pre-orbicularis oculi muscle proximal to a first eye of the individual; and (c) administering a unit dose of the modified BoNT / A to the lateral inferior orbicularis oculi muscle (preferably the lateral inferior preseptal orbicularis oculi muscle) proximal to the first eye of the individual.

13. A modified botulinum neurotoxin A (BoNT / A) for use in treating atypical hemifacial spasm, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of an individual, the method comprising: a) administering a unit dose of a modified BoNT / A to the orbicularis oris muscle affected by hemifacial spasm (e.g., administering one unit dose of the modified BoNT / A to the upper orbicularis oris muscle and / or administering one unit dose to the lower orbicularis oris muscle affected by hemifacial spasm; preferably administering one unit dose of the modified BoNT / A to the upper orbicularis oris muscle and one unit dose to the lower orbicularis oris muscle affected by said hemifacial spasm); and b) optionally, administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by the hemifacial spasm according to the following dosing regimen: (i) administering a unit dose to the zygomaticus major muscle; (ii) administering a unit dose to the zygomaticus minor muscle; (iii) administering up to five unit doses (preferably one unit dose) to the frontalis muscle; (iv) administering a unit dose to the mentalis muscle; (v) administering a unit dose to the platysma muscle; (vi) administering a unit dose to the buccinator muscle; (vii) administering up to two unit doses (preferably one unit dose) to the masseter muscle; (viii) administering a unit dose to the nasal muscle; (ix) administering a unit dose to the levator palpebrae superioris muscle; and / or c) optionally, administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by the hemifacial spasm according to the following dosing regimen: The unit dose is injected at each of up to six different injection sites in the superior orbicularis oculi muscle, selected from: (i) medial superior orbital septum preorbicularis oculi muscle; (ii) supraorbital orbicularis oculi; (iii) lateral superior orbital septum preorbicularis oculi muscle; (iv) lateral orbital orbicularis oculi; (v) medial superior tarsal preorbital orbicularis oculi muscle; and (vi) lateral superior tarsal preorbital orbicularis oculi muscle; and / or The unit dose is injected at up to two different injection sites in the inferior orbicularis oculi muscle, each selected from: (i) medial inferior orbicularis oculi muscle; and (ii) lateral inferior orbicularis oculi muscle; and / or The unit dose is injected at up to two different injection sites, each selected from: (i) two different injection sites in the corrugator supercilii muscle; and (ii) one injection site in the procerus muscle; wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A, wherein the total dose administered during the treatment period is greater than 24,000 pg and up to 82,500 pg (e.g., up to 75,000 pg) of the modified BoNT / A, and wherein the modified BoNT / A comprises a botulinum neurotoxin A (BoNT / A) light chain and a translocation domain (HN) and a BoNT / B receptor binding domain (H C domain).

14. A method of treating atypical hemifacial spasm, the method comprising administering a modified BoNT / A by intramuscular injection at multiple sites on the face of an individual, the method comprising: a) administering a unit dose of a modified BoNT / A to the orbicularis oris muscle affected by hemifacial spasm (e.g., administering one unit dose of the modified BoNT / A to the upper orbicularis oris muscle and / or administering one unit dose to the lower orbicularis oris muscle affected by hemifacial spasm; preferably administering one unit dose of the modified BoNT / A to the upper orbicularis oris muscle and one unit dose to the lower orbicularis oris muscle affected by said hemifacial spasm); and b) optionally, administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by the hemifacial spasm according to the following dosing regimen: (i) administering a unit dose to the zygomaticus major muscle; (ii) administering a unit dose to the zygomaticus minor muscle; (iii) administering up to five unit doses (preferably one unit dose) to the frontalis muscle; (iv) administering a unit dose to the mentalis muscle; (v) administering a unit dose to the platysma muscle; (vi) administering a unit dose to the buccinator muscle; (vii) administering up to two unit doses (preferably one unit dose) to the masseter muscle; (viii) administering a unit dose to the nasal muscle; (ix) administering a unit dose to the levator palpebrae superioris muscle; and / or c) optionally, administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by the hemifacial spasm according to the following dosing regimen: The unit dose is injected at each of up to six different injection sites in the superior orbicularis oculi muscle, selected from: (i) medial superior orbital septum preorbicularis oculi muscle; (ii) supraorbital orbicularis oculi; (iii) lateral superior orbital septum preorbicularis oculi muscle; (iv) lateral orbital orbicularis oculi; (v) medial superior tarsal preorbital orbicularis oculi muscle; and (vi) lateral superior tarsal preorbital orbicularis oculi muscle; and / or The unit dose is injected at up to two different injection sites in the inferior orbicularis oculi muscle, each selected from: (i) medial inferior orbicularis oculi muscle; and (ii) lateral inferior orbicularis oculi muscle; and / or The unit dose is injected at up to two different injection sites, each selected from: (i) two different injection sites in the corrugator supercilii muscle; and (ii) one injection site in the procerus muscle; wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A, wherein the total dose administered during the treatment period is greater than 24,000 pg and up to 82,500 pg (e.g., up to 75,000 pg) of the modified BoNT / A, and wherein the modified BoNT / A comprises a botulinum neurotoxin A (BoNT / A) light chain and a translocation domain (HN) and a BoNT / B receptor binding domain (H C domain).

15. Use of a modified botulinum neurotoxin A (BoNT / A) in the preparation of a medicament for treating atypical hemifacial spasm, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of an individual, the treatment comprising: a) administering a unit dose of a modified BoNT / A to the orbicularis oris muscle affected by hemifacial spasm (e.g., administering one unit dose of the modified BoNT / A to the upper orbicularis oris muscle and / or administering one unit dose to the lower orbicularis oris muscle affected by hemifacial spasm; preferably administering one unit dose of the modified BoNT / A to the upper orbicularis oris muscle and one unit dose to the lower orbicularis oris muscle affected by said hemifacial spasm); and b) optionally, administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by the hemifacial spasm according to the following dosing regimen: (i) administering a unit dose to the zygomaticus major muscle; (ii) administering a unit dose to the zygomaticus minor muscle; (iii) administering up to five unit doses (preferably one unit dose) to the frontalis muscle; (iv) administering a unit dose to the mentalis muscle; (v) administering a unit dose to the platysma muscle; (vi) administering a unit dose to the buccinator muscle; (vii) administering up to two unit doses (preferably one unit dose) to the masseter muscle; (viii) administering a unit dose to the nasal muscle; (ix) administering a unit dose to the levator palpebrae superioris muscle; and / or c) optionally, administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by the hemifacial spasm according to the following dosing regimen: The unit dose is injected at each of up to six different injection sites in the superior orbicularis oculi muscle, selected from: (i) medial superior orbital septum preorbicularis oculi muscle; (ii) supraorbital orbicularis oculi; (iii) lateral superior orbital septum preorbicularis oculi muscle; (iv) lateral orbital orbicularis oculi; (v) medial superior tarsal preorbital orbicularis oculi muscle; and (vi) lateral superior tarsal preorbital orbicularis oculi muscle; and / or The unit dose is injected at up to two different injection sites in the inferior orbicularis oculi muscle, each selected from: (i) medial inferior orbicularis oculi muscle; and (ii) lateral inferior orbicularis oculi muscle; and / or The unit dose is injected at up to two different injection sites, each selected from: (i) two different injection sites in the corrugator supercilii muscle; and (ii) one injection site in the procerus muscle; wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A, wherein the total dose administered during the treatment period is greater than 24,000 pg and up to 82,500 pg (e.g., up to 75,000 pg) of the modified BoNT / A, and wherein the modified BoNT / A comprises a botulinum neurotoxin A (BoNT / A) light chain and a translocation domain (HN) and a BoNT / B receptor binding domain (H C domain).

16. A modified botulinum neurotoxin A (BoNT / A) for use in a method of treating blepharospasm in an individual, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of the individual, the method comprising: a) administering a unit dose of a modified BoNT / A to the lateral superior orbicularis oculi muscle proximal to a first eye of the individual; b) administering a unit dose of the modified BoNT / A to the medial superior orbicularis oculi muscle proximal to the first eye of the individual; as well as c) administering a unit dose of a modified BoNT / A to the lateral inferior orbicularis oculi muscle proximal to a first eye of the individual, wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A, wherein the total dose administered during the treatment period is greater than 24,000 pg and up to 82,500 pg (e.g., up to 75,000 pg) of the modified BoNT / A, and wherein the modified BoNT / A comprises a BoNT / A light chain and a translocation domain (H N ) and the BoNT / B receptor binding domain (H C domain).

17. A method of treating blepharospasm in an individual, the method comprising administering a modified BoNT / A by intramuscular injection at multiple sites on the face of the individual, the method comprising: a) administering a unit dose of a modified BoNT / A to the lateral superior orbicularis oculi muscle proximal to a first eye of the individual; b) administering a unit dose of the modified BoNT / A to the medial superior orbicularis oculi muscle proximal to the first eye of the individual; as well as c) administering a unit dose of a modified BoNT / A to the lateral inferior orbicularis oculi muscle proximal to a first eye of the individual, wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A, wherein the total dose administered during the treatment period is greater than 24,000 pg and up to 82,500 pg (e.g., up to 75,000 pg) of the modified BoNT / A, and wherein the modified BoNT / A comprises a BoNT / A light chain and a translocation domain (H N ) and the BoNT / B receptor binding domain (H C domain).

18. Use of a modified botulinum neurotoxin A (BoNT / A) in the preparation of a medicament for treating blepharospasm in a subject, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of the subject, the treatment comprising: a) administering a unit dose of a modified BoNT / A to the lateral superior orbicularis oculi muscle proximal to a first eye of the individual; b) administering a unit dose of the modified BoNT / A to the medial superior orbicularis oculi muscle proximal to the first eye of the individual; as well as c) administering a unit dose of a modified BoNT / A to the lateral inferior orbicularis oculi muscle proximal to a first eye of the individual, wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A, wherein the total dose administered during the treatment period is greater than 24,000 pg and up to 82,500 pg (e.g., up to 75,000 pg) of the modified BoNT / A, and wherein the modified BoNT / A comprises a BoNT / A light chain and a translocation domain (H N ) and the BoNT / B receptor binding domain (H C domain).

19. A modified botulinum neurotoxin A (BoNT / A) for use in a method of treating classic hemifacial spasm, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of an individual, the method comprising: a) administering a unit dose of a modified BoNT / A to the lateral superior orbicularis oculi muscle proximal to the eye affected by hemifacial spasm; as well as b) administering a unit dose of the modified BoNT / A to the medial superior orbicularis oculi muscle proximal to the eye affected by hemifacial spasm; as well as c) administering a unit dose of the modified BoNT / A to the lateral inferior orbicularis oculi muscle proximal to the eye affected by hemifacial spasm; as well as d) administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by the hemifacial spasm according to the following dosing regimen: (i) administering one unit dose to the superior orbicularis oris muscle; (ii) administering one unit dose to the inferior orbicularis oris muscle; (iii) administering a unit dose to the zygomaticus major muscle; (iv) administering a unit dose to the zygomaticus minor muscle; (v) administering up to five unit doses (preferably one unit dose) to the frontalis muscle; (vi) administering a unit dose to the mentalis muscle; (vii) administering a unit dose to the platysma muscle; (viii) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle; (ix) administering a unit dose to the buccinator muscle; (x) administering up to two unit doses (preferably one unit dose) to the masseter muscle; (xi) administering a unit dose to the procerus muscle; (xii) administering a unit dose to the nasal muscle; and / or (xiii) administering one unit dose to the levator palpebrae superioris muscle; wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A, wherein the total dose administered during the treatment period is greater than 24,000 pg and up to 82,500 pg (e.g., up to 75,000 pg) of the modified BoNT / A, and wherein the modified BoNT / A comprises a botulinum neurotoxin A (BoNT / A) light chain and a translocation domain (H N ) and the BoNT / B receptor binding domain (H C domain).

20. A method of treating classic hemifacial spasm, the method comprising administering a modified BoNT / A by intramuscular injection at multiple sites on the face of an individual, the method comprising: a) administering a unit dose of a modified BoNT / A to the lateral superior orbicularis oculi muscle proximal to the eye affected by hemifacial spasm; b) administering a unit dose of the modified BoNT / A to the medial superior orbicularis oculi muscle proximal to the eye affected by hemifacial spasm; c) administering a unit dose of the modified BoNT / A to the lateral inferior orbicularis oculi muscle proximal to the eye affected by hemifacial spasm; as well as d) administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by the hemifacial spasm according to the following dosing regimen: (i) administering one unit dose to the superior orbicularis oris muscle; (ii) administering one unit dose to the inferior orbicularis oris muscle; (iii) administering a unit dose to the zygomaticus major muscle; (iv) administering a unit dose to the zygomaticus minor muscle; (v) administering up to five unit doses (preferably one unit dose) to the frontalis muscle; (vi) administering a unit dose to the mentalis muscle; (vii) administering a unit dose to the platysma muscle; (viii) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle; (ix) administering a unit dose to the buccinator muscle; (x) administering up to two unit doses (preferably one unit dose) to the masseter muscle; (xi) administering a unit dose to the procerus muscle; (xii) administering a unit dose to the nasal muscle; and / or (xiii) administering one unit dose to the levator palpebrae superioris muscle; wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A, wherein the total dose administered during the treatment period is greater than 24,000 pg and up to 82,500 pg (e.g., up to 75,000 pg) of the modified BoNT / A, and wherein the modified BoNT / A comprises a botulinum neurotoxin A (BoNT / A) light chain and a translocation domain (H N ) and the BoNT / B receptor binding domain (H C domain).

21. Use of a modified botulinum neurotoxin A (BoNT / A) in the preparation of a medicament for treating classic hemifacial spasm, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of an individual, the treatment comprising: a) administering a unit dose of a modified BoNT / A to the lateral superior orbicularis oculi muscle proximal to the eye affected by hemifacial spasm; b) administering a unit dose of the modified BoNT / A to the medial superior orbicularis oculi muscle proximal to the eye affected by hemifacial spasm; c) administering a unit dose of the modified BoNT / A to the lateral inferior orbicularis oculi muscle proximal to the eye affected by hemifacial spasm; as well as d) administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by the hemifacial spasm according to the following dosing regimen: (i) administering one unit dose to the superior orbicularis oris muscle; (ii) administering one unit dose to the inferior orbicularis oris muscle; (iii) administering a unit dose to the zygomaticus major muscle; (iv) administering a unit dose to the zygomaticus minor muscle; (v) administering up to five unit doses (preferably one unit dose) to the frontalis muscle; (vi) administering a unit dose to the mentalis muscle; (vii) administering a unit dose to the platysma muscle; (viii) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle; (ix) administering a unit dose to the buccinator muscle; (x) administering up to two unit doses (preferably one unit dose) to the masseter muscle; (xi) administering a unit dose to the procerus muscle; (xii) administering a unit dose to the nasal muscle; and / or (xiii) administering one unit dose to the levator palpebrae superioris muscle; wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A, wherein the total dose administered during the treatment period is greater than 24,000 pg and up to 82,500 pg (e.g., up to 75,000 pg) of the modified BoNT / A, and wherein the modified BoNT / A comprises a botulinum neurotoxin A (BoNT / A) light chain and a translocation domain (H N ) and the BoNT / B receptor binding domain (H C domain).

22. A modified botulinum neurotoxin A (BoNT / A) for use in treating atypical hemifacial spasm, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of an individual, the method comprising: a) administering a unit dose of a modified BoNT / A to the orbicularis oris muscle affected by hemifacial spasm (e.g., administering one unit dose of the modified BoNT / A to the upper orbicularis oris muscle and / or administering one unit dose to the lower orbicularis oris muscle affected by hemifacial spasm; preferably administering one unit dose of the modified BoNT / A to the upper orbicularis oris muscle and one unit dose to the lower orbicularis oris muscle affected by said hemifacial spasm); and b) optionally, administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by the hemifacial spasm according to the following dosing regimen: (i) administering a unit dose to the zygomaticus major muscle; (ii) administering a unit dose to the zygomaticus minor muscle; (iii) administering up to five unit doses (preferably one unit dose) to the frontalis muscle; (iv) administering a unit dose to the mentalis muscle; (v) administering a unit dose to the platysma muscle; (vi) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle; (vii) administering a unit dose to the buccinator muscle; (viii) administering up to two unit doses (preferably one unit dose) to the masseter muscle; (ix) administering a unit dose to the procerus muscle; (x) administering a unit dose to the nasal muscle; (xi) administering one unit dose to the lateral superior orbicularis oculi muscle; (xii) administering one unit dose to the medial superior orbicularis oculi muscle; (xiii) administering a unit dose to the lateral inferior orbicularis oculi muscle; and / or (xiv) administering a unit dose to the levator palpebrae superioris muscle; wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A, wherein the total dose administered during the treatment period is greater than 24,000 pg and up to 82,500 pg (e.g., up to 75,000 pg) of the modified BoNT / A, and wherein the modified BoNT / A comprises a botulinum neurotoxin A (BoNT / A) light chain and a translocation domain (H N ) and the BoNT / B receptor binding domain (H C domain).

23. A method of treating atypical hemifacial spasm, the method comprising administering a modified BoNT / A by intramuscular injection at multiple sites on the face of an individual, the method comprising: a) administering a unit dose of a modified BoNT / A to the orbicularis oris muscle affected by hemifacial spasm (e.g., administering one unit dose of the modified BoNT / A to the upper orbicularis oris muscle and / or administering one unit dose to the lower orbicularis oris muscle affected by hemifacial spasm; preferably administering one unit dose of the modified BoNT / A to the upper orbicularis oris muscle and one unit dose to the lower orbicularis oris muscle affected by said hemifacial spasm); and b) optionally, administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by the hemifacial spasm according to the following dosing regimen: (i) administering a unit dose to the zygomaticus major muscle; (ii) administering a unit dose to the zygomaticus minor muscle; (iii) administering up to five unit doses (preferably one unit dose) to the frontalis muscle; (iv) administering a unit dose to the mentalis muscle; (v) administering a unit dose to the platysma muscle; (vi) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle; (vii) administering a unit dose to the buccinator muscle; (viii) administering up to two unit doses (preferably one unit dose) to the masseter muscle; (ix) administering a unit dose to the procerus muscle; (x) administering a unit dose to the nasal muscle; (xi) administering one unit dose to the lateral superior orbicularis oculi muscle; (xii) administering one unit dose to the medial superior orbicularis oculi muscle; (xiii) administering a unit dose to the lateral inferior orbicularis oculi muscle; and / or (xiv) administering a unit dose to the levator palpebrae superioris muscle; wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A, wherein the total dose administered during the treatment period is greater than 24,000 pg and up to 82,500 pg (e.g., up to 75,000 pg) of the modified BoNT / A, and wherein the modified BoNT / A comprises a botulinum neurotoxin A (BoNT / A) light chain and a translocation domain (H N ) and the BoNT / B receptor binding domain (H C domain).

24. Use of a modified botulinum neurotoxin A (BoNT / A) in the preparation of a medicament for treating atypical hemifacial spasm, wherein the modified BoNT / A is administered by intramuscular injection at multiple sites on the face of an individual, the treatment comprising: a) administering a unit dose of a modified BoNT / A to the orbicularis oris muscle affected by hemifacial spasm (e.g., administering one unit dose of the modified BoNT / A to the upper orbicularis oris muscle and / or administering one unit dose to the lower orbicularis oris muscle affected by hemifacial spasm; preferably administering one unit dose of the modified BoNT / A to the upper orbicularis oris muscle and one unit dose to the lower orbicularis oris muscle affected by said hemifacial spasm); and b) optionally, administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by the hemifacial spasm according to the following dosing regimen: (i) administering a unit dose to the zygomaticus major muscle; (ii) administering a unit dose to the zygomaticus minor muscle; (iii) administering up to five unit doses (preferably one unit dose) to the frontalis muscle; (iv) administering a unit dose to the mentalis muscle; (v) administering a unit dose to the platysma muscle; (vi) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle; (vii) administering a unit dose to the buccinator muscle; (viii) administering up to two unit doses (preferably one unit dose) to the masseter muscle; (ix) administering a unit dose to the procerus muscle; (x) administering a unit dose to the nasal muscle; (xi) administering one unit dose to the lateral superior orbicularis oculi muscle; (xii) administering one unit dose to the medial superior orbicularis oculi muscle; (xiii) administering a unit dose to the lateral inferior orbicularis oculi muscle; and / or (xiv) administering a unit dose to the levator palpebrae superioris muscle; wherein the unit dose of the modified BoNT / A is at least 240 pg (preferably 240 pg to 8,000 pg) of the modified BoNT / A, wherein the total dose administered during the treatment period is greater than 24,000 pg and up to 82,500 pg (e.g., up to 75,000 pg) of the modified BoNT / A, and wherein the modified BoNT / A comprises a botulinum neurotoxin A (BoNT / A) light chain and a translocation domain (H N ) and the BoNT / B receptor binding domain (H C domain).

25. The modified BoNT / A for use, method or use of any preceding claim, further comprising administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by the blepharospasm according to the following dosing regimen: (i) administering one unit dose to the superior orbicularis oris muscle; (ii) administering one unit dose to the inferior orbicularis oris muscle; (iii) administering a unit dose to the zygomaticus major muscle; (iv) administering a unit dose to the zygomaticus minor muscle; (v) administering up to five unit doses (preferably one unit dose) to the frontalis muscle; (vi) administering a unit dose to the mentalis muscle; (vii) administering a unit dose to the platysma muscle; (viii) administering up to two unit doses (preferably one unit dose) to the corrugator supercilii muscle; (ix) administering a unit dose to the buccinator muscle; (x) administering up to two unit doses (preferably one unit dose) to the masseter muscle; (xi) administering a unit dose to the procerus muscle; (xii) administering a unit dose to the nasal muscle; and / or (xiii) Administer one unit dose to the levator palpebrae superioris muscle.

26. The modified BoNT / A for use, method or use according to any of the preceding claims, further comprising administering one or more unit doses of the modified BoNT / A to one or more other muscles affected by the blepharospasm according to the following dosing regimen: (i) Administer one unit dose to the levator palpebrae superioris muscle.

27. The modified BoNT / A for use, method or use according to any one of the preceding claims, wherein the unit dose of the modified BoNT / A is 240 pg to 5,500 pg of modified BoNT / A.

28. The modified BoNT / A for use, method or use according to any one of the preceding claims, wherein the unit dose of the modified BoNT / A is 240 pg to 5,000 pg of modified BoNT / A.

29. The modified BoNT / A for use, method or use according to any one of the preceding claims, wherein the unit dose of the modified BoNT / A is 240 pg to 2,400 pg of modified BoNT / A.

30. The modified BoNT / A for use, method or use according to any one of the preceding claims, wherein the unit dose of the modified BoNT / A is 240 pg to 2,000 pg of modified BoNT / A.

31. The modified BoNT / A for use, method, or use according to any of the preceding claims, wherein the unit dose (eg, the lower limit of a single unit dose) is at least 500 pg of the modified BoNT / A.

32. The modified BoNT / A for use, method, or use according to any of the preceding claims, wherein the unit dose (eg, the lower limit of a single unit dose) is at least 1,000 pg of modified BoNT / A.

33. The modified BoNT / A for use, method, or use according to any one of claims 1-28, wherein the unit dose of the modified BoNT / A is 2,000 pg to 4,500 pg of modified BoNT / A.

34. The modified BoNT / A for use, method or use according to any one of the preceding claims, wherein the total dose administered during the treatment period is 25,000 pg to 50,000 pg of modified BoNT / A.

35. The modified BoNT / A for use, method, or use according to any one of claims 1-28 or 33, wherein the unit dose of the modified BoNT / A is 2,000 to 4,500 pg of modified BoNT / A; and wherein the total dose administered during the treatment period is 25,000 pg to 50,000 pg of modified BoNT / A.

36. The modified BoNT / A for use, method or use according to any preceding claim, wherein the modified BoNT / A comprises a polypeptide sequence having at least 70% sequence identity to SEQ ID NO:

6.

37. The modified BoNT / A for use, method, or use of any of the preceding claims, wherein the modified BoNT / A has a safety ratio greater than 7, wherein the safety ratio is calculated as: toxin dose required for -10% body weight change (measured in pg / mouse) divided by the DAS ED50 (measured in pg / mouse), where ED50 = dose required to produce a DAS score of 2.

38. The modified BoNT / A for use, method or use according to any one of the preceding claims, wherein the method for treating blepharospasm further comprises: administering a unit dose of the modified BoNT / A to the lateral superior orbicularis oculi muscle proximal to a second eye of the individual; administering a unit dose of the modified BoNT / A to the medial superior orbicularis oculi muscle proximal to the second eye of the individual; as well as A unit dose of the modified BoNT / A is administered to the lateral inferior orbicularis oculi muscle proximal to the subject's second eye.

39. The modified BoNT / A for use, method, or use according to any of the preceding claims, wherein the method for treating blepharospasm further comprises administering: a unit dose of the modified BoNT / A to the inner inferior orbicularis oculi muscle proximal to the individual's eye, wherein the total dose of the modified BoNT / A administered during the treatment period does not exceed the dose (e.g., in the preceding claims).

40. The modified BoNT / A for use, method, or use according to any of the preceding claims, wherein the method for treating blepharospasm further comprises administering: at least a unit dose (e.g., two unit doses) of the modified BoNT / A to the frontalis muscle proximal to the eye of the individual, wherein the total dose of the modified BoNT / A administered during the treatment period does not exceed the dose (e.g., in the preceding claims).

41. The modified BoNT / A for use, method, or use according to any of the preceding claims, wherein the method for treating blepharospasm further comprises administering: at least a unit dose (e.g., two unit doses) of the modified BoNT / A to the corrugator supercilii muscle proximal to the eye of the individual, wherein the total dose of the modified BoNT / A administered during the treatment period does not exceed the dose (e.g., in the preceding claims).

42. The modified BoNT / A for use, method, or use according to any of the preceding claims, wherein the method for treating blepharospasm further comprises administering: a unit dose of the modified BoNT / A to the inner inferior orbicularis oculi muscle proximal to the individual's eye, wherein the total dose of the modified BoNT / A administered during the treatment period does not exceed the dose (e.g., in the preceding claims).

43. The modified BoNT / A for use, method or use according to any one of the preceding claims, wherein the modified BoNT / A is administered as a single unit dose per injection site.

44. A unit dosage form of a modified BoNT / A, comprising: a) at least 10 units (preferably 10 units to 333 units) of a modified BoNT / A, wherein 1 unit corresponds to the calculated mouse median lethal dose (LD 50 ) of a modified BoNT / A; or b) at least 240 pg (preferably 240 pg to 8,000 pg) of modified BoNT / A; and c) optionally, a pharmaceutically acceptable carrier, excipient, adjuvant and / or salt, wherein the modified BoNT / A comprises a BoNT / A light chain and a translocation domain and a BoNT / B receptor binding domain (H C domain).

45. A kit comprising: a) a unit dosage form according to claim 44; and b) instructions for use in the treatment of blepharospasm; and c) Optionally, a diluent.

46. ​​A kit comprising: (a) the unit dosage form according to claim 44; and (b) instructions for use in the treatment of typical hemifacial spasm; and (c) Optionally, a diluent.

47. A kit comprising: (a) the unit dosage form according to claim 44; and (b) instructions for use in the treatment of atypical hemifacial spasm; and Optionally, a diluent.